Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	13809	514/211.08, 514/222.5, 514/225.2, 514/224.2, 514/227.8, 514/235.2, 514/269, 514/333, 514/338, 514/340, 514/345, 514/351, 514/355, 540/545, 544/8, 544/35, 544/51, 544/60, 544/82, 544/333, 546/19, 546/255, 546/256, 546/272.1, 546/280.1, 546/285, 546/313, 546/316, 546/280.4, 546/279.7, 546/281.1	US-PGPUB; USPAT	OR	OFF	2005/12/14 14:36
L2	69313	pyridyl$ or acylsulfimide?	US-PGPUB; USPAT	OR	OFF	2005/12/14 14:37
L3	7761	l1 and l2	US-PGPUB; USPAT	OR	OFF	2005/12/14 14:37

KM

Day : Wednesday
Date: 12/14/2005
Time: 14:15:43

PALM INTRANET

Inventor Information for 10/773471

Inventor Name	City	State/Country
SHERMOLOVICH, YURIY GRIGORIEVICH	KIEV	UKRAINE
KORNUTA, PAVEL PETROVICH	KIEV	UKRAINE
KOMUTA, NATALIYA OLEZANDRIVNA	KIEV	UKRAINE
DOLLER, UWE	RODGAU	GERMANY
ORT, OSWALD	GLASHUTTEN	GERMANY
SCHAPER, WOLFGANG	DIEDORF	GERMANY
JANS, DANIELA	BAD HOMBURG V. D. H.	GERMANY
SANFT, ULRICH	EPPSTEIN/TS	GERMANY
THONESSEN, MARIA-THERESIA	HEIDESHEIM	GERMANY
BECKMANN, MARION	WIESBADEN	GERMANY
WAIBEL, JUTTA MARIA	FRANKFURT	GERMANY
PAZENOK, SERGIY	KELKHEIM	GERMANY

Appln Info | Contents | Petition Info | Atty/Agent Info | Continuity Data | Foreign Data

Search Another: Application# [ ] Search **or Patent#** [ ] Search

PCT / [ ] / [ ] Search **or PG PUBS #** [ ] Search

Attorney Docket # [ ] Search

Bar Code # [ ] Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

7 8 9
ring nodes :
1 2 3 4 5 6
ring/chain nodes :
10
chain bonds :
5-7 7-8 7-9 9-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
7-8 7-9 9-10
exact bonds :
5-7
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:O,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 09:49:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 81 TO ITERATE

100.0% PROCESSED 81 ITERATIONS 20 ANSWERS
SEARCH TIME: 00.00.01

```
FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         1081 TO     2159
PROJECTED ANSWERS:             132 TO      668

L2           20 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 09:49:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     1589 TO ITERATE

100.0% PROCESSED     1589 ITERATIONS                          367 ANSWERS
SEARCH TIME: 00.00.01

L3          367 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               161.33     161.54

FILE 'CAPLUS' ENTERED AT 09:49:59 ON 14 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 14 Dec 2005  VOL 143 ISS 25
FILE LAST UPDATED: 13 Dec 2005  (20051213/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4           71 L3

=> d ibib abs hitstr tot
```

L4 ANSWER 1 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:1216425 CAPLUS
TITLE: Preparation of benzene derivatives containing amide moiety as ACC inhibitors
INVENTOR(S): Suzuki, Nobuyasu; Nihei, Yukio; Ichinose, Hidehiro; Tanaka, Hideyuki; Yasa, Noriko; Hatanaka, Toshihiro; Masuzawa, Youko; Nakanishi, Eiji; Kondo, Nobuo
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: PCT Int. Appl., 227 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005108370	A1	20051117	WO 2005-JP7392	20050418

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:		
JP 2004-122199	A	20040416
JP 2004-122200	A	20040416
JP 2004-122201	A	20040416
JP 2005-21616	A	20050128

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = Q1, etc.; ring A = (un)substituted aromatic hydrocarbon, (un)substituted aromatic heterocycle, (un)substituted cyclic alkenyl, etc.; B = single bond, -CO-, -NHCO-, etc.; R7 = (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, etc.; n = 0-5; V = Q2, etc.; R1-R3 = (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, etc.; R4-R6, R8 = (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, etc.] were prepared For example, amidation of compound II [R= OH], e.g., prepared from 4-nitrobenzoic acid in 4 steps, with anthranilic acid Et ester followed by hydrolysis using NaOH afforded compound II [R = 2-carboxyphenylamino]. In ACC (acetyl CoA carboxylase) inhibition assays, compound II [R = 2-carboxyphenylamino] exhibited the activity of 53%. Compds. I are claimed useful for the

L4 ANSWER 1 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
treatment of hyperlipidemia, diabetes, etc.
IT 869577-82-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzene derivs. containing amide moiety as ACC inhibitors for treatment of hyperlipidemia, diabetes, etc.)
RN 869577-82-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



REFERENCE COUNT: 67 THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:1155549 CAPLUS
DOCUMENT NUMBER: 143:405690
TITLE: Preparation of phenoxyphenylacetamides as non-nucleoside reverse transcriptase inhibitors
INVENTOR(S): Dunn, James Patrick; Hirschfeld, Donald Roy; Silva, Tania; Sweeney, Zachary Kevin; Vora, Harit
PATENT ASSIGNEE(S): Roche Palo Alto LLC, USA
SOURCE: U.S. Pat. Appl. Publ., 61 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005239881	A1	20051027	US 2005-112591	20050422
WO 2005102989	A1	20051103	WO 2005-EP4048	20050415

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:	
US 2004-565117P	P 20040423
US 2004-565116P	P 20040423

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X1 = O; R1 and R2 independently = H, alkyl, haloalkyl, etc. or together R1 and R2 are -O-CH=CH- or -O-CH2CH2- with provisions; R3 and R4 independently = H, alkoxy, alkylthio, etc.; R5 = substituted aryl; Ar = substituted aryl] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of non-nucleoside reverse transcriptase. Thus, e.g., II was prepared by hydrolysis of III followed by chlorination and subsequent amidation using 4-amino-benzenesulfonamide. The inhibitory activity of I towards HIV1-RT was evaluated using radioactivity assay and it was revealed that selected compds. of the invention possessed IC50 values in the range of 0.0045 up to 0.027. I as inhibitor of non-nucleoside reverse transcriptase should prove useful in the treatment of HIV infection. Pharmaceutical compns. comprising I are disclosed.
IT 867365-54-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenoxyphenylacetamides as non-nucleoside reverse transcriptase inhibitors)
RN 867365-54-6 CAPLUS

L4 ANSWER 2 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 3-Pyridinecarboxamide, N-[[4-[[[4-chloro-3-(3-chloro-5-cyanophenoxy)-2-fluorophenyl]acetyl]amino]-3-methylphenyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

L4 ANSWER 3 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:1155548 CAPLUS
DOCUMENT NUMBER: 143:416204
TITLE: Use of phenylacetamides as non-nucleoside reverse transcriptase inhibitors for treating retroviral infections
PATENT ASSIGNEE(S): Roche Palo Alto LLC, USA
SOURCE: U.S. Pat. Appl. Publ., 67 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005239880	A1	20051027	US 2005-112590	20050422
WO 2005102989	A1	20051103	WO 2005-EP4048	20050415

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-565116P P 20040423
US 2004-565117P P 20040423

GI

L4 ANSWER 3 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

L4 ANSWER 3 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I



II



III

AB Title compds. I [X1 = O, S, CH2, C(O); R1 and R2 independently = H, alkyl, haloalkyl, etc. or together R1 and R2 are -O-CH:CH- or -O-CH2CH2- with provisions; R3 and R4 independently = H, alkoxy, alkylthio, etc.; R5 = alkyl, haloalkyl, cycloalkyl aryl or heteroaryl; Ar = (un)substituted aryl or heteroaryl; R6 = H, alkyl; addnl. details are given in the claims] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of non-nucleoside reverse transcriptase for use in treating or preventing an HIV infection, or treating AIDS or ARC. Although the methods of preparation are not claimed, .apprx.60 example prepns. are included.

For example, II was prepared by hydrolysis of III followed by chlorination and subsequent amidation using 4-aminobenzenesulfonamide. The inhibitory activity of I towards HIV1-RT was evaluated using radioactivity assay and it was revealed that selected compds. of the invention possessed IC50 values = 0.0045-0.027.

IT **867365-54-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(use of phenylacetamides as non-nucleoside reverse transcriptase inhibitors for treating retroviral infections)

RN 867365-54-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-[[[4-chloro-3-(3-chloro-5-cyanophenoxy)-2-fluorophenyl]acetyl]amino]-3-methylphenyl]sulfonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2005:480040 CAPLUS
DOCUMENT NUMBER: 143:90225
TITLE: Pharmacophore, Drug Metabolism, and Pharmacokinetics Models on Non-Peptide AT1, AT2, and AT1/AT2 Angiotensin II Receptor Antagonists
AUTHOR(S): Berellini, Giuliano; Cruciani, Gabriele; Mannhold, Raimund
CORPORATE SOURCE: Laboratory for Chemometrics and Cheminformatics, Department of Chemistry, University of Perugia, Perugia, I-06123, Italy
SOURCE: Journal of Medicinal Chemistry (2005), 48(13), 4389-4399
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB About 20 nonpeptide angiotensin II receptor antagonists are in various stages of clin. development. Different modeling approaches were used to predict the pharmacophoric requirements for AT1 (angiotensin II receptor subtype 1) affinity. However, to our knowledge, none was used to predict both the selectivity toward AT1 and AT2 (angiotensin II receptor subtype 2) receptor subtypes. In this paper, partial least squares discriminant anal. is applied to derive the chemical features guiding AT1 and AT2 selectivity or mixed AT1/AT2 receptor binding. The method can be used to modulate AT1 vs. AT2 selectivity. Concerns that unopposed stimulation of the AT2 receptor might produce adverse effects initiated a search for new balanced antagonists. Moreover, it can serve as a fast filtering procedure in database searches. Finally, some relevant pharmacokinetics and metabolic properties of the database of 53 compds. are calculated using the VolSurf and MetaSite software to allow the simultaneous characterization of pharmacodynamic and pharmacokinetics properties of the chemical space of angiotensin II receptor antagonists.

IT **160632-48-4**, L 735286
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(L 735286; pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists)

RN 160632-48-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4'-[(2-ethyl-4,6-dimethyl-1H-benzimidazol-1-yl)methyl][1,1'-biphenyl]-2-yl]sulfonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS

L4 ANSWER 4 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:472142 CAPLUS
DOCUMENT NUMBER: 143:26639
TITLE: Preparation of N-acylsulfonamide apoptosis promoters
INVENTOR(S): Bruncko, Milan; Ding, Hong; Elmore, Steven; Kunzer, Aaron R.; Lynch, Christopher L.; Mcclellan, William; Park, Cheol-Min; Petros, Andrew; Song, Xiaohong; Wang, Xilu; Tu, Noah; Wendt, Michael D.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 507 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005049594	A1	20050602	WO 2004-US37911	20041112
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005159427	A1	20050721	US 2004-988338	20041112
PRIORITY APPLN. INFO.:			US 2003-519695P	P 20031113
OTHER SOURCE(S):	MARPAT 143:26639			

GI

L4 ANSWER 5 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I



II

AB Disclosed are N-acylsulfonamide compds. I [A1 = N, CA2; one or two or three or each of A2, B1, D1 and E1 = R1, OR1, SR1, NHR1, etc., and the remainder = H, halo, CN, etc.; Y1 = H, CN, NO2, CO2H, etc.; or B1 and Y1, together with the atoms to which they are attached, = imidazole or triazole; one or two or each of A2, D1 and E1 = R1, OR1, SR1, etc., and the remainder = H, halo, CF3, etc.; R1 = Ph (un)fused with (hetero)arene, heteroaryl (un)fused with (hetero)arene, etc.; Z1 = substituted Ph (un)fused with (hetero)arene, heteroaryl (un)fused with (hetero)arene] which inhibit the activity of anti-apoptotic protein family members, compns. containing the compds. I and uses of the compds. I for preparing medicaments for treating diseases during which occurs expression of one or more than one anti-apoptotic protein family member. Over 450 synthetic examples were presented (no characterization data for intermediates). E.g., a multi-step synthesis of (1R)-II, starting from piperazine and Et 4-fluorobenzoate, was given. The compds. I were found to be inhibitors of anti-apoptotic Bcl-XL protein and anti-apoptotic Bcl-2 (data given).

IT **852810-24-3P 852810-28-7P 852810-29-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-acylsulfonamide apoptosis promoters)

RN 852810-24-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 852810-28-7 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

RN 852810-29-8 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 5 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:472141 CAPLUS
DOCUMENT NUMBER: 143:26638
TITLE: Preparation of N-acylsulfonamide apoptosis promoters
INVENTOR(S): Bruncko, Milan; Elmore, Steven; Kunzer, Aaron R.; Lynch, Christopher L.; Wang, Xilu; Wendt, Michael D.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 471 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005049593	A2	20050602	WO 2004-US36770	20041103
WO 2005049593	A3	20050707		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005159427	A1	20050721	US 2004-988338	20041112

PRIORITY APPLN. INFO.: US 2003-519695P P 20031113
OTHER SOURCE(S): MARPAT 143:26638
GI



I



II

AB Disclosed are N-acylsulfonamide compds. I [A1 = N, CA2; one or two or three or each of A2, B1, D1 and E1 = R1, OR1, SR1, NHR1, etc., and the remainder = H, halo, CN, etc.; Y1 = H, CN, NO2, CO2H, etc.; or B1 and Y1, together with the atoms to which they are attached, = imidazole or triazole; one or two or each of A2, D1 and E1 = R1, OR1, SR1, etc., and the remainder = H, halo, CF3, etc.; R1 = Ph (un)fused with (hetero)arene, heteroaryl (un)fused with (hetero)arene, etc.; Z1 = substituted Ph (un)fused with (hetero)arene, heteroaryl (un)fused with (hetero)arene] which inhibit the activity of anti-apoptotic protein family members, compns. contg. the compds. I and uses of the compds. I for prepg. medicaments for treating diseases during which occurs expression of one or more than one anti-apoptotic protein family member. Over 440 synthetic examples were presented (no characterization data for intermediates). E.g., a multi-step synthesis of (1R)-II, starting from piperazine and Et 4-fluorobenzoate, was given. The compds. I were found to be inhibitors of anti-apoptotic Bcl-XL protein and anti-apoptotic Bcl-2 (data given).

L4 ANSWER 6 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

IT **852810-24-3P 852810-28-7P 852810-29-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-acylsulfonamide apoptosis promoters)

RN 852810-24-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L4 ANSWER 6 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 852810-28-7 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L4 ANSWER 6 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



L4 ANSWER 6 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B

RN 852810-29-8 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[(4'-chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L4 ANSWER 7 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:648518 CAPLUS
DOCUMENT NUMBER: 141:174066
TITLE: Preparation of (aryloxyalkyl)furans and related compounds as EP4 receptor antagonists for treatment of migraines
INVENTOR(S): Clark, David Edward; Clark, Kenneth Lyle; Coleman, Robert Alexander; Davis, Richard Jon; Fenton, Garry; Harris, Neil Victor; Hynd, George; Newton, Christoper Gregory; Oxford, Alexander William; Stuttle, Keith Alfred James; Sutton, Jonathan Mark
PATENT ASSIGNEE(S): Pharmagene Laboratories Limited, UK
SOURCE: PCT Int. Appl., 176 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004067524	A1	20040812	WO 2004-GB347	20040129
W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI				
CA 2514220	AA	20040812	CA 2004-2514220	20040129
US 2004192767	A1	20040930	US 2004-766030	20040129
PRIORITY APPLN. INFO.:			GB 2003-2094	A 20030129
			US 2003-443872P	P 20030131
			US 2003-509521P	P 20031009
			WO 2004-GB347	W 20040129

OTHER SOURCE(S): MARPAT 141:174066
GI



I



II

L4 ANSWER 7 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

AB Title compds. I [wherein R2 = H, (un)substituted alkyl; Y = (CH2)nX, NRN1, CONRN2; n = 1, 2; X = O, S, SO, SO2; RN1 = H, (un)substituted alkyl; RN2 = H, (un)substituted alkyl, aryl; R3 = (un)substituted aryl linked to an (un)substituted aryl group, wherein if both aryl groups are benzene rings, there may be an O bridge between the two rings; A = a single bond, alkylene; R5 = carboxy, CONHSO2R, SO2NHCOR, tetrazol-5-yl; R = (un)substituted alkyl, aryl, NRN3RN4; RN3 and RN4 = independently (un)substituted alkyl; and pharmaceutically acceptable salts thereof] were prepared as prostaglandin EP4 receptor antagonists. For example, (2-methylfuran-3-yl)methanol was coupled with tert-butyldiphenylsilyl chloride in the presence imidazole in DMF to give the protected alc., 3-(tert-butyldiphenylsilanyloxymethyl)-2-methylfuran. Reaction of the furan with BuLi in THF, followed by addition of CO2 provided 4-(tert-butyldiphenylsilanyloxymethyl)-5-methylfuran-2-carboxylic acid. The latter was loaded onto 2-chlorotrityl chloride resin swelled with CH2Cl2 using diisopropylethylamine, and the loaded resin treated with tetrabutylammonium fluoride in THF. The resin-bound alc. was coupled with 4-hydroxy-4'-methoxybiphenyl using PPh3 and diisopropyl azodicarboxylate in THF and the acid cleaved with TFA /H2O to afford II. In binding assays using cells stably transfected with human EP receptor cDNA, II demonstrated selectivity for antagonizing EP4 receptors over EP3 and EP2 receptors (pKi = >6.5, <5, and <5, resp.). Thus, I and their pharmaceutical compns. are useful for the treatment of conditions alleviated by antagonism of an EP4 receptor, such as primary headache disorder and migraine (no data).

IT **736182-66-4P**, 4-(Biphenyl-4-yloxymethyl)-5-methylfuran-2-sulfonic acid [(pyridin-3-yl)carbonyl]amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(EP4 receptor antagonist; preparation of (aryloxyalkyl)furans and related compds. as EP4 receptor antagonists for treatment of migraines)

RN 736182-66-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[[4-[([1,1'-biphenyl]-4-yloxy)methyl]-5-methyl-2-furanyl]sulfonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:928962 CAPLUS
DOCUMENT NUMBER: 140:163801
TITLE: Palladium-catalyzed intramolecular α-arylation of sulfoximines
AUTHOR(S): Bolm, Carsten; Okamura, Hiroaki; Verrucci, Marinella
CORPORATE SOURCE: Institut fur Organische Chemie, RWTH Aachen, Aachen, D-52056, Germany
SOURCE: Journal of Organometallic Chemistry (2003), 687(2), 444-450
CODEN: JORCAI; ISSN: 0022-328X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:163801
GI



AB The palladium-catalyzed cyclization of N-(2-bromobenzyl)- and N-(2-bromobenzoyl)sulfoximines afforded six-membered heterocycles I (X = CH; R1 = H, NO2, OMe; R2 = H; R1 = H; R2 = Bu; X = N; R1 = R2 = H) and II (X = CH, N; R1 = H; X = CH; R1 = OMe) in moderate to good yield. In both cases, the α-arylations of the sulfoximine Me groups are catalyzed by combination of Pd(OAc)2 and rac-BINAP, in the presence of a base.

IT **654084-10-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (bromobenzoyl)methyl(phenyl)sulfoximines via N-benzoylation of methyl(phenyl)sulfoximine with benzoyl chlorides in the preparation of benzothiazinone oxides)

RN 654084-10-3 CAPLUS

CN Sulfoximine, N-[(2-bromo-3-pyridinyl)carbonyl]-S-methyl-S-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:397000 CAPLUS
DOCUMENT NUMBER: 138:397327
TITLE: Protein and cDNA sequences of a human gene EIT-6 and use for treating estrogen-dependent breast cancer
INVENTOR(S): Polyak, Kornelia; Pankaj, Seth
PATENT ASSIGNEE(S): Dana-Farber Cancer Institute, Inc., USA
SOURCE: PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003042363	A2	20030522	WO 2002-US35899	20021108
WO 2003042363	A3	20031120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2465912	AA	20030522	CA 2002-2465912	20021108
EP 1451341	A2	20040901	EP 2002-803193	20021108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 2004248139	A1	20041209	US 2004-494930	20040803
PRIORITY APPLN. INFO.:			US 2001-337754P	P 20011109
			WO 2002-US35899	W 20021108

AB The invention provides protein and cDNA sequences of a human gene EIT-6. Also featured by the invention are methods of inhibiting the activity and expression of EIT-6. The invention also provides pyridine-2,5-dicarboxylic acid analogs and their use in treating estrogen-dependent breast cancer.

IT **138834-73-8 138834-74-9 138834-75-0 138834-76-1 138834-77-2 152457-91-5 527687-33-8 527687-34-9 527687-35-0 527687-36-1**
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(protein and cDNA sequences of human gene EIT-6 and use for treating estrogen-dependent breast cancer)

RN 138834-73-8 CAPLUS

CN 2-Pyridinecarboxylic acid, 5-[[(methylsulfonyl)amino]carbonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 138834-74-9 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[(1-methylethyl)sulfonyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 138834-75-0 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[(phenylsulfonyl)amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 138834-76-1 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[(phenylmethyl)sulfonyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 138834-77-2 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[(1-naphthalenylsulfonyl)amino]carbonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 2-Pyridinecarboxylic acid, 5-[[[(5-chloro-2-thienyl)sulfonyl]amino]carbony l]- (9CI) (CA INDEX NAME)



RN 527687-35-0 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[(4,5-dibromo-2-thienyl)sulfonyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 527687-36-1 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-(4,7-dichloro-2-quinolinyl)phenyl]sulfonyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 152457-91-5 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[(4-methoxyphenyl)sulfonyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 527687-33-8 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[(8-quinolinylsulfonyl)amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 527687-34-9 CAPLUS

L4 ANSWER 10 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:	2003:282278 CAPLUS
DOCUMENT NUMBER:	138:282805
TITLE:	Preparation of N-thionicotinamide derivatives as pesticides
INVENTOR(S):	Beckmann, Marion; Ort, Oswald; Doeller, Uwe; Krautstrunk, Gerhard; Schaper, Wolfgang; Luemmen, Peter; Jans, Daniela; Hempel, Waltraud; Waibel, Jutta Maria; Loerkens, Barbara
PATENT ASSIGNEE(S):	Bayer CropScience GmbH, Germany; et al.
SOURCE:	PCT Int. Appl., 73 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	German
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003028458	A1	20030410	WO 2002-EP10279	20020913
W: AE, AG, AL, AM, AU, AZ, BA, BB, BR, BY, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, RU, SG, SI, TJ, TM, TN, TT, UA, US, UZ, VC, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10146873	A1	20030417	DE 2001-10146873	20010924
EP 1432313	A1	20040630	EP 2002-762475	20020913
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005504104	T2	20050210	JP 2003-531811	20020913
US 2003119852	A1	20030626	US 2002-246220	20020918
US 2004192712	A1	20040930	US 2004-811578	20040329
PRIORITY APPLN. INFO.:			DE 2001-10146873 A	20010924
			WO 2002-EP10279 W	20020913
			US 2002-246220 B1	20020918
OTHER SOURCE(S):	MARPAT 138:282805			

GI



AB The N-thionicotinamide derivs. I and II [X = CH or N; Y = O or S; n = 0 or 1; m = n or 2; R1 = halo, (halo)alkyl, etc.; R2, R3 = H, halo, (halo)alkyl, etc.; R4 = H, un(substituted) (cyclo)alkyl, alkenyl, alkynyl aryl, heterocyclyl or alkanoyl; R5 = H, (un)substituted alkyl, alkenyl, alkynyl. etc. R6 = H, (un)substituted (cyclo)alkyl, etc.] are prepared as

L4 ANSWER 10 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
insecticides, acaricides and veterinary parasiticides.
IT 506427-14-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant in preparation of N-thionicotinamide pesticide)
RN 506427-14-1 CAPLUS
CN Sulfilimine, S,S-bis(1-methylpropyl)-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:221441 CAPLUS
DOCUMENT NUMBER: 138:216842
TITLE: Herbicide combinations with safeners
INVENTOR(S): Ziemer, Frank; Willms, Lothar; Rosinger, Christopher; Bieringer, Hermann; Hacker, Erwin
PATENT ASSIGNEE(S): Bayer CropScience GmbH, Germany
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003022050	A1	20030320	WO 2002-EP9973	20020906
W: AE, AG, AL, AM, AU, AZ, BA, BB, BR, BY, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, RU, SG, SI, TJ, TM, TN, TT, UA, US, UZ, VC, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10145019	A1	20030403	DE 2001-10145019	20010913
CA 2460481	AA	20030320	CA 2002-2460481	20020906
EP 1427281	A1	20040616	EP 2002-764874	20020906
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012488	A	20040824	BR 2002-12488	20020906
CN 1553769	A	20041208	CN 2002-817899	20020906
JP 2005501910	T2	20050120	JP 2003-526192	20020906
US 2003130120	A1	20030710	US 2002-241136	20020911
US 6914035	B2	20050705		

PRIORITY APPLN. INFO.: DE 2001-10145019 A 20010913
WO 2002-EP9973 W 20020906
OTHER SOURCE(S): MARPAT 138:216842
GI

L4 ANSWER 11 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I

II

AB The invention concerns compns. containing an azole herbicide I [R = H or alkoxycarbonyl; R1 = H, (halo)alkyl, (halo)alkenyl, (halo)alkynyl, alkoxyalkyl, alkylthio, etc.; R2 = halo, nitro, cyano, (halo)alkyl, (halo)alkenyl, (halo)alkynyl, alkoxyalkyl, etc.; q = 0,1-4] and a safener II [X = CH or N; R3 = H, (un)substituted (cyclo)alkyl, (cyclo)alkenyl, alkynyl, Ph or heterocyclyl; R4 = H, (un)substituted alkyl, alkenyl or alkynyl; R3NR4 = pyrrolidinyl or piperidinyl; R5 = halo, nitro, (halo)alkyl, (halo)alkoxy, alkylsulfonyl, alkoxycarbonyl or alkylcarbonyl; R 6 = H alkyl, alkenyl or alkynyl; R7 = R5, cycloalkyl, Ph, cyano, alkylthio or alkylsulfinyl; s = 0,1 or 2; o = 1 or 2].
IT 500905-91-9 500905-92-0
RL: AGR (Agricultural use); BIOL (Biological study); USES (Uses)
(safened herbicide)
RN 500905-91-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-methoxy-N-[[4-[[(1-methylethyl)amino]carbonyl]phenyl]sulfonyl]-, mixt. with (5-cyclopropyl-4-isoxazolyl)[2-(methylsulfonyl)-4-(trifluoromethyl)phenyl]methanone (9CI) (CA INDEX NAME)

CM 1

CRN 221670-20-8
CMF C17 H19 N3 O5 S



CM 2

CRN 141112-29-0
CMF C15 H12 F3 N O4 S

L4 ANSWER 11 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 500905-92-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-[(cyclopropylamino)carbonyl]phenyl]sulfonyl]-2-methoxy-, mixt. with (5-cyclopropyl-4-isoxazolyl)[2-(methylsulfonyl)-4-(trifluoromethyl)phenyl]methanone (9CI) (CA INDEX NAME)

CM 1

CRN 221670-23-1
CMF C17 H17 N3 O5 S



CM 2

CRN 141112-29-0
CMF C15 H12 F3 N O4 S



L4 ANSWER 11 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:154243 CAPLUS
DOCUMENT NUMBER: 138:204839
TITLE: Preparation of benzamides affecting glucokinase for combined treatment or prevention of type 2 diabetes and obesity
INVENTOR(S): Boyd, Scott; Caulkett, Peter William Rodney; Hargreaves, Rodney Brian; Bowker, Suzanne Saxon; James, Roger; Johnstone, Craig; Jones, Clifford David; McKerrecher, Darren; Block, Michael Howard
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 156 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003015774	A1	20030227	WO 2002-GB3745	20020815
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2457410	AA	20030227	CA 2002-2457410	20020815
EP 1420784	A1	20040526	EP 2002-755165	20020815
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012008	A	20040928	BR 2002-12008	20020815
US 2005080106	A1	20050414	US 2003-486496	20020815
EP 1529530	A1	20050511	EP 2004-28298	20020815
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
NZ 531193	A	20050729	NZ 2002-531193	20020815
JP 2005525291	T2	20050825	JP 2003-520733	20020815
EP 1568367	A1	20050831	EP 2004-28297	20020815
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
ZA 2004001015	A	20050506	ZA 2004-1015	20040206
NO 2004000686	A	20040217	NO 2004-686	20040217
JP 2005320343	A2	20051117	JP 2005-168987	20050609

PRIORITY APPLN. INFO.:	SE 2001-2764	A	20010817
	EP 2002-755165	A3	20020815
	JP 2003-520733	A3	20020815
	WO 2002-GB3745	W	20020815

OTHER SOURCE(S): MARPAT 138:204839
GI

L4 ANSWER 12 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I

AB The invention relates to the use of benzamides (shown as I; variables defined below; e.g. 2-[[3,5-di(2-chlorobenzyloxy)benzoyl]amino]thiazole) or a salt, solvate or prodrug thereof, in the preparation of a medicament for the treatment or prevention of a disease condition mediated through glucokinase (GLK; no data), such as type 2 diabetes, and to the compds. I and methods for preparing them. Twelve pharmaceutical compns. are included. For I: m is 0-2; n is 0-4; and n + m > 0; each R1 = OH, -(CH2)1-4OH, -CH3-aFa, -(CH2)1-4[CH3-aFa, -OCH3-aFa, halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, NH2, -NH-C1-4alkyl, -N-di(C1-4alkyl), CN, formyl, Ph or heterocyclyl optionally substituted by C1-6alkyl. Each R2 is the group Y-X- wherein each X is a linker = -O-Z-, -O-Z-O-Z-, -C(O)O-Z-, -OC(O)-Z-, -S-Z-, -SO-Z-, -SO2-Z-, -N(R6)-Z-, -N(R6)SO2-Z-, -SO2N(R6)-Z-, -(CH2)1-4-, -CH:CH-Z-, -C.tplbond.C-Z-, -N(R6)CO-Z-, -CON(R6)-Z-, -C(O)N(R6)S(O)2-Z-, -S(O)2N(R6)C(O)-Z-, -C(O)-Z-, -Z-, -C(O)-Z-O-Z-, -N(R6)-C(O)-Z-O-Z-, -O-Z-N(R6)-Z-, -O-C(O)-Z-O-Z- or a direct bond; each Z = a direct bond, C2-6alkenylene or -(CH2)p-C(R6a)2-(CH2)q-; each Y = acyl-Z1-, heterocyclyl-Z1-, C3-7cycloalkyl-Z1-, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, -(CH2)1-4CH3-aFa or -CH(OH)CH3-aFa; R3 = Ph or a heterocyclyl; addnl. details are given in the claims. More than 30 example prepns. of I are included and >300 specific examples of I are included with characterization data. For example, to prepare 2-[[3,5-di(2-chlorobenzyloxy)benzoyl]amino]thiazole, diisopropylethylamine (2.0 mmol) then 4-dimethylaminopyridine (0.1 mmol) were added to a solution of 2-aminothiazole (1.0 mmol) and 3,5-di(2-chlorobenzyloxy)benzoic acid chloride (1.0 mmol) in CH2Cl2 (10 mL) under Ar at ambient temperature After 80 mins the reaction mixture was filtered, washed with CH2Cl2 and dried under high vacuum to give the title compound as a colorless solid (41%).

IT **499991-22-9P 499991-27-4P**, N-(5-(((Methylsulfonyl)amino)carbonyl)pyridin-2-yl)-3-isopropoxy-5-(2-(thien-3-yl)ethoxy)benzamide **499991-28-5P**, N-(5-((((4-Fluorophenyl)sulfonyl)amino)carbonyl)pyridin-2-yl)-3-isopropoxy-5-(2-(thien-3-yl)ethoxy)benzamide **499991-29-6P**, N-(5-((((Trifluoromethyl)sulfonyl)amino)carbonyl)pyridin-2-yl)-3-isopropoxy-5-(2-(thien-3-yl)ethoxy)benzamide **499991-30-9P**, N-(5-((((Pyridin-3-yl)sulfonyl)amino)carbonyl)pyridin-2-yl)-3-isopropoxy-5-(2-(thien-3-yl)ethoxy)benzamide **499991-31-0P**, N-(5-((((3,5-Dimethylisoxazol-4-yl)sulfonyl)amino)carbonyl)pyridin-2-yl)-3-isopropoxy-5-(2-(thien-3-yl)ethoxy)benzamide **499991-32-1P**, N-(5-((((5-Chloro-1,3-dimethylpyrazol-4-yl)sulfonyl)amino)carbonyl)pyridin-2-yl)-3-isopropoxy-5-(2-(thien-3-yl)ethoxy)benzamide **499991-33-2P**, N-(5-((((2-Fluorophenyl)sulfonyl)amino)carbonyl)pyridin-2-yl)-3-isopropoxy-5-(2-(thien-3-yl)ethoxy)benzamide **499991-34-3P**, N-(5-((((5-Chlorothien-2-yl)sulfonyl)amino)carbonyl)pyridin-2-yl)-3-isopropoxy-5-(2-(thien-3-yl)ethoxy)benzamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzamides affecting glucokinase for combined treatment or prevention of type 2 diabetes and obesity)

L4 ANSWER 12 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 499991-22-9 CAPLUS
CN 3-Pyridinecarboxamide, 6-[[3-(1-methylethoxy)-5-(2-methylpropoxy)benzoyl]amino]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 499991-27-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-[[3-(1-methylethoxy)-5-[2-(3-thienyl)ethoxy]benzoyl]amino]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 499991-28-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[(4-fluorophenyl)sulfonyl]-6-[[3-(1-methylethoxy)-5-[2-(3-thienyl)ethoxy]benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 499991-29-6 CAPLUS
CN 3-Pyridinecarboxamide, 6-[[3-(1-methylethoxy)-5-[2-(3-thienyl)ethoxy]benzoyl]amino]-N-[(trifluoromethyl)sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 499991-30-9 CAPLUS
CN 3-Pyridinecarboxamide, 6-[[3-(1-methylethoxy)-5-[2-(3-thienyl)ethoxy]benzoyl]amino]-N-(3-pyridinylsulfonyl)- (9CI) (CA INDEX NAME)



RN 499991-31-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-6-[[3-(1-methylethoxy)-5-[2-(3-thienyl)ethoxy]benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 499991-32-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[(5-chloro-1,3-dimethyl-1H-pyrazol-4-yl)sulfonyl]-6-[[3-(1-methylethoxy)-5-[2-(3-thienyl)ethoxy]benzoyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 499991-33-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[(2-fluorophenyl)sulfonyl]-6-[[3-(1-methylethoxy)-5-[2-(3-thienyl)ethoxy]benzoyl]amino]- (9CI) (CA INDEX NAME)



RN 499991-34-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[(5-chloro-2-thienyl)sulfonyl]-6-[[3-(1-methylethoxy)-5-[2-(3-thienyl)ethoxy]benzoyl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:5781 CAPLUS
DOCUMENT NUMBER: 138:73179
TITLE: Preparation of phenylvinyl-nicotinic acid derivatives for therapeutic use glucokinase (GLK) activators
INVENTOR(S): Hayter, Barry Raymond; Currie, Gordon Stuart; Hargreaves, Rodney Brian; Caulkett, Peter William Rodney; James, Roger
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000262	A1	20030103	WO 2002-GB2903	20020624
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1406620	A1	20040414	EP 2002-743377	20020624
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005500311	T2	20050106	JP 2003-506907	20020624
US 2005054715	A1	20050310	US 2004-482264	20040806
PRIORITY APPLN. INFO.:			SE 2001-2299	A 20010626
			WO 2002-GB2903	W 20020624

OTHER SOURCE(S): MARPAT 138:73179
GI



I

II

AB Phenylvinyl-nicotinic acid derivs., such as I [R1 = OH, (CH2)1-4OH, NO2, NH2, haloalkyl, haloalkyloxy, alkyl, alkenyl, alkylamino, etc.; R2 = X-Y;

L4 ANSWER 13 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

X = linking group, such as O, CO, amino, Z-O-Z, etc; Z = alkylene, alkenylene, etc.; R3 = OH, alkoxy, alkylamino, etc.; m = 0-2; n = 0-4; m + n > 0], as well as other phenylvinyl-heteroaryl derivs., were prepd. for pharmaceutical use in the treatment of diseases or conditions mediated through glucokinase (GLK), such as type 2 diabetes. Thus, nicotinic acid deriv. II (R3 = OH) was prepd. via condensation of Me 6-methylnicotinate with PhO-3-C6H4CHO using AcOH at 120° for 24 h to give the corresponding Me ester II (R3 = OMe) in 49% yield, followed by hydrolysis of the ester using 1M aq. NaOH in THF to give the desired acid in 76% yield. The prepd. compds. were assayed for their effect on GLK activity, and pharmaceutical compns. of the prepd. compds. were presented.

IT **479723-33-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylvinyl-nicotinic acid derivs. for therapeutic use glucokinase (GLK) activators)

RN 479723-33-6 CAPLUS
CN 3-Pyridinecarboxamide, N-(methylsulfonyl)-6-[(1E)-2-[5-(methylthio)-2-(phenylmethoxy)phenyl]ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:505411 CAPLUS
DOCUMENT NUMBER: 137:78769
TITLE: Preparation of N-arylcarbonyl- and heteroarylcarbonyl benzenesulfonamide inhibitors of Bcl-Xl and Bcl-2 as promoters of apoptosis
INVENTOR(S): Augeri, David J.; Baumeister, Steven A.; Bruncko, Milan; Dickman, Daniel A.; Ding, Hong; Dinges, Jurgen; Fesik, Stephen W.; Hajduk, Philip J.; Kunzer, Aaron R.; McClellan, William; Nettesheim, David G.; Oost, Thorsten; Petros, Andrew M.; Rosenberg, Saul H.; Wang, Shen; Thomas, Sheela A.; Wang, Xilu; Wendt, Michael D.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: U.S. Pat. Appl. Publ., 126 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002086887	A1	20020704	US 2001-957276	20010920
US 6720338	B2	20040413		
US 2004192681	A1	20040930	US 2004-820097	20040407
PRIORITY APPLN. INFO.:			US 2000-233866P P	20000920
			US 2001-957276 A3	20010920

OTHER SOURCE(S): MARPAT 137:78769
GI



I



II

AB N-aryl- and N-heteroarylcarbonyl benzenesulfonamides I [A = (un)substituted Ph, 5- or 6-membered heterocyclic ring with 1-3 N, O, or S

L4 ANSWER 14 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
atoms; R1 = alkyl, haloalkyl, NO2, NR6R7; R2, R3 = H, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, etc.; R4 = aryl, arylalkenyl, arylalkoxy, cycloalkenyl, cycloalkyl, halo, heterocyclyl, heterocyclyloxy; R5 = H, alkyl, halo; R6, R7 = H, alkenyl, alkoxyalkyl, alkoxycarbonylalkyl, alkyl, heterocyclyl, etc.; R6R7N = imidazolyl, morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, etc.] are prepd. Over 500 I are prepd. E.g., N-biphenylcarbonyl benzenesulfonamide II was prepd. by Pd-catalyzed coupling of 4-FC6H4B(OH)2 and 4-BrC6H4CO2Me, hydrolysis of the ester with LiOH, acylation of 4-chloro-3-nitrobenzenesulfonamide with the resulting acid in the presence of EDCI and DMAP, and nucleophilic arom. substitution of the chlorobenzenesulfonamide with 2,2-dimethylcyclopentylamine. Compds. of the invention inhibit Bcl-Xl with IC50 values between 0.011 μM and 10 μM, and inhibit Bcl-2 with IC50 values between 0.017 μM and 10 μM.
IT 406230-32-8P 406230-66-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-aryl- and heteroarylcarbonyl benzenesulfonamide inhibitors of Bcl-Xl and Bcl-2 as promoters of apoptosis)
RN 406230-32-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-[[(1R)-5-amino-1-[(phenylthio)methyl]pentyl]amino]-3-nitrophenyl]sulfonyl]-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 406230-66-8 CAPLUS
CN 3-Pyridinecarboxamide, 6-(4-fluorophenyl)-N-[[3-nitro-4-[[2-(phenylthio)ethyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS

L4 ANSWER 15 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:354097 CAPLUS
DOCUMENT NUMBER: 136:355074
TITLE: Preparation of N-arylcarbonyl- and heteroarylcarbonyl benzenesulfonamide inhibitors of Bcl-Xl and Bcl-2 as promoters of apoptosis
INVENTOR(S): Augeri, David J.; Baumeister, Steven A.; Bruncko, Milan; Dickman, Daniel A.; Ding, Hong; Dinges, Jurgen; Fesik, Stephen W.; Hajduk, Philip J.; Kunzer, Aaron R.; McClellan, William; Nettesheim, David G.; Oost, Thorsten; Petros, Andrew M.; Rosenberg, Saul H.; Shen, Wang; Thomas, Sheela A.; Wang, Xilu; Wendt, Michael D.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 126 pp., Cont.-in-part of U.S. Ser. No. 666,508.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002055631	A1	20020509	US 2001-935581	20010824
CA 2423103	AA	20020328	CA 2001-2423103	20010920
WO 2002024636	A2	20020328	WO 2001-US29432	20010920
WO 2002024636	A3	20020926		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001091151	A5	20020402	AU 2001-91151	20010920
EP 1318978	A2	20030618	EP 2001-971244	20010920
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004529852	T2	20040930	JP 2002-529049	20010920
BR 2001010101	A	20050607	BR 2001-10101	20010920
PRIORITY APPLN. INFO.:			US 2000-666508	A2 20000920
			US 2001-935581	A 20010824
			WO 2001-US29432	W 20010920

OTHER SOURCE(S): MARPAT 136:355074
GI

L4 ANSWER 15 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I



II

AB N-aryl- and N-heteroarylcarbonyl benzenesulfonamides I [A = (un)substituted Ph, 5- or 6-membered heterocyclic ring with 1-3 N, O, or S atoms; R1 = alkyl, haloalkyl, NO2, NR6R7; R2, R3 = H, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, etc.; R4 = aryl, arylalkenyl, arylalkoxy, cycloalkenyl, cycloalkyl, halo, heterocyclyl, heterocyclyloxy; R5 = H, alkyl, halo; R6, R7 = H, alkenyl, alkoxyalkyl, alkoxycarbonylalkyl, alkyl, heterocyclyl, etc.; R6R7N = imidazolyl, morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, etc.] are prepared Over 500 I are prepared E.g., N-biphenylcarbonyl benzenesulfonamide II was prepared by Pd-catalyzed coupling of 4-FC6H4B(OH)2 and 4-BrC6H4CO2Me, hydrolysis of the ester with LiOH, acylation of 4-chloro-3-nitrobenzenesulfonamide with the resulting acid in the presence of EDCI and DMAP, and nucleophilic aromatic substitution of the chlorobenzenesulfonamide with 2,2-dimethylcyclopentylamine. Compds. of the invention inhibit Bcl-Xl with IC50 values between 0.011 μM and 10 μM, and inhibit Bcl-2 with IC50 values between 0.017 μM and 10 μM.

IT **406230-32-8P 406230-66-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-aryl- and heteroarylcarbonyl benzenesulfonamide inhibitors of Bcl-Xl and Bcl-2 as promoters of apoptosis)

RN 406230-32-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-[[(1R)-5-amino-1-[(phenylthio)methyl]pentyl]amino]-3-nitrophenyl]sulfonyl]-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 15 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 406230-66-8 CAPLUS
CN 3-Pyridinecarboxamide, 6-(4-fluorophenyl)-N-[[3-nitro-4-[[2-(phenylthio)ethyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 16 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:328512 CAPLUS
DOCUMENT NUMBER: 138:89662
TITLE: Synthesis and antibacterial activity of 2-(arylthioureido)-3-(p-toluenesulfonamidocarbonyl)pyridines
AUTHOR(S): Patel, N. B.; Bhagat, P. R.
CORPORATE SOURCE: Department of Chemistry, South Gujarat University, Surat, 395007, India
SOURCE: Journal of Indian Council of Chemists (2001), 18(1), 56-58
CODEN: JICCE7; ISSN: 0971-5037
PUBLISHER: Indian Council of Chemists
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 138:89662
GI



I

AB Title compds. I (R = H, 4-CO2H, 2-OMe, 4-OMe, 2-Me, 3-Me, 4-Me, etc.) were prepared from the 2-chloropyridine analogs and arylthioureas. Antibacterial activity screening for all I was carried out.

IT **484650-13-7P 484650-14-8P 484650-15-9P**
484650-16-0P 484650-17-1P 484650-18-2P
484650-19-3P 484650-20-6P 484650-21-7P
484650-22-8P 484650-23-9P 484650-24-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antibacterial activity of 2-(arylthioureido)-3-(p-toluenesulfonamidocarbonyl)pyridines)

RN 484650-13-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[(4-methylphenyl)sulfonyl]-2-[[(phenylamino)thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 484650-14-8 CAPLUS
CN Benzoic acid, 4-[[[[3-[[[(4-methylphenyl)sulfonyl]amino]carbonyl]-2-pyridinyl]amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 484650-15-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(2-methoxyphenyl)amino]thioxomethyl]amino]-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 484650-16-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(4-methoxyphenyl)amino]thioxomethyl]amino]-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 484650-17-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(2-methylphenyl)amino]thioxomethyl]amino]-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 484650-18-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(3-methylphenyl)amino]thioxomethyl]amino]-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 484650-19-3 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(4-methylphenyl)amino]thioxomethyl]amino]-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 484650-20-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[(4-methylphenyl)sulfonyl]-2-[[[(2-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 484650-21-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[(4-methylphenyl)sulfonyl]-2-[[[(3-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)



RN 484650-22-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[(4-methylphenyl)sulfonyl]-2-[[[(4-nitrophenyl)amino]thioxomethyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 484650-23-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(3-chlorophenyl)amino]thioxomethyl]amino]-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 484650-24-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[[[(4-chlorophenyl)amino]thioxomethyl]amino]-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 16 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 113513-63-6
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation and antibacterial activity of 2-(arylthioureido)-3-(p-toluenesulfonamidocarbonyl)pyridines)
RN 113513-63-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:240717 CAPLUS
DOCUMENT NUMBER: 136:279215
TITLE: Preparation of N-arylcarbonyl- and heteroarylcarbonyl benzenesulfonamide inhibitors of Bcl-Xl and Bcl-2 as promoters of apoptosis
INVENTOR(S): McClellan, William; Oost, Thorsten; Bruncko, Milan; Wang, Xilu; Augeri, David J.; Baumeister, Steven A.; Dickman, Daniel A.; Ding, Hong; Dinges, Jurgen; Fesik, Stephen W.; Hajduk, Philip J.; Kunzer, Aaron R.; Nettesheim, David G.; Petros, Andrew M.; Rosenberg, Saul H.; Shen, Wang; Thomas, Sheela A.; Wendt, Michael D.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 292 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002024636	A2	20020328	WO 2001-US29432	20010920
WO 2002024636	A3	20020926		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002055631	A1	20020509	US 2001-935581	20010824
CA 2423103	AA	20020328	CA 2001-2423103	20010920
AU 2001091151	A5	20020402	AU 2001-91151	20010920
EP 1318978	A2	20030618	EP 2001-971244	20010920
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004529852	T2	20040930	JP 2002-529049	20010920
BR 2001010101	A	20050607	BR 2001-10101	20010920

PRIORITY APPLN. INFO.: US 2000-666508 A 20000920
US 2001-935581 A 20010824
WO 2001-US29432 W 20010920

OTHER SOURCE(S): MARPAT 136:279215
GI

L4 ANSWER 17 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





II

AB N-aryl- and N-heteroarylcarbonyl benzenesulfonamides I [A = (un)substituted Ph, 5- or 6-membered heterocyclic ring with 1-3 N, O, or S atoms; R1 = alkyl, haloalkyl, NO2, NR6R7; R2, R3 = H, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, etc.; R4 = aryl, arylalkenyl, arylalkoxy, cycloalkenyl, cycloalkyl, halo, heterocyclyl, heterocyclyloxy; R5 = H, alkyl, halo; R6, R7 = H, alkenyl, alkoxyalkyl, alkoxycarbonylalkyl, alkyl, heterocyclyl, etc.; R6R7N = imidazolyl, morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, etc.] are prepared Over 500 I are prepared E.g.,
N-biphenylcarbonyl benzenesulfonamide II was prepared by Pd-catalyzed coupling of 4-FC6H4B(OH)2 and 4-BrC6H4CO2Me, hydrolysis of the ester with LiOH, acylation of 4-chloro-3-nitrobenzenesulfonamide with the resulting acid in the presence of EDCI and DMAP, and nucleophilic aromatic substitution
of the chlorobenzenesulfonamide with 2,2-dimethylcyclopentylamine. Compds. of the invention inhibit Bcl-Xl with IC50 values between 0.011 μM and 10 μM, and inhibit Bcl-2 with IC50 values between 0.017 μM and 10 μM.
IT 406230-32-8P 406230-66-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-aryl- and heteroarylcarbonyl benzenesulfonamide inhibitors
of Bcl-Xl and Bcl-2 as promoters of apoptosis)
RN 406230-32-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-[[(1R)-5-amino-1-[(phenylthio)methyl]pentyl]amino]-3-nitrophenyl]sulfonyl]-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. .

L4 ANSWER 17 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 406230-66-8 CAPLUS
CN 3-Pyridinecarboxamide, 6-(4-fluorophenyl)-N-[[3-nitro-4-[[2-(phenylthio)ethyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



own work

L4 ANSWER 18 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:713312 CAPLUS
DOCUMENT NUMBER: 135:272885
TITLE: Preparation of pyridinyl acylsulfimides as insecticides, acaricides, and nematocides
INVENTOR(S): Kornuta, Pavel Petrovich; Shermolovich, Yuriy Grigorievich; Doeller, Uwe; Ort, Oswald; Schaper, Wolfgang; Jans, Daniela; Sanft, Ulrich; Thoenessen, Maria-Theresia; Beckmann, Marion; Waibel, Jutta Maria; Pazenok, Sergiy
PATENT ASSIGNEE(S): Aventis CropScience GmbH, Germany; Kornuta, Nataliya Olexandrivna
SOURCE: PCT Int. Appl., 119 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001070692	A2	20010927	WO 2001-EP3083	20010317
WO 2001070692	A3	20020314		
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 10014006	A1	20010927	DE 2000-10014006	20000322
DE 10057911	A1	20020523	DE 2000-10057911	20001121
CA 2403807	AA	20020920	CA 2001-2403807	20010317
EP 1274683	A2	20030115	EP 2001-936093	20010317
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001009473	A	20030603	BR 2001-9473	20010317
JP 2003528081	T2	20030924	JP 2001-568904	20010317
US 2002032328	A1	20020314	US 2001-812309	20010320
ZA 2002007479	A	20031009	ZA 2002-7479	20020918
US 2004167334	A1	20040826	US 2004-773471	20040205
PRIORITY APPLN. INFO.:			DE 2000-10014006 A	20000322
			DE 2000-10057911 A	20001121
			WO 2001-EP3083 W	20010317
			US 2001-812309 B1	20010320

OTHER SOURCE(S): MARPAT 135:272885
GI



I

AB Title compds. [I; X = CH, N; Y = O, S; m, n = 0, 1; R1 = haloalkyl; R2, R3 = H, halo, (O-, S-, N-interrupted) (substituted) alkyl; R4, R5 = R6, CWR7, C(:NOR7)R7, C(:NNR72)R7, C(:W)OR7, etc.; R6 = alkyl alkenyl, alkynyl, cycloalkyl, cycloalkenyl, etc.; R7 = H, R6; W = O, S; R4R5 = (substituted) heterocyclyl], were prepared Thus, N-(2,4,6-trimethylbenzenesulfonyl)methyl thien-3-ylsulfimide and 4-trifluoromethylnicotinyl chloride in CH2Cl2 were dropwise treated with Et3N in CH2Cl2 followed by stirring at room temperature for 1.5 days to give 81.6% I (R1 = CF3; R2, R3 = H; R4 = Me; R5 = thien-3-yl; X = CH; Y = O; m, n = 0). Tested I gave 90-100% kill of aphids on vicia faba.

IT 326873-12-5P 362724-12-7P 362724-14-9P
362724-15-0P 362724-17-2P 362724-18-3P
362724-19-4P 362724-20-7P 362724-21-8P
362724-22-9P 362724-23-0P 362724-24-1P
362724-25-2P 362724-26-3P 362724-27-4P
362724-28-5P 362724-29-6P 362724-30-9P
362724-31-0P 362724-32-1P 362724-33-2P
362724-34-3P 362724-35-4P 362724-36-5P
362724-37-6P 362724-38-7P 362724-39-8P
362724-40-1P 362724-41-2P 362724-42-3P
362724-43-4P 362724-44-5P 362724-45-6P
362724-46-7P 362724-47-8P 362724-48-9P
362724-49-0P 362724-50-3P 362724-51-4P
362724-52-5P 362724-53-6P 362724-54-7P
362724-55-8P 362724-56-9P 362724-57-0P
362724-58-1P 362724-59-2P 362724-60-5P
362724-61-6P 362724-62-7P 362724-63-8P
362724-64-9P 362724-65-0P 362724-66-1P
362724-67-2P 362724-68-3P 362724-69-4P
362724-70-7P 362724-71-8P 362724-72-9P
362724-73-0P 362724-74-1P 362724-75-2P
362724-76-3P 362724-77-4P 362724-78-5P
362724-79-6P 362724-80-9P 362724-81-0P
362724-82-1P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridinyl acylsulfimides as insecticides, acaricides, and nematocides)

RN 326873-12-5 CAPLUS
CN Imidosulfurous diamide, N,N,N',N'-tetrapropyl-N''-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-12-7 CAPLUS
CN Sulfilimine, S-methyl-S-3-thienyl-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-14-9 CAPLUS
CN Sulfilimine, S,S-diphenyl-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-15-0 CAPLUS
CN Benzonitrile, 2-fluoro-6-[4-[S-methyl-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]sulfonimidoyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 362724-17-2 CAPLUS
CN Sulfoximine, S,S-diphenyl-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-18-3 CAPLUS
CN Sulfilimine, S,S-dimethyl-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-19-4 CAPLUS
CN Sulfilimine, S,S-bis(1-methylethyl)-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-20-7 CAPLUS
CN Sulfilimine, S,S-diethyl-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-21-8 CAPLUS
CN Imidosulfurous diamide, N,N,N',N'-tetramethyl-N''-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 18 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 362724-22-9 CAPLUS
CN Imidosulfurous diamide, N,N,N',N'-tetraethyl-N''-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-23-0 CAPLUS
CN Morpholine, 4,4'-[[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]sulfinimidoyl]bis- (9CI) (CA INDEX NAME)



RN 362724-24-1 CAPLUS
CN Piperidine, 1,1'-[[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]sulfinimidoyl]bis- (9CI) (CA INDEX NAME)



RN 362724-25-2 CAPLUS
CN Imidosulfurous diamide, N,N,N',N'-tetrakis(1-methylethyl)-N''-[[4-

L4 ANSWER 18 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 362724-30-9 CAPLUS
CN Imidosulfurous diamide, N,N'-dicyclohexyl-N,N'-bis(phenylmethyl)-N''-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-31-0 CAPLUS
CN Imidosulfurous diamide, N,N'-dibutyl-N,N'-bis(phenylmethyl)-N''-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-32-1 CAPLUS
CN 3-Pyridinecarboxamide, 2,6-dichloro-N-(2,3,4,5-tetrahydro-1λ4-1,2,6-thiadiazin-1-yl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 362724-33-2 CAPLUS
CN 3-Pyridinecarboxamide, 2,6-dichloro-N-(3,4,5,6-tetrahydro-2H-1λ4-

L4 ANSWER 18 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-26-3 CAPLUS
CN Sulfilimine, S,S-bis(2-methylpropyl)-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-27-4 CAPLUS
CN Sulfilimine, S,S-bis(phenylmethyl)-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-28-5 CAPLUS
CN Imidosulfurous diamide, N,N'-bis(1,1-dimethylethyl)-N,N'-bis(phenylmethyl)-N''-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-29-6 CAPLUS
CN Imidosulfurous diamide, N,N'-dimethyl-N,N'-diphenyl-N''-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 18 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
1,2,7-thiadiazepin-1-yl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 362724-34-3 CAPLUS
CN Sulfilimine, N-[[2,6-dichloro-4-(trifluoromethyl)-3-pyridinyl]carbonyl]-S,S-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 362724-35-4 CAPLUS
CN Morpholine, 4,4'-[[[6-chloro-2-(diethylamino)-4-(trifluoromethyl)-3-pyridinyl]carbonyl]sulfinimidoyl]bis- (9CI) (CA INDEX NAME)



RN 362724-36-5 CAPLUS
CN Imidosulfurous diamide, N''-[[2,6-dichloro-4-(trifluoromethyl)-3-pyridinyl]carbonyl]-N,N,N',N'-tetramethyl- (9CI) (CA INDEX NAME)



RN 362724-37-6 CAPLUS
CN Imidosulfurous diamide, N''-[[6-chloro-2-(dimethylamino)-4-(trifluoromethyl)-3-pyridinyl]carbonyl]-N,N,N',N'-tetramethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 18 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 362724-38-7 CAPLUS
CN Morpholine, 4,4'-[[[6-chloro-2-[(4-methylcyclohexyl)amino]-4-(trifluoromethyl)-3-pyridinyl]carbonyl]sulfinimidoyl]bis- (9CI) (CA INDEX NAME)



RN 362724-39-8 CAPLUS
CN Sulfilimine, S-[(4-methylphenyl)methyl]-S-phenyl-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-40-1 CAPLUS
CN Sulfilimine, S-methyl-S-(1-methylethyl)-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-41-2 CAPLUS

L4 ANSWER 18 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-46-7 CAPLUS
CN Sulfilimine, S-(1-methylethyl)-S-[1-(4-methylphenyl)ethyl]-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-47-8 CAPLUS
CN Sulfilimine, S-(1-methylethyl)-S-[[4-(trifluoromethyl)phenyl]methyl]-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-48-9 CAPLUS
CN Sulfilimine, S-[(4-methoxyphenyl)methyl]-S-(1-methylethyl)-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-49-0 CAPLUS
CN Sulfilimine, S-(1-methylethyl)-S-[(4-nitrophenyl)methyl]-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 18 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Sulfilimine, S-methyl-S-(4-methylphenyl)-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-42-3 CAPLUS
CN Sulfilimine, S-[(2,5-dimethylphenyl)methyl]-S-methyl-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-43-4 CAPLUS
CN Sulfilimine, S-(2,5-dimethylphenyl)-S-ethyl-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-44-5 CAPLUS
CN Sulfilimine, S-(1-methylethyl)-S-propyl-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-45-6 CAPLUS
CN Sulfilimine, S-(cyclopropylmethyl)-S-(1-methylethyl)-N-[[4-

L4 ANSWER 18 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 362724-50-3 CAPLUS
CN Sulfilimine, S-(1-methylethyl)-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]-S-[(2,4,6-trimethylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 362724-51-4 CAPLUS
CN Sulfilimine, S-[(2,6-difluorophenyl)methyl]-S-(1-methylethyl)-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-52-5 CAPLUS
CN Sulfilimine, S-(2-furanylmethyl)-S-(1-methylethyl)-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-53-6 CAPLUS
CN Sulfilimine, S-(4-methoxyphenyl)-S-(1-methylethyl)-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 18 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 362724-54-7 CAPLUS
CN Sulfilimine, S-(2,5-dimethylphenyl)-S-(1-methylethyl)-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-55-8 CAPLUS
CN Sulfilimine, S-(1-methylethyl)-S-2-pyridinyl-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-56-9 CAPLUS
CN Sulfilimine, S-butyl-S-(4-chlorophenyl)-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-57-0 CAPLUS
CN Sulfilimine, S-(1-methylpropyl)-S-[(4-nitrophenyl)methyl]-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 18 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 362724-58-1 CAPLUS
CN Sulfilimine, S-[(4-methoxyphenyl)methyl]-S-(1-methylpropyl)-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-59-2 CAPLUS
CN Sulfilimine, S-(1-methylpropyl)-S-[[4-(trifluoromethyl)phenyl]methyl]-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-60-5 CAPLUS
CN Sulfilimine, S-(1-methylpropyl)-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]-S-[(2,4,6-trimethylphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 362724-61-6 CAPLUS
CN Sulfilimine, S-[(3,5-dimethyl-4-isoxazolyl)methyl]-S-(1-methylpropyl)-N-

L4 ANSWER 18 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-62-7 CAPLUS
CN Sulfilimine, S-(4-methoxyphenyl)-S-(2-methylpropyl)-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-63-8 CAPLUS
CN Sulfilimine, S-(2,5-dimethylphenyl)-S-(2-methylpropyl)-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-64-9 CAPLUS
CN Sulfilimine, S-(cyclopropylmethyl)-S-phenyl-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-65-0 CAPLUS

L4 ANSWER 18 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 2H-Thiopyran, 1,1,3,4,5,6-hexahydro-1-[[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]imino]- (9CI) (CA INDEX NAME)



RN 362724-66-1 CAPLUS
CN Sulfilimine, S-[(2,6-difluorophenyl)methyl]-S-phenyl-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-67-2 CAPLUS
CN Sulfilimine, S-[(2,6-difluorophenyl)methyl]-S-(2,5-dimethylphenyl)-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-68-3 CAPLUS
CN Sulfilimine, S-[(2,6-difluorophenyl)methyl]-S-(4-methoxyphenyl)-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-69-4 CAPLUS
CN Sulfilimine, S-phenyl-S-[5-(trifluoromethyl)-2-pyridinyl]-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 18 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 362724-70-7 CAPLUS
CN Sulfilimine, S-phenyl-S-3-thienyl-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-71-8 CAPLUS
CN Dibenzothiophene, 5,5-dihydro-5-[[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]imino]- (9CI) (CA INDEX NAME)



RN 362724-72-9 CAPLUS
CN Phenoxathiin, 10,10-dihydro-10-[[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]imino]- (9CI) (CA INDEX NAME)

L4 ANSWER 18 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 362724-73-0 CAPLUS
CN Thianthrene, 5,5-dihydro-5-[[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]imino]- (9CI) (CA INDEX NAME)



RN 362724-74-1 CAPLUS
CN 10H-Phenothiazine, 5,5-dihydro-10-methyl-5-[[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]imino]- (9CI) (CA INDEX NAME)

L4 ANSWER 18 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 362724-75-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[N-propyl-S-(propylamino)sulfinimidoyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 362724-76-3 CAPLUS
CN Morpholine, 4,4'-[[[2,6-dichloro-4-(trifluoromethyl)-3-pyridinyl]carbonyl]sulfinimidoyl]bis- (9CI) (CA INDEX NAME)



RN 362724-77-4 CAPLUS
CN Sulfilimine, S-(2,5-dimethylphenyl)-S-(2-ethyl-2-butenyl)-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 18 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 362724-78-5 CAPLUS
CN Sulfoximine, S,S-bis(1-methylethyl)-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-79-6 CAPLUS
CN Sulfoximine, S-(1-methylethyl)-S-[[4-(trifluoromethyl)phenyl]methyl]-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-80-9 CAPLUS
CN Sulfilimine, S-(2,5-dimethylphenyl)-S-[[4-(trifluoromethoxy)phenyl]methyl]-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-81-0 CAPLUS
CN Sulfilimine, S-(4-chlorophenyl)-S-[[4-(trifluoromethoxy)phenyl]methyl]-N-

L4 ANSWER 18 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-82-1 CAPLUS
CN Sulfilimine, S-phenyl-S-[[4-(trifluoromethoxy)phenyl]methyl]-N-[[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



IT **362724-10-5P 362724-11-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyridinyl acylsulfimides as insecticides, acaricides, and nematocides)
RN 362724-10-5 CAPLUS
CN Imidosulfurous dichloride, [[4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 362724-11-6 CAPLUS
CN Imidosulfurous dichloride, [[2,6-dichloro-4-(trifluoromethyl)-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 18 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 19 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:715779 CAPLUS
DOCUMENT NUMBER: 132:60427
TITLE: Antidote activity of N-(3-pyridoyl)-S,S-dialkylsulfilimine derivates on soybean
AUTHOR(S): Schwartau, V. V.
CORPORATE SOURCE: Institute of Plant Physiology and Genetics, National Academy of Sciences of Ukraine, Kiev, 252022, Ukraine
SOURCE: Fiziologiya i Biokhimiya Kul'turnykh Rastenii (1999), 31(4), 303-307
CODEN: FBKRAT; ISSN: 0532-9310
PUBLISHER: Izdatel'stvo "Logos"
DOCUMENT TYPE: Journal
LANGUAGE: Russian
AB The effect of new N-(3-pyridoyl)-S,S-dialkylsulfilimine derivates on dinitroaniline phytotoxicity was studied. The new compds. protected soybean plants from trifluralin injury. The antidote action was related to effects of the new compds. on nitrogenase activity and herbicide degradation in soil.
IT **162441-90-9 253333-95-8 253333-96-9**
253333-97-0 253333-98-1 253333-99-2
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study); USES (Uses)
(herbicide antidote activity of pyridoyldialkylsulfilimine derivates on soybean)
RN 162441-90-9 CAPLUS
CN Sulfilimine, N-[(1-methylpyridinium-3-yl)carbonyl]-S,S-bis(1-methylethyl)-, iodide (9CI) (CA INDEX NAME)



● I⁻

RN 253333-95-8 CAPLUS
CN Sulfilimine, S,S-dimethyl-N-(3-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 253333-96-9 CAPLUS
CN Sulfilimine, S,S-bis(1-methylethyl)-N-(3-pyridinylcarbonyl)- (9CI) (CA

L4 ANSWER 19 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
INDEX NAME)



RN 253333-97-0 CAPLUS
CN Sulfilimine, S,S-diethyl-N-(3-pyridinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 253333-98-1 CAPLUS
CN Sulfilimine, S,S-dimethyl-N-[(1-methylpyridinium-3-yl)carbonyl]-, iodide (9CI) (CA INDEX NAME)



● I⁻

RN 253333-99-2 CAPLUS
CN Sulfilimine, S,S-diethyl-N-[(1-methylpyridinium-3-yl)carbonyl]-, iodide (9CI) (CA INDEX NAME)



● I⁻

L4 ANSWER 20 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:233898 CAPLUS
DOCUMENT NUMBER: 130:252154
TITLE: Preparation of acylsulfamoylbenzoic acid amides as herbicide safeners.
INVENTOR(S): Ziemer, Frank; Willms, Lothar; Auler, Thomas; Bieringer, Hermann; Rosinger, Christopher
PATENT ASSIGNEE(S): Hoechst Schering Agrevo G.m.b.H., Germany
SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9916744	A1	19990408	WO 1998-EP6097	19980924
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
DE 19742951	A1	19990415	DE 1997-19742951	19970929
CA 2305313	AA	19990408	CA 1998-2305313	19980924
AU 9910265	A1	19990423	AU 1999-10265	19980924
EP 1019368	A1	20000719	EP 1998-952644	19980924
EP 1019368	B1	20030305		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE				
BR 9812564	A	20000801	BR 1998-12564	19980924
JP 2001518461	T2	20011016	JP 2000-513830	19980924
AT 233730	E	20030315	AT 1998-952644	19980924
RU 2205824	C2	20030610	RU 2000-110730	19980924
ES 2194358	T3	20031116	ES 1998-952644	19980924
US 6251827	B1	20010626	US 1998-161120	19980925
ZA 9808826	A	19990329	ZA 1998-8826	19980928
PRIORITY APPLN. INFO.:			DE 1997-19742951 A	19970929
			WO 1998-EP6097 W	19980924

OTHER SOURCE(S): MARPAT 130:252154
GI



I

L4 ANSWER 20 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 221670-29-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[[2,4-dichloro-5-[(cyclopropylamino)carbonyl]phenyl]sulfonyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 221670-31-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[[2-chloro-5-[(cyclopropylamino)carbonyl]phenyl]sulfonyl]-2-methoxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
AB Plant protection agents optionally containing ≥1 pesticide and containing ≥1 title compds. [I; X = CH, N; R1 = H, (substituted) heterocyclyl, hydrocarbyl; R2 = H, OH, (substituted) alkyl, alkenyl, alkynyl, alkoxy, alkenyloxy; R1R2 = atoms to form 3-8 membered ring; R3 = halo, cyano, NO2, amino, OH, CO2H, CHO, CONH2, SO2NH2, etc.; R4 = H, alkyl, alkenyl, alkynyl; R5 = halo, cyano, NO2, amino, OH, CO2H, CHO, CONH2, SO2NH2, phosphoryl, etc.; m = 0-5; n = 0-4; with provisos], are claimed (no data). Thus, 2-chlorobenzoic acid in THF was treated with carbonyldiimidazole followed by 30 min stirring at room temperature and 30 min. at reflux; N-propyl-4-sulfamoylbenzamide and then DBU were added and the mixture was refluxed 3 h to give 54% 4-(2-chlorobenzoylsulfamoyl)-N-propylbenzamide.
IT 221670-20-8P 221670-23-1P 221670-26-4P
221670-29-7P 221670-31-1P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acylsulfamoylbenzoic acid amides as herbicide safeners)
RN 221670-20-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-methoxy-N-[[4-[[(1-methylethyl)amino]carbonyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 221670-23-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-[(cyclopropylamino)carbonyl]phenyl]sulfonyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 221670-26-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-[[(1,2-dimethylpropyl)amino]carbonyl]phenyl]sulfonyl]-2-methoxy- (9CI) (CA INDEX NAME)

L4 ANSWER 21 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:178823 CAPLUS
DOCUMENT NUMBER: 126:171487
TITLE: Preparation of aminopyridinecarboxylic acids and related compounds as inhibitors of the pain enhancing effects of E-type prostaglandins.
INVENTOR(S): Breault, Gloria Anne
PATENT ASSIGNEE(S): Zeneca Limited, UK; Breault, Gloria Anne
SOURCE: PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9700864	A1	19970109	WO 1996-GB1443	19960617
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
TW 502026	B	20020911	TW 1996-85107057	19960612
IL 118663	A1	20010430	IL 1996-118663	19960616
CA 2220529	AA	19970109	CA 1996-2220529	19960617
AU 9662321	A1	19970122	AU 1996-62321	19960617
AU 699691	B2	19981210		
EP 847391	A1	19980617	EP 1996-920937	19960617
EP 847391	B1	20011219		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				
CN 1193966	A	19980923	CN 1996-196394	19960617
CN 1114598	B	20030716		
BR 9608908	A	19990302	BR 1996-8908	19960617
JP 11507939	T2	19990713	JP 1997-503654	19960617
NZ 311083	A	20000128	NZ 1996-311083	19960617
AT 211132	E	20020115	AT 1996-920937	19960617
SK 282458	B6	20020205	SK 1997-1733	19960617
PT 847391	T	20020628	PT 1996-920937	19960617
ES 2169248	T3	20020701	ES 1996-920937	19960617
CZ 290924	B6	20021113	CZ 1997-4110	19960617
RU 2198878	C2	20030220	RU 1998-100866	19960617
HR 960289	B1	20021031	HR 1996-960289	19960618
ZA 9605201	A	19961220	ZA 1996-5201	19960619
US 6100258	A	20000808	US 1997-973915	19971216
NO 9705984	A	19971219	NO 1997-5984	19971219
NO 311131	B1	20011015		
BG 63778	B1	20021229	BG 1998-102174	19980109
US 6313148	B1	20011106	US 2000-541306	20000403
PRIORITY APPLN. INFO.:			GB 1995-12475 A	19950620
			GB 1996-1465 A	19960125
			WO 1996-GB1443 W	19960617
			US 1997-973915 A3	19971216

OTHER SOURCE(S): MARPAT 126:171487
AB DOACHR3NR2BR1 [A = (substituted) Ph, naphthyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, thienyl, thiazolyl, oxazolyl, thiadiazolyl, provided that the CH(R3)N(R2)BR1 and OD groups are positioned in a 1,2 relationship to one another on ring carbon atoms and the ring atom

L4 ANSWER 21 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
positioned ortho to the OD linking group (and therefore in the 3-position relative to the CHR3NR2 linking group) is not substituted; B = (substituted) Ph, pyridyl, thiazolyl, oxazolyl, thienyl, thiadiazolyl, imidazolyl, pyrazinyl, pyridazinyl, pyrimidinyl; R1 = CO2H, carboxyalkyl, tetrazolyl, tetrazolylalkyl, tetronic acid, hydroxamic acid, sulfonic acid, aminocarbonyl, azolyl, etc., and is positioned on ring B in a 1,3 or 1,4 relationship with the CH(R3)N(R2) group; R2 = H, (substituted) alkyl, alkenyl, (provided the double bond is not in the 1-position), alkynyl (provided the triple bond is not in the 1-position), phenylalkyl, pyridylalkyl; R3 = H, Me, Et; D = H, (substituted) 5-7 membered carbocyclic ring contg. 1 double bond, alkyl substituted by a (substitute) 5-7 membered carbocyclic ring contg. 1 double bond, (CH2)nCH(R4)C(R5):CR6R7; R4 = H, Me, Et; R5 = H, Me, Br, Cl, F, CF3; R6, R7 = H, alkyl, Br, Cl, F, CF3; n = 0, 1; and N- and S-oxides thereof, with specific exceptions], were prepd. Thus, Me 2-[N-[5-bromo-2-(2-chloroallyloxy)benzyl]-N-ethylamino]-5-pyridylcarboxylate (prepn. given) was stirred with aq. NaOH in MeOH to give 2-[N-[5-bromo-2-(2-chloroallyloxy)benzyl]-N-ethylamino]-5-pyridylcarboxylic acid. Tested title compds. inhibited PGE2-induced contraction of guinea pig ileum with pA2 >5.3.

IT **187229-70-5P 187229-71-6P 187229-72-7P**
187229-73-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aminopyridazinecarboxylic acids and related compds. as inhibitors of the pain enhancing effects of E-type prostaglandins)

RN 187229-70-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-[[[5-bromo-2-[(2-methyl-2-propenyl)oxy]phenyl]methyl]ethylamino]-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 187229-71-6 CAPLUS
CN 3-Pyridinecarboxamide, 6-[[[5-bromo-2-[(2-methyl-2-propenyl)oxy]phenyl]methyl]ethylamino]-N-(propylsulfonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 21 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 187229-72-7 CAPLUS
CN 3-Pyridinecarboxamide, 6-[[[5-bromo-2-[(2-chloro-2-propenyl)oxy]phenyl]methyl]ethylamino]-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 187229-73-8 CAPLUS
CN 3-Pyridinecarboxamide, 6-[[[5-bromo-2-[(2-chloro-2-propenyl)oxy]phenyl]methyl]ethylamino]-N-(propylsulfonyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 22 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:	1996:666870 CAPLUS
DOCUMENT NUMBER:	125:301001
TITLE:	Preparation of 3-(2'-sulfamoylbiphenyl-4-yl)methyl-2-imino-1,3,4-thiazolidine derivatives as antihypertensives
INVENTOR(S):	Sakae, Shinya; Yokomoto, Masaharu; Inoe, Satoshi; Nishimura, Koji; Hirata, Akikage; Iguma, Kenichi; Tamura, Koichi
PATENT ASSIGNEE(S):	Wakunaga Seiyaku Kk, Japan
SOURCE:	Jpn. Kokai Tokkyo Koho, 31 pp. CODEN: JKXXAF
DOCUMENT TYPE:	Patent
LANGUAGE:	Japanese
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
JP 08208632	A2	19960813	JP 1995-280093		19951027
PRIORITY APPLN. INFO.:			JP 1995-280093	A	19951027
			JP 1994-264755		19941028

OTHER SOURCE(S): MARPAT 125:301001
GI



AB The title compds. [I; R1 = H, COR2; wherein R2 = (un)substituted lower alkyl, cycloalkyl, or cycloalkenyl, (un)substituted aryl-lower alkyl or aryl-lower alkenyl, Ph, or aromatic heterocyclyl, lower alkoxy or aralkyloxy; R3 = halo, lower alkyl or cycloalkyl, (un)substituted Ph, lower alkyl alkoxy; R4 = H, lower alkyl, acyl; R5, R6 = H, halo, lower alkyl], which show potent angiotensin II-antagonizing, smooth muscle-relaxing, and antihypertensive activity, are prepared Thus, 533 mg 5-ethyl-2-trifluoroacetamido-1,3,4-thiadiazole and 1.00 g 4-bromomethyl-2'-(N-tert-butylsulfamoylbiphenyl-4-yl)biphenyl were added to DMF and stirred at room temperature for 4 h to give 606 mg I (R1 = CF3CO, R3 = Et, R5 = R6 = H, R4 = tert-butyl). I (R1 = Q, R3 = Et, R4 = CO2Et, R5 = R6 = H) and I (R1 = 2-ClC6H4CO, R3 = Et, R4 = COC6H4CO2Me-2, R5 = R6 = H) in vitro showed IC50 of 3.0 and 5.3 nM, resp., for inhibiting angiotensin II and in vivo inhibited angiotensin II-induced hypertension of rats by 53.4 and 62.3%, resp., at 0.1 mg/kg i.v.

IT **183000-06-8P 183000-42-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of [(sulfamoylbiphenylyl)methyl]iminothiazolidine derivs. as antihypertensives, angiotensin II antagonists, and smooth muscle relaxants)

RN 183000-06-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4'-[[2-[(cyclopropylcarbonyl)imino]-5-ethyl-1,3,4-thiadiazol-3(2H)-yl]methyl][1,1'-biphenyl]-2-yl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 183000-42-2 CAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-N-[[4'-[[2-[(cyclopropylcarbonyl)imino]-5-ethyl-1,3,4-thiadiazol-3(2H)-yl]methyl][1,1'-biphenyl]-2-yl]sulfonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 23 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:367337 CAPLUS
DOCUMENT NUMBER: 125:33683
TITLE: Aromatic amino ethers as pain relieving agents
INVENTOR(S): Breault, Gloria Anne; Oldfield, John; Tucker, Howard; Warner, Peter
PATENT ASSIGNEE(S): Zeneca Limited, UK
SOURCE: PCT Int. Appl., 140 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9603380	A1	19960208	WO 1995-GB1728	19950721
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2192088	AA	19960208	CA 1995-2192088	19950721
AU 9529883	A1	19960222	AU 1995-29883	19950721
AU 688541	B2	19980312		
EP 773930	A1	19970521	EP 1995-925943	19950721
EP 773930	B1	20001011		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1154106	A	19970709	CN 1995-194340	19950721
CN 1085663	B	20020529		
BR 9508335	A	19970930	BR 1995-8335	19950721
HU 76606	A2	19971028	HU 1996-3338	19950721
JP 10503487	T2	19980331	JP 1995-505573	19950721
AT 196898	E	20001015	AT 1995-925943	19950721
ES 2150577	T3	20001201	ES 1995-925943	19950721
PT 773930	T	20010131	PT 1995-925943	19950721
TW 411328	B	20001111	TW 1995-84107606	19950722
ZA 9506149	A	19960207	ZA 1995-6149	19950724
FI 9700261	A	19970122	FI 1997-261	19970122
FI 116219	B1	20051014		
NO 9700314	A	19970313	NO 1997-314	19970124
NO 308032	B1	20000710		
US 5843942	A	19981201	US 1997-776275	19970124
CN 1286254	A	20010307	CN 2000-104017	20000310
GR 3034603	T3	20010131	GR 2000-402119	20001012

PRIORITY APPLN. INFO.:	GB 1994-14924	A	19940725
	GB 1995-1288	A	19950124
	WO 1995-GB1728	W	19950721

OTHER SOURCE(S): MARPAT 125:33683
GI



L4 ANSWER 23 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

AB The invention relates to compds. I [A = (un)substituted Ph, naphthyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidyl, thienyl, thiazolyl, oxazolyl, thiadiazolyl having ≥ 2 adjacent ring C atoms, or bicyclic ring system, provided that the shown sidechains on A are in a 1,2-relationship, and the 3-position is unsubstituted; B, D = (un)substituted ring system; R1 = various groups; R2 = H, alk(en/yn)yl, phenylalkyl, 5- or 6-membered heteroarylalkyl; R3, R4 = H or alkyl] and their N-oxides, S-oxides, pharmaceutically acceptable salts, and in vivo-hydrolyzable esters and amides. Also claimed are processes for their preparation, intermediates, use as therapeutic agents, and pharmaceutical compns. I are analgesics which are structurally different from NSAIDS and opiates, and which may also possess antiinflammatory, antipyretic, and antidiarrheal properties. For example, condensation of 6-chloropyridazine-3-carboxamide with N-ethyl-N-(2-benzyloxy-5-bromobenzyl)amine-HCl in N-methylpyrrolidinone containing NaHCO3 at 115° (85%), and hydrolysis of the carboxamide function with NaOH in iso-PrOH (97%), gave title compound II. I generally had pA2 > 5.3 for inhibition of PGE2-induced contraction of guinea pig ileum in vitro, and ED50 of 0.01-100 mg/kg orally in the i.p.-induced writhing test.

IT **177758-29-1P 177758-44-0P 177758-45-1P**
177758-46-2P 177758-47-3P 177758-48-4P
177758-49-5P 177758-50-8P 177758-51-9P
177758-52-0P 177758-53-1P 177758-56-4P
177758-98-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aromatic amino ethers as analgesics)

RN 177758-29-1 CAPLUS
CN 3-Pyridinecarboxamide, 6-[[[5-bromo-2-(phenylmethoxy)phenyl]methyl]ethylamino]-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 23 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 177758-44-0 CAPLUS
CN 3-Pyridinecarboxamide, 6-[[[5-bromo-2-(phenylmethoxy)phenyl]methyl]ethylamino]-N-(propylsulfonyl)- (9CI) (CA INDEX NAME)



RN 177758-45-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[[5-(acetylamino)-1,3,4-thiadiazol-2-yl]sulfonyl]-6-[[[5-bromo-2-(phenylmethoxy)phenyl]methyl]ethylamino]- (9CI) (CA INDEX NAME)



RN 177758-46-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-[[[5-bromo-2-(phenylmethoxy)phenyl]methyl]ethylamino]-N-[[5-(2-pyridinyl)-2-thienyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 177758-47-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-[[[5-bromo-2-(phenylmethoxy)phenyl]methyl]ethylam

L4 ANSWER 23 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
ino]-N-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 177758-48-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-[[[5-bromo-2-(phenylmethoxy)phenyl]methyl]ethylamino]-N-[(2-hydroxyethyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 177758-49-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-[ethyl[[5-(methylsulfonyl)-2-(phenylmethoxy)phenyl]methyl]amino]-N-[(phenylmethyl)sulfonyl]- (9CI) (CA

L4 ANSWER 23 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
INDEX NAME)



RN 177758-50-8 CAPLUS
CN 3-Pyridinecarboxamide, 6-[[[5-bromo-2-(phenylmethoxy)phenyl]methyl]ethylamino]-N-[(1,3,5-trimethyl-1H-pyrazol-4-yl)sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 23 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A



RN 177758-51-9 CAPLUS
CN 3-Pyridinecarboxamide, 6-[[[5-bromo-2-(phenylmethoxy)phenyl]methyl]ethylamino]-N-[(5-chloro-2-thienyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 177758-52-0 CAPLUS
CN 3-Pyridinecarboxamide, 6-[[[5-bromo-2-(phenylmethoxy)phenyl]methyl]ethylamino]-N-[(4-fluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 177758-53-1 CAPLUS
CN 3-Pyridinecarboxamide, 6-[[[5-bromo-2-(phenylmethoxy)phenyl]methyl]ethylamino]-N-[(tetrahydro-1,1-dioxido-3-thienyl)sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 23 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 177758-56-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-[ethyl[[2-(phenylmethoxy)phenyl]methyl]amino]-N-[(2-hydroxyethyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 177758-98-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-[[[5-bromo-2-(phenylmethoxy)phenyl]methyl]ethylamino]-N-[[5-[(methylamino)carbonyl]-1,3,4-thiadiazol-2-yl]sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 23 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 24 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:607987 CAPLUS
DOCUMENT NUMBER: 123:286034
TITLE: Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists
INVENTOR(S): Ashton, Wallace T.; Chang, Linda L.; MacCoss, Malcolm; Chakravarty, Prasun K.; Greenlee, William J.; Patchett, Arthur A.; Flanagan, Kelly
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: U.S., 90 pp. Cont.-in-part of U.S. Ser. No. 899,868, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5411980	A	19950502	US 1992-994228	19921221
ZA 9204916	A	19930331	ZA 1992-4916	19920702
PRIORITY APPLN. INFO.:			US 1989-386328 B2	19890728
			US 1990-504507 B2	19900404
			US 1991-725720 B2	19910703
			US 1991-812891 B2	19911220
			US 1992-899868 B2	19921217

OTHER SOURCE(S): MARPAT 123:286034
GI



I

AB There are disclosed new substituted triazolinone compds. I [R2a = H, halo; R2b = H, halo, C1-4-alkyl; R3a = H, halo; R3b = H, halo, C1-4-alkyl; E is a single bond; R6 = (un)substituted C1-6-alkyl; R23 = e.g., (un)substituted Ph, branched C3-7-alkyl, C3-7-cycloalkyl; V1 = H, Me, CF3, halogen, with the proviso that V1 = CF3 when V2 = H; V2 = e.g., H, NO2, NR10R21; R10 = H, C1-4-alkyl; R21 = H or R22; R22 = e.g., C1-6-alkyl, C3-7-cycloalkyl; aryl] which are useful as angiotensin II antagonists. Thus, e.g., reaction of 4-bromomethyl-2'-(t-butoxycarbonyl)biphenyl with K phthalimide afforded 82% N-[[2'-(t-butoxycarbonyl)biphenyl-4-yl]methyl]phthalimide; hydrazinolysis afforded 88% 4-aminomethyl-2'-(t-butoxycarbonyl)biphenyl; reaction with CS2/MeI afforded 84% Me N-[[2'-(t-butoxycarbonyl)biphenyl-4-yl]methyl]dithiocarbamate; reaction of the latter with hydrazine afforded 79% 4-[[2'-(t-butoxycarbonyl)biphenyl-4-yl]methyl]-3-thiosemicarbazide; heterocyclization with tri-Me orthovalerate afforded 63% 4-[[2'-(t-butoxycarbonyl)biphenyl-4-yl]methyl]-5-butyl-2,4-dihydro-3H-1,2,4-triazole-3-thione; removal of the t-Bu group with trifluoroacetic acid afforded the corresponding 2'-carboxy deriv. (21%). Representative compds. of the invention act as angiotensin II receptor antagonists with activity of at least IC50 < 50 μM. Pharmaceutical formulations were given.

IT **159044-96-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists)

RN 159044-96-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4'-[[3-butyl-1,5-dihydro-5-oxo-1-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-4-yl]methyl][1,1'-biphenyl]-2-yl]sulfonyl]-2-chloro- (9CI) (CA INDEX NAME)



L4 ANSWER 25 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:488487 CAPLUS
DOCUMENT NUMBER: 122:233298
TITLE: Influence of S,S-diisopropyl-N-(1-methyl-2-pyridoyl)sulfylimine on trifluralin toxicity to soybeans (Glycine maximum L.)
AUTHOR(S): Shvartau, V. V.; Akimenko, L. I.; Merezhinsky, Yu. G.; Meletskyaya, O. S.; Shvartau, V. V.; Slusarenko, E. I.; Danchenko, E. A.; Shermolovich, Yu. G.
CORPORATE SOURCE: Inst. Fiziol. Rast. Genet., Kiev, Ukraine
SOURCE: Dopovidi Akademii Nauk Ukraini (1994), (7), 124-6
CODEN: DNUKEM
PUBLISHER: Naukova Dumka
DOCUMENT TYPE: Journal
LANGUAGE: Russian

AB To search for antidotes of dinitroaniline herbicides a new biol. active compound, S,S-diisopropoyl-N-(1-methyl-3-pyridoyl)sulfylimine ("A"), was synthesized. The evaluation of antidote activity of "A" indicated that the compound effectively protected soybean plants from trifluralin injury. The antidote action of "A" was in accord with "A" influence on herbicide degradation enhancing in soil. Antidote "A" was more effective than cartolin and dichlormid (R-25788).

IT **162441-90-9P**
RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and herbicide antidote activity of)

RN 162441-90-9 CAPLUS
CN Sulfilimine, N-[(1-methylpyridinium-3-yl)carbonyl]-S,S-bis(1-methylethyl)-, iodide (9CI) (CA INDEX NAME)



● I-

L4 ANSWER 26 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:354646 CAPLUS
DOCUMENT NUMBER: 123:83393
TITLE: Pyridine derivatives, herbicidal composition containing them, and method for killing weeds
INVENTOR(S): Miyazaki, Masahiro; Matsuzawa, Masafumi; Toriyabe, Keiji; Hirata, Michiya
PATENT ASSIGNEE(S): Kumiai Chemical Industries Co., Ltd., Japan; Ihara Chemical Industries Co., Ltd.
SOURCE: U.S., 45 pp. Cont.-in-part of U.S. Ser. No. 927,281.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5380700	A	19950110	US 1992-996042	19921223
JP 05331163	A2	19931214	JP 1991-84556	19910326
US 5385880	A	19950131	US 1992-927281	19920917
IN 178208	A	19970315	IN 1994-CA798	19940930
IN 178419	A	19970419	IN 1994-CA799	19940930
PRIORITY APPLN. INFO.:			JP 1991-84556 A	19910326
			US 1992-927281 A2	19920917
			WO 1992-JP362 W	19920326
			IN 1992-CA401 A1	19920604
			IN 1992-CA402 A1	19920604

OTHER SOURCE(S): MARPAT 123:83393
GI



I

AB The present invention provides a novel pyridine derivative having the following general formula and its salt: I wherein R is a hydrogen atom, a hydroxyl group, an alkoxy group, an alkoxyalkoxy group, and derivs.; R1 and R2 may be the same or different, and are a hydrogen atom, an alkoxy group, a halogen atom, an alkylamino group, a dialkylamino group; Z is a methine group or a nitrogen atom; X1 is an acylamino group, a cycloalkyl group, a halogen-substituted alkoxy group, an alkenyloxy group, an alkynyloxy group, an alkoxycarbonyl group, an alkylamino group, a dialkylamino group, a Ph group. The pyridine derivative and its salt of the present invention achieve an excellent herbicidal effect on annual and perennial weeds growing in paddy fields and upland fields at a very small dosage. The pyridine derivative and its salt of the present invention are safe to rice, wheat, cotton and corn, and can be suitably applied as a herbicide to a field where these plants are cultivated.

IT **147078-07-7P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)

L4 ANSWER 26 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(herbicidal (pyrmidinylthio)- and (triazinylthio)pyridine derivs.)
RN 147078-07-7 CAPLUS
CN 3-Pyridinecarboxamide, 4-(3-chlorophenyl)-2-[(4,6-dimethoxy-2-pyrimidinyl)thio]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 27 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:316923 CAPLUS
DOCUMENT NUMBER: 122:97140
TITLE: Characterization of the binding of [125I]L-735,286: a new nonpeptide angiotensin II AT1 receptor radioligand
AUTHOR(S): Chen, T. B.; Brenner, N. J.; Gibson, R. E.; Burns, H. D.; Chang, R. S. L.
CORPORATE SOURCE: Dep. New Lead Pharm., Pharm. Merck Res. Labs., West Point, PA, 19486, USA
SOURCE: Life Sciences (1995), 56(8), 629-35
CODEN: LIFSAK; ISSN: 0024-3205
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
AB [125I]L-735,286, a new potent and AT1-selective nonpeptide angiotensin II receptor radioligand, bound saturably to whole adrenal membranes. Scatchard and Hill plot anal. indicates a single class of high affinity (Kd = 0.5 nM) binding sites. The potencies of various angiotensin II agonists and antagonists in displacing specific [125I]L-735,286 binding are in good agreement with their potencies in displacing the binding of [125I]Sar1,Ile8-AII to adrenal AT1 receptors. The AT2 selective ligand, PD121981 had no effect on specific [125I]L-735,286 binding. In autoradiog. studies using rat kidney slices, specific labeling of [125I]L-735,286 was abolished by coincubation with saralasin. Collectively, the data indicated that [125I]L-735,286 represents a new, potent nonpeptide antagonist radioligand suitable for the study of angiotensin II AT1 receptors.
IT 160632-48-4, L 735286
RL: ARG (Analytical reagent use); BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)
(L-735,286 as angiotensin AT1 receptor radioligand)
RN 160632-48-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4'-[(2-ethyl-4,6-dimethyl-1H-benzimidazol-1-yl)methyl][1,1'-biphenyl]-2-yl]sulfonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 28 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1994:700817 CAPLUS
DOCUMENT NUMBER: 121:300817
TITLE: Triazolinone Biphenylsulfonamide Derivatives as Orally Active Angiotensin II Antagonists with Potent AT1 Receptor Affinity and Enhanced AT2 Affinity
AUTHOR(S): Ashton, Wallace T.; Chang, Linda L.; Flanagan, Kelly L.; Hutchins, Steven M.; Naylor, Elizabeth M.; Chakravarty, Prasun K.; Patchett, Arthur A.; Greenlee, William J.; Chen, Tsing-Bau; Faust, Kristie A.; Chang, Raymond S. L.; Lotti, Victor J.; Zingaro, Gloria J.; Schorn, Terry W.; Siegl, Peter K. S.; Kivlighn, Salah D.
CORPORATE SOURCE: Merck Research Laboratories, Rahway, NJ, 07065, USA
SOURCE: Journal of Medicinal Chemistry (1994), 37(17), 2808-24
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Several series of 2,4-dihydro-2,4,5-trisubstituted-3H-1,2,4-triazol-3-ones with acidic sulfonamide replacements of tetrazole at the 2'-position of the biphenyl-4-ylmethyl side chain at N4 were prepared and tested as angiotensin II (AII) antagonists. Preferred substituents on the triazolinone ring were Bu at C5 and 2-(trifluoromethyl)phenyl at N2. Subnanomolar IC50 values at the AT1 receptor subtype were observed for a variety of acylsulfonamides, including aroyl, heteroaroyl, and cycloalkylcarbonyl derivs. Certain other acidic sulfonamides, such as sulfonylcarbamates and disulfimides also displayed high affinity for the AT1 receptor. In addition, AT2 binding for some of these compds. was increased by as much as 1000-fold over the corresponding tetrazole, e.g. AT2 IC50 17 nM for I (R = Me3CO). When evaluated for inhibition of the AII pressor response, the benchmark benzoylsulfonamide I (R = Ph) (L-159,913) was efficacious in several species and was superior to losartan in conscious rhesus monkeys. Several subsequent analogs, including the I (R = 2-ClC6H4 , 3-chlorothiophene-2-yl, (S)-2,2-dimethylcyclopropyl, Me3CO) derivs., were highly effective in rats, surpassing I (R = Ph) and losartan in duration of action and/or potency. Compound I (R = 2-ClC6H4) (L-162,223) displayed very prolonged AII antagonism in the rat model (>24 h at 1 mg/kg i.v.). At 1 mg/kg po in rats, I (R = 2-ClC6H4) and I (R = Me3CO) (L-162,234) produced 85-87% peak inhibition of the AII pressor response with duration exceeding 6 h. The

L4 ANSWER 28 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
identification of triazolinone-based sulfonamide derivs. combining high AT1 affinity, considerably enhanced AT2 potency, and favorable in vivo properties provides insights relevant to the design of dual AT1/AT2 receptor antagonists.
IT 159044-96-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and angiotensin II antagonist activity of)
RN 159044-96-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4'-[[3-butyl-1,5-dihydro-5-oxo-1-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-4-yl]methyl][1,1'-biphenyl]-2-yl]sulfonyl]-2-chloro- (9CI) (CA INDEX NAME)



L4 ANSWER 29 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1994:605212 CAPLUS
DOCUMENT NUMBER: 121:205212
TITLE: Preparation of nicotinamides as pesticides
INVENTOR(S): Toki, Tadaaki; Koyanagi, Toru; Morita, Masayuki; Yoneda, Tetsuo; Kagimoto, Chiharu; Okada, Hiroshi
PATENT ASSIGNEE(S): Ishihara Sangyo Kaisha, Ltd., Japan
SOURCE: Eur. Pat. Appl., 39 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 580374	A1	19940126	EP 1993-305622	19930716
EP 580374	B1	19960103		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 06321903	A2	19941122	JP 1993-214766	19930630
JP 2994182	B2	19991227		
CA 2100011	AA	19940124	CA 1993-2100011	19930707
CA 2100011	C	19980203		
ZA 9305042	A	19940405	ZA 1993-5042	19930713
IL 106340	A1	19990312	IL 1993-106340	19930714
SK 281481	B6	20010409	SK 1993-750	19930715
AT 132489	E	19960115	AT 1993-305622	19930716
ES 2085118	T3	19960516	ES 1993-305622	19930716
AU 9342106	A1	19940203	AU 1993-42106	19930721
AU 657056	B2	19950223		
BR 9302960	A	19940216	BR 1993-2960	19930722
RU 2083562	C1	19970710	RU 1993-50289	19930722
PL 173611	B1	19980430	PL 1993-299769	19930722
CN 1081670	A	19940209	CN 1993-109092	19930723
CN 1044233	B	19990721		
US 5360806	A	19941101	US 1993-95192	19930723
HU 68334	A2	19950628	HU 1993-2144	19930723
HU 214279	B	19980302		
CZ 286147	B6	20000112	CZ 1993-1502	19930723
PRIORITY APPLN. INFO.:			JP 1992-238804	A 19920723
			JP 1993-57668	A 19930205
			JP 1993-96428	A 19930317

OTHER SOURCE(S): MARPAT 121:205212
GI



I II

AB Title compds. [I; R = halomethyl; R1,R2 = H, (cyclo)alkyl, alkenyl,

L4 ANSWER 29 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
alkynsulfonyl, etc.; NR1R2 = heterocyclyl; X = O or S; m = 0 or 1] were prepd. Thus, 4-trifluoromethylpyridine-3-carboxylic acid was amidated by H2NCH2CN to give title compd. II which gave complete control of Myzus persicae larvae on eggplant leaf dipped in an 800ppm soln.
IT 158063-57-1P 158063-60-6P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as pesticide)
RN 158063-57-1 CAPLUS
CN 3-Pyridinecarboxamide, N-(methylsulfonyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 158063-60-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[(dimethylamino)sulfonyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 30 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1994:557652 CAPLUS
DOCUMENT NUMBER: 121:157652
TITLE: {[(Tetrazolylbiphenylyl)methyl]amino}pyridinecarboxylates as Angiotensin II Receptor Antagonists
INVENTOR(S): Winn, Martin; De, Biswanath; Zydowsky, Thomas M.; Kerkman, Daniel J.; Debernardis, John F.; Rosenberg, Saul H.; Shiosaki, Kazumi; Basha, Fatima Z.; Tasker, Andrew S.; et al.
PATENT ASSIGNEE(S): Abbott laboratories, USA
SOURCE: U.S., 98 pp. Cont.-in-part of U.S. Ser. No. 744,241.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5250548	A	19931005	US 1992-844351	19920302
CA 2050723	AA	19920311	CA 1991-2050723	19910905
AU 9183744	A1	19920312	AU 1991-83744	19910909
AU 647174	B2	19940317		
JP 04261156	A2	19920917	JP 1991-258343	19910910
JP 07053551	A2	19950228	JP 1993-187412	19930630
PRIORITY APPLN. INFO.:			US 1990-580400	B2 19900910
			US 1991-744241	A2 19910815

OTHER SOURCE(S): MARPAT 121:157652
GI



I

AB The title compds., [{(tetrazolylbiphenylyl)methyl]amino}pyridinecarboxylates I (R3 = H, alkyl, halo; R5 = alkyl) were disclosed. Pharmacol. test data for I as angiotensin receptor antagonists were reported.
IT 151323-15-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as angiotensin antagonist)
RN 151323-15-8 CAPLUS
CN 3-Pyridinecarboxamide, N-(phenylsulfonyl)-2-{propyl[{2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amino}- (9CI) (CA INDEX NAME)

L4 ANSWER 30 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





IT 157362-03-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for [{(tetrazolylbiphenylyl)methyl]amino}pyrimidinecarboxylate)
RN 157362-03-3 CAPLUS
CN 3-Pyridinecarboxamide, N-(phenylsulfonyl)-2-{propyl[{2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]amino}- (9CI) (CA INDEX NAME)



L4 ANSWER 31 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1994:457525 CAPLUS
DOCUMENT NUMBER: 121:57525
TITLE: Preparation of pyrimidine derivatives as herbicides
INVENTOR(S): Myazaki, Masahiro; Matsuzawa, Masafumi; Toyabe, Keiji; Hirata, Micha
PATENT ASSIGNEE(S): Kumiai Chemical Industry Co, Japan; Ihara Chemical Ind Co
SOURCE: Jpn. Kokai Tokkyo Koho, 79 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 06041116	A2	19940215	JP 1992-97313	19920325
JP 3217848	B2	20011015		
PRIORITY APPLN. INFO.:			JP 1992-97313	19920325

OTHER SOURCE(S): MARPAT 121:57525
GI



AB The title compds. [I; R = OH, alkoxy, benzyloxy, etc.; R1, R2 = alkoxy, alkyl, halo, etc. ; X = alkyl, alkoxy, (un)substituted Ph, etc.; W = O, S, etc.; ; Z = methine, N ; n = 0 - 3] are prepared A mixture of hydroxynicotinic acid ester II, K2CO3, and chloropyrimidine III in DMF was heated at 100° for 4 h to give pyrimidine IV. IV at 10 g/are gave 70 - 90% control of Echinochloa oryzicola.
IT 147078-07-7P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as herbicide)

L4 ANSWER 31 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 147078-07-7 CAPLUS
CN 3-Pyridinecarboxamide, 4-(3-chlorophenyl)-2-[(4,6-dimethoxy-2-pyrimidinyl)thio]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 32 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1994:435344 CAPLUS
DOCUMENT NUMBER: 121:35344
TITLE: Preparation of sulfonamidopyridine-2-carboxylic acid esters and N-oxides thereof as fibrosuppressants.
INVENTOR(S): Weidmann, Klaus; Bickel, Martin; Gunzler-Pukall, Volkmar; Baringhaus, Karl Heinz
PATENT ASSIGNEE(S): Hoechst A.-G., Germany
SOURCE: Eur. Pat. Appl., 91 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 590520	A1	19940406	EP 1993-115361	19930923
EP 590520	B1	19960612		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
DE 4233124	A1	19940407	DE 1992-4233124	19921002
US 5428046	A	19950627	US 1993-124683	19930922
AT 139227	E	19960615	AT 1993-115361	19930923
ES 2090806	T3	19961016	ES 1993-115361	19930923
CN 1089603	A	19940720	CN 1993-118248	19930929
IL 107155	A1	19990922	IL 1993-107155	19930929
FI 9304303	A	19940403	FI 1993-4303	19930930
FI 103881	B1	19991015		
CZ 283869	B6	19980617	CZ 1993-2044	19930930
CA 2107514	AA	19940403	CA 1993-2107514	19931001
NO 9303521	A	19940405	NO 1993-3521	19931001
NO 180085	B	19961104		
NO 180085	C	19970212		
AU 9348726	A1	19940414	AU 1993-48726	19931001
AU 662448	B2	19950831		
ZA 9307298	A	19940425	ZA 1993-7298	19931001
HU 67292	A2	19950328	HU 1993-2778	19931001
RU 2117660	C1	19980820	RU 1993-56156	19931001
PL 176772	B1	19990730	PL 1993-300561	19931001
JP 06211795	A2	19940802	JP 1993-247717	19931004
PRIORITY APPLN. INFO.:			DE 1992-4233124 A	19921002

OTHER SOURCE(S): MARPAT 121:35344
GI



AB Title compds. [I; A = R3, B = XNR5R6, or B = R3, A = XNR5R6; X = bond, CO; R1-R3 = H, alkyl, alkoxy, halo, cyano, OH, amino; R4 = (substituted) acyloxyalkyl, alkyl, alkenyl, alkynyl, alkenynyl, aryl, aralkyl, heteroaryl; R5 = H, alkyl, protecting group, physiol. acceptable cation; R6 = Y(CU)rDW; Y = SO2, CO; C = bond, (substituted) (cyclo)alkanediyl,

L4 ANSWER 32 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(cyclo)alkenediyl, alkynediyl, alkenyndiyl; U = bond, H, CO, CO2, O, SO, SO2, CONH, etc.; D = bond, H, (substituted) alkanediyl, alkenediyl, alkynediyl, alkenyndiyl; W = bond, H, (substituted) cycloaliphatyl, aryl, heteroaryl; n = 0, 1; r = 1-4; with provisos], were prepd. Thus, a soln. of 4-methoxybenzenesulfonamide in THF at 0° was treated with KOCMe3 and then with a soln. of 2-methoxycarbonylpyridine-5-carbonyl chloride; the mixt. was stirred 3 h while warming to room temp. to give Me 5-[[(4-methoxyphenylsulfonyl)amino]carbonyl]pyridine-2-carboxylate. This was sapond. with NaOH in MeOH/H2O followed by esterification with 2-propanol/conc. H2SO4 to give title compd. II. In the CCl4-induced liver fibrosis test in rats, I were active at 1-100 mg/kg orally or i.p.
IT 155881-76-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 155881-76-8 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[(phenoxyacetyl)amino]phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



IT 138834-65-8P 138834-71-6P 138834-75-0P
152457-91-5P 152458-01-0P 152458-04-3P
155881-74-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for drug for treatment of fibrotic disease)
RN 138834-65-8 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[(phenylsulfonyl)amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 138834-71-6 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[(4-methoxyphenyl)sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 138834-75-0 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[(phenylsulfonyl)amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 152457-91-5 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[(4-methoxyphenyl)sulfonyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 152458-01-0 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[[(2-phenylethyl)amino]carbonyl]phenyl]sulfonyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 152458-04-3 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[2-[(2-chloro-5-methoxybenzoyl)amino]ethyl]phenyl]sulfonyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 152457-97-1 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-(trifluoromethoxy)phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 152458-00-9 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[[(2-phenylethyl)amino]carbonyl]phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 152458-02-1 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[2-[(2-chloro-5-methoxybenzoyl)amino]ethyl]phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 152458-06-5 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[(1-oxo-4-phenylbutyl)amino]phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 155881-74-6 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[[(3-ethoxypropyl)amino]carbonyl]phenyl]sulfonyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



IT 152457-92-6P 152457-96-0P 152457-97-1P
152458-00-9P 152458-02-1P 152458-06-5P
155881-39-3P 155881-40-6P 155881-41-7P
155881-42-8P 155881-43-9P 155881-44-0P
155881-45-1P 155881-46-2P 155881-47-3P
155881-48-4P 155881-49-5P 155881-50-8P
155881-51-9P 155881-52-0P 155881-53-1P
155881-54-2P 155881-55-3P 155881-56-4P
155881-57-5P 155881-58-6P 155881-59-7P
155881-60-0P 155881-61-1P 155881-62-2P
155881-63-3P 155881-64-4P 155881-65-5P
155881-66-6P 155881-67-7P 155881-68-8P
155881-69-9P 155881-70-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for treatment of fibrotic disease)

RN 152457-92-6 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[(4-fluorophenyl)sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 152457-96-0 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[(4-butoxyphenyl)sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 155881-39-3 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[(4-methoxyphenyl)sulfonyl]amino]carbonyl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 155881-40-6 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[(phenylsulfonyl)amino]carbonyl]-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)



RN 155881-41-7 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[(butylsulfonyl)amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 155881-42-8 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[[(3-phenylpropyl)amino]carbonyl]phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 155881-43-9 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[[(4-phenylbutyl)amino]carbonyl]phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 155881-44-0 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[[[2-(4-methoxyphenyl)ethyl]amino]carbonyl]phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 155881-45-1 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]carbonyl]phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 155881-46-2 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[[[2-(2-methoxyphenyl)ethyl]amino]carbo

L4 ANSWER 32 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 155881-50-8 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[2-(benzoylamino)ethyl]phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 155881-51-9 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenyl]sulfonyl]amino]carbonyl]-, methyl ester, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 155881-52-0 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 155881-53-1 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[2-[(1-oxo-3-phenylpropyl)amino]ethyl]phenyl]sulfonyl]amino]carbonyl]-, methyl ester, monosodium salt (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
nyl]phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 155881-47-3 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[[(3-ethoxypropyl)amino]carbonyl]phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 155881-48-4 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[2-[(1-oxopentyl)amino]ethyl]phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 155881-49-5 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[2-[(1-oxobutyl)amino]ethyl]phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 32 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 155881-54-2 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[2-[(phenoxyacetyl)amino]ethyl]phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 155881-55-3 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[2-[(cyclohexylacetyl)amino]ethyl]phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 155881-56-4 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[2-[(2-methyl-1-oxopropyl)amino]ethyl]phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 32 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 155881-57-5 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[(acetylamino)methyl]phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 155881-58-6 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[2-[(3-methyl-1-oxobutyl)amino]ethyl]phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 155881-59-7 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[2-[(4-methyl-1-oxopentyl)amino]ethyl]phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 155881-60-0 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[[(3-methyl-1-oxobutyl)amino]methyl]phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 155881-64-4 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[[(3-ethoxypropyl)amino]carbonyl]phenyl]sulfonyl]amino]carbonyl]-, 1-methylethyl ester, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 155881-65-5 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[2-chloro-4-[[(2-phenylethyl)amino]carbonyl]phenyl]sulfonyl]amino]carbonyl]-, methyl ester, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 155881-66-6 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[2-chloro-4-[[(3-ethoxypropyl)amino]carbonyl]phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 155881-67-7 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[2-(acetylamino)ethyl]phenyl]sulfonyl]amino]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 32 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 155881-61-1 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[[(4-methyl-1-oxopentyl)amino]methyl]phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 155881-62-2 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[[(2-phenylethyl)amino]carbonyl]phenyl]sulfonyl]amino]carbonyl]-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)



RN 155881-63-3 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[3-[[(2-phenylethyl)amino]carbonyl]phenyl]sulfonyl]amino]carbonyl]-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 32 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 155881-68-8 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[2-[(2-chloro-5-methoxybenzoyl)amino]ethyl]phenyl]sulfonyl]amino]carbonyl]-, 1-ethylpropyl ester (9CI) (CA INDEX NAME)



RN 155881-69-9 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[2-[[(3,4-dimethoxyphenyl)acetyl]amino]ethyl]phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 155881-70-2 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[[[2-(4-methoxyphenyl)ethyl]amino]carbonyl]phenyl]sulfonyl]amino]carbonyl]-, methyl ester, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 155881-44-0
CMF C24 H23 N3 O7 S

L4 ANSWER 32 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 77-86-1
CMF C4 H11 N O3



L4 ANSWER 33 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1994:270116 CAPLUS
DOCUMENT NUMBER: 120:270116
TITLE: Preparation of 4- or 5-(sulf)imido- and -(sulfon)amidopyridines and their N-oxides as fibrosuppressive agents
INVENTOR(S): Weidmann, Klaus; Bickel, Martin; Guenzler-Pukall, Volkmar
PATENT ASSIGNEE(S): Hoechst A.-G., Germany
SOURCE: Eur. Pat. Appl., 73 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 567997	A1	19931103	EP 1993-106797	19930427
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
ZA 9302983	A	19931115	ZA 1993-2983	19930428
CA 2095206	AA	19931031	CA 1993-2095206	19930429
NO 9301560	A	19931101	NO 1993-1560	19930429
AU 9338225	A1	19931104	AU 1993-38225	19930429
CN 1079466	A	19931215	CN 1993-105255	19930429
JP 06087831	A2	19940329	JP 1993-128332	19930430
PRIORITY APPLN. INFO.:			DE 1992-4214465 A	19920430
			DE 1992-4224440 A	19920724

OTHER SOURCE(S): MARPAT 120:270116
GI



AB Title compds. [I; 1 of A,B = R3 and the other = XNR6R7; R1-R3 = H, alkyl, alkoxy, halo, etc.; R4 = a group physiol. convertable to a carboxylate function; R4 = ester or amide; R6 = H, alkyl, protective group, etc.; R7 = YR8; R8 = H, cycloalk(en)yl, (hetero)aryl, etc.; X = bond, CO; Y = SO2, CO, etc.; n = 0 or 1] were prepared as fibrosuppressives (no data). Thus, Me 5-aminopyridine-2-carboxylate was amidated by 4-FC6H4SO2Cl and the product treated with LAH to give title compd, II.

IT 153685-23-5P 153685-24-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of fibrosuppressive agent)

RN 153685-23-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-(hydroxymethyl)-N-[[4-[[(2-phenylethyl)amino]carbonyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 33 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 153685-24-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-[2-[(2-chloro-5-methoxybenzoyl)amino]ethyl]phenyl]sulfonyl]-6-(chloromethyl)-, monosodium salt (9CI) (CA INDEX NAME)



● Na

IT 153684-98-1P 153684-99-2P 153685-03-1P
153685-04-2P 153685-05-3P 153685-06-4P
153685-07-5P 153685-08-6P 153685-09-7P
153685-10-0P 153685-11-1P 153685-12-2P
153685-13-3P 153685-14-4P 153685-15-5P
153685-16-6P 153685-17-7P 153685-18-8P
153685-19-9P 153685-20-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as fibrosuppressive agent)

RN 153684-98-1 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(phenylmethoxy)methyl]-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 153684-99-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-(hydroxymethyl)-N-[(4-phenoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 33 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 153685-03-1 CAPLUS
CN 3-Pyridinecarboxamide, 6-(ethoxymethyl)-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 153685-04-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[(4-butoxyphenyl)sulfonyl]-6-(methoxymethyl)- (9CI) (CA INDEX NAME)



RN 153685-05-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[(4-butoxyphenyl)sulfonyl]-6-(hydroxymethyl)- (9CI) (CA INDEX NAME)



RN 153685-06-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-(hydroxymethyl)-N-[[4-[[(2-phenylethyl)amino]carbonyl]phenyl]sulfonyl]-, monoammonium salt (9CI) (CA INDEX NAME)

L4 ANSWER 33 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● NH_3

RN 153685-07-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-[2-[(2-chloro-5-methoxybenzoyl)amino]ethyl]phenyl]sulfonyl]-6-(hydroxymethyl)-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 153685-08-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-[(butylamino)carbonyl]phenyl]sulfonyl]-6-[(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)



RN 153685-09-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-[2-[(2-methyl-1-oxopropyl)amino]ethyl]phenyl]sulfonyl]-6-[(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 33 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 153685-13-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-[2-[(cyclohexylacetyl)amino]ethyl]phenyl]sulfonyl]-6-(ethoxymethyl)- (9CI) (CA INDEX NAME)



RN 153685-14-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-(ethoxymethyl)-N-[[4-[2-[(1-oxohexyl)amino]ethyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 153685-15-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-(ethoxymethyl)-N-[[4-[2-[(4-methyl-1-oxopentyl)amino]ethyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 153685-16-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-[(butylamino)carbonyl]phenyl]sulfonyl]-6-(ethoxymethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 33 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 153685-10-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-[2-[(4-methyl-1-oxopentyl)amino]ethyl]phenyl]sulfonyl]-6-[(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

$-CH_2-Ph$

RN 153685-11-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-[[(2-phenylethyl)amino]carbonyl]phenyl]sulfonyl]-6-[(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)



RN 153685-12-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-(ethoxymethyl)-N-[[4-[[(2-phenylethyl)amino]carbonyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 33 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 153685-17-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[[3-[(butylamino)carbonyl]phenyl]sulfonyl]-6-(ethoxymethyl)- (9CI) (CA INDEX NAME)



RN 153685-18-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[[2-chloro-5-[[[2-(4-fluorophenyl)ethyl]amino]carbonyl]phenyl]sulfonyl]-6-(hydroxymethyl)-, monoammonium salt (9CI) (CA INDEX NAME)



● NH_3

RN 153685-19-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-[2-[(cyclohexylacetyl)amino]ethyl]phenyl]sulfonyl]-6-(hydroxymethyl)-, monoammonium salt (9CI) (CA INDEX NAME)



● NH_3

RN 153685-20-2 CAPLUS

L4 ANSWER 33 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 3-Pyridinecarboxamide, 6-(hydroxymethyl)-N-[[4-[2-[(2-methyl-1-oxopropyl)amino]ethyl]phenyl]sulfonyl]-, monoammonium salt (9CI) (CA INDEX NAME)



● NH_3

L4 ANSWER 34 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1994:106786 CAPLUS
DOCUMENT NUMBER: 120:106786
TITLE: Preparation of sulfonamido(carbon)pyridine-2-carboxamides as bibrosuppressives
INVENTOR(S): Weidmann, Klaus; Bickel, Martin; Guenzler-Pukall, Volkmar
PATENT ASSIGNEE(S): Hoechst A.-G., Germany
SOURCE: Eur. Pat. Appl., 92 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 562512	A1	19930929	EP 1993-104658	19930322
EP 562512	B1	20010221		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
FI 102895	B1	19990315	FI 1993-1250	19930322
SK 280884	B6	20000912	SK 1993-223	19930322
AT 199250	E	20010315	AT 1993-104658	19930322
ES 2154266	T3	20010401	ES 1993-104658	19930322
PT 562512	T	20010629	PT 1993-104658	19930322
CA 2092276	AA	19930925	CA 1993-2092276	19930323
NO 9301056	A	19930927	NO 1993-1056	19930323
NO 179867	B	19960923		
NO 179867	C	19970102		
CN 1076691	A	19930929	CN 1993-103349	19930323
AU 9335369	A1	19930930	AU 1993-35369	19930323
AU 657608	B2	19950316		
ZA 9302047	A	19931019	ZA 1993-2047	19930323
JP 06049030	A2	19940222	JP 1993-63723	19930323
PL 173677	B1	19980430	PL 1993-298195	19930323
RU 2129545	C1	19990427	RU 1993-4764	19930323
HU 69685	A2	19950928	HU 1993-850	19930324
HU 219224	B	20010328		
US 5607954	A	19970304	US 1994-355419	19941213
HK 1011987	A1	20010824	HK 1998-113239	19981211
GR 3035479	T3	20010531	GR 2001-400321	20010228

PRIORITY APPLN. INFO.:			
	DE 1992-4209424	A	19920324
	DE 1992-4238506	A	19921114
	US 1993-28438	B1	19930309

OTHER SOURCE(S): MARPAT 120:106786
GI

L4 ANSWER 34 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I

II

AB Title compds. [I; 1 of A, B = R3 and the other = XNR6R7; R1-R3 = H, halo, alkyl, alkoxy, etc.; R4, R5 = H, alkoxy, alkyl, aryl, etc.; R6 = H, alkyl, N-protective group, etc.; R7 = Y(ZU)rDW; X = bond or CO; Y = CO or SO2; Z = bond, H, alk(en)ylene, etc.; U = null, bond, H, CO, O, SO2, etc.; D = null, bond, H, alk(en)ylene, etc.; W = null, bond (sic), H, alk(en)yl, etc.; n = 0 or 1; r = 1-4] were prepared Thus, 2-methoxycarbonylpyridine-5-carboxylic acid was treated with SOCl2 and the product condensed with 4-(MeO)C6H4SO2NH2 to give, after amidation with HOCH2CH2NH2, title compound II. I were effective (sic) at 1-100 ng/kg orally or i.p. in the CCl4-induced liver fibrosis model employing rats.

IT **138834-65-8P 138834-71-6P 152457-91-5P 152457-92-6P 152457-93-7P 152457-96-0P 152457-97-1P 152458-00-9P 152458-01-0P 152458-02-1P 152458-04-3P 152458-06-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of fibrosuppressive agent)

RN 138834-65-8 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[(phenylsulfonyl)amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 138834-71-6 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[(4-methoxyphenyl)sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 152457-91-5 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[(4-methoxyphenyl)sulfonyl]amino]carbonyl]-(9CI) (CA INDEX NAME)



RN 152457-92-6 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[(4-fluorophenyl)sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 152457-93-7 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[(4-fluorophenyl)sulfonyl]amino]carbonyl]-(9CI) (CA INDEX NAME)



RN 152457-96-0 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[(4-butoxyphenyl)sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 152457-97-1 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-(trifluoromethoxy)phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 152458-00-9 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[[(2-phenylethyl)amino]carbonyl]phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 152458-01-0 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[[(2-phenylethyl)amino]carbonyl]phenyl]sulfonyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 152458-02-1 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[2-[(2-chloro-5-methoxybenzoyl)amino]ethyl]phenyl]sulfonyl]amino]carbonyl]-, methyl ester

L4 ANSWER 34 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(9CI) (CA INDEX NAME)



RN 152458-04-3 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[2-[(2-chloro-5-methoxybenzoyl)amino]ethyl]phenyl]sulfonyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 152458-06-5 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-[(1-oxo-4-phenylbutyl)amino]phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



IT **152457-41-5P 152457-42-6P 152457-43-7P**
152457-48-2P 152457-49-3P 152457-50-6P
152457-51-7P 152457-52-8P 152457-53-9P
152457-54-0P 152457-55-1P 152457-56-2P
152457-57-3P 152457-58-4P 152457-59-5P
152457-60-8P 152457-61-9P 152457-62-0P
152457-63-1P 152457-64-2P 152457-65-3P
152457-66-4P 152457-67-5P 152457-68-6P
152457-69-7P 152457-70-0P 152457-71-1P
152457-72-2P 152457-73-3P 152457-74-4P
152457-75-5P 152457-76-6P 152457-77-7P
152457-78-8P 152457-79-9P 152457-80-2P
152457-81-3P 152457-82-4P 152457-83-5P
152457-84-6P 152457-85-7P 152457-86-8P

L4 ANSWER 34 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
152457-87-9P 152457-88-0P 152457-89-1P
152457-90-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as fibrosuppressive agent)
RN 152457-41-5 CAPLUS
CN 2,5-Pyridinedicarboxamide, N2-(2-hydroxyethyl)-N5-[(4-methoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 152457-42-6 CAPLUS
CN Glycine, N-[[5-[[[(4-methoxyphenyl)sulfonyl]amino]carbonyl]-2-pyridinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 152457-43-7 CAPLUS
CN 2,5-Pyridinedicarboxamide, N2-(2-hydroxyethyl)-N5-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 152457-48-2 CAPLUS
CN 2,5-Pyridinedicarboxamide, N5-[(4-butoxyphenyl)sulfonyl]-N2-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 152457-49-3 CAPLUS
CN 2,5-Pyridinedicarboxamide, N2-(2-hydroxyethyl)-N5-[[4-(trifluoromethoxy)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 152457-50-6 CAPLUS
CN 2,5-Pyridinedicarboxamide, N5-[[2,5-bis(2,2,2-trifluoroethoxy)phenyl]sulfonyl]-N2-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 152457-51-7 CAPLUS
CN 2,5-Pyridinedicarboxamide, N5-(butylsulfonyl)-N2-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 152457-52-8 CAPLUS
CN 2,5-Pyridinedicarboxamide, N2-(2-hydroxyethyl)-N5-[[4-[3-(trifluoromethyl)phenoxy]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 152457-53-9 CAPLUS
CN 2,5-Pyridinedicarboxamide, N2-(2-methoxyethyl)-N5-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 152457-54-0 CAPLUS
CN Glycine, N-[[5-[[(phenylsulfonyl)amino]carbonyl]-2-pyridinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 152457-55-1 CAPLUS
CN Glycine, N-[[5-[[(phenylsulfonyl)amino]carbonyl]-2-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 34 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
PAGE 1-B

RN 152457-59-5 CAPLUS
CN 2,5-Pyridinedicarboxamide, N5-[[4-[(butylamino)carbonyl]phenyl]sulfonyl]-N2-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)



RN 152457-60-8 CAPLUS
CN 2,5-Pyridinedicarboxamide, N2-(2-hydroxyethyl)-N5-[[3-[[(2-phenylethyl)amino]carbonyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 152457-61-9 CAPLUS
CN 2,5-Pyridinedicarboxamide, N5-[[4-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]carbonyl]phenyl]sulfonyl]-N2-(2-methoxyethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 152457-62-0 CAPLUS
CN Glycine, N-[[5-[[[[4-[[(2-phenylethyl)amino]carbonyl]phenyl]sulfonyl]amino

L4 ANSWER 34 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 152457-56-2 CAPLUS
CN 2,5-Pyridinedicarboxamide, N2-(2-hydroxyethyl)-N5-[[4-[[(2-phenylethyl)amino]carbonyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 152457-57-3 CAPLUS
CN 2,5-Pyridinedicarboxamide, N2-(2-hydroxyethyl)-N5-[[4-[[[2-(4-methoxyphenyl)ethyl]amino]carbonyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 152457-58-4 CAPLUS
CN 2,5-Pyridinedicarboxamide, N5-[[4-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]carbonyl]phenyl]sulfonyl]-N2-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 34 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
]carbonyl]-2-pyridinyl]carbonyl]-, methyl ester, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 152457-63-1 CAPLUS
CN Glycine, N-[[5-[[[[4-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]carbonyl]phenyl]sulfonyl]amino]carbonyl]-2-pyridinyl]carbonyl]-, methyl ester, monosodium salt (9CI) (CA INDEX NAME)

PAGE 1-A



● Na

PAGE 1-B

RN 152457-64-2 CAPLUS
CN Glycine, N-[[5-[[[[4-[(butylamino)carbonyl]phenyl]sulfonyl]amino]carbonyl]-2-pyridinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



Habte

L4 ANSWER 34 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 152457-65-3 CAPLUS
CN Glycine, N-[[5-[[[[4-[[(3-ethoxypropyl)amino]carbonyl]phenyl]sulfonyl]amino]carbonyl]-2-pyridinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 152457-66-4 CAPLUS
CN Glycine, N-[[5-[[[[3-[(butylamino)carbonyl]phenyl]sulfonyl]amino]carbonyl]-2-pyridinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 152457-67-5 CAPLUS
CN Glycine, N-[[5-[[[[3-[(butylamino)carbonyl]phenyl]sulfonyl]amino]carbonyl]-2-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 152457-68-6 CAPLUS
CN Glycine, N-[[5-[[[[4-[[[2-(3,4-dimethoxyphenyl)ethyl]amino]carbonyl]phenyl]sulfonyl]amino]carbonyl]-2-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 152457-72-2 CAPLUS
CN 2,5-Pyridinedicarboxamide, N5-[[4-[2-[(2-chloro-5-methoxybenzoyl)amino]ethyl]phenyl]sulfonyl]-N2-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OH

RN 152457-73-3 CAPLUS
CN 2,5-Pyridinedicarboxamide, N5-[[4-[2-[[3-(3,4-dimethoxyphenyl)-1-oxopropyl]amino]ethyl]phenyl]sulfonyl]-N2-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



L4 ANSWER 34 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B

—CO_2H

RN 152457-69-7 CAPLUS
CN Glycine, N-[[5-[[[[4-[(butylamino)carbonyl]phenyl]sulfonyl]amino]carbonyl]-2-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 152457-70-0 CAPLUS
CN Glycine, N-[[5-[[[[4-[[(3-ethoxypropyl)amino]carbonyl]phenyl]sulfonyl]amino]carbonyl]-2-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 152457-71-1 CAPLUS
CN Glycine, N-[[5-[[[[4-[[(2-phenylethyl)amino]carbonyl]phenyl]sulfonyl]amino]carbonyl]-2-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 152457-74-4 CAPLUS
CN 2,5-Pyridinedicarboxamide, N2-(2-hydroxyethyl)-N5-[[4-[2-[(phenoxyacetyl)amino]ethyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OH

RN 152457-75-5 CAPLUS
CN 2,5-Pyridinedicarboxamide, N2-(2-hydroxyethyl)-N5-[[4-[2-[(4-methyl-1-oxopentyl)amino]ethyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—CH_2-CH_2-OH

RN 152457-76-6 CAPLUS
CN 2,5-Pyridinedicarboxamide, N5-[[4-[2-[[3-(3,4-dimethoxyphenyl)-1-oxopropyl]amino]ethyl]phenyl]sulfonyl]-N2-(2-methoxyethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



RN 152457-77-7 CAPLUS
CN 2,5-Pyridinedicarboxamide, N2-(2-methoxyethyl)-N5-[[4-[2-[(4-methyl-1-oxopentyl)amino]ethyl]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 152457-78-8 CAPLUS
CN Glycine, N-[[5-[[[[4-[2-[(2-chloro-5-methoxybenzoyl)amino]ethyl]phenyl]sulfonyl]amino]carbonyl]-2-pyridinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B



RN 152457-81-3 CAPLUS
CN Glycine, N-[[5-[[[[4-[2-[(3,4-diethoxybenzoyl)amino]ethyl]phenyl]sulfonyl]amino]carbonyl]-2-pyridinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 152457-82-4 CAPLUS
CN Glycine, N-[[5-[[[[4-[2-[(cyclohexylacetyl)amino]ethyl]phenyl]sulfonyl]amino]carbonyl]-2-pyridinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 152457-83-5 CAPLUS
CN Glycine, N-[[5-[[[[4-[2-[(2-methyl-1-oxopropyl)amino]ethyl]phenyl]sulfonyl]amino]carbonyl]-2-pyridinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 34 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 152457-79-9 CAPLUS
CN Glycine, N-[[5-[[[[4-[2-[(1-oxohexyl)amino]ethyl]phenyl]sulfonyl]amino]carbonyl]-2-pyridinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

RN 152457-80-2 CAPLUS
CN Glycine, N-[[5-[[[[4-[2-[[3-(3,4-dimethoxyphenyl)-1-oxopropyl]amino]ethyl]phenyl]sulfonyl]amino]carbonyl]-2-pyridinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 34 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 152457-84-6 CAPLUS
CN Glycine, N-[[5-[[[[4-[2-[(4-methyl-1-oxopentyl)amino]ethyl]phenyl]sulfonyl]amino]carbonyl]-2-pyridinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 152457-85-7 CAPLUS
CN Glycine, N-[[5-[[[[4-[2-[(1-oxohexyl)amino]ethyl]phenyl]sulfonyl]amino]carbonyl]-2-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 34 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B

—CO_2H

RN 152457-86-8 CAPLUS
CN Glycine, N-[[5-[[[[4-[2-[(3,4-diethoxybenzoyl)amino]ethyl]phenyl]sulfonyl]amino]carbonyl]-2-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—CO_2H

RN 152457-87-9 CAPLUS
CN Glycine, N-[[5-[[[[4-[2-[(cyclohexylacetyl)amino]ethyl]phenyl]sulfonyl]amino]carbonyl]-2-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 34 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT **152457-98-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of fibrosuppressive agent)
RN 152457-98-2 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[2,5-bis(2,2,2-trifluoroethoxy)phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 34 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-B

—CO_2H

RN 152457-88-0 CAPLUS
CN Glycine, N-[[5-[[[[4-[2-[(2-methyl-1-oxopropyl)amino]ethyl]phenyl]sulfonyl]amino]carbonyl]-2-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 152457-89-1 CAPLUS
CN Glycine, N-[[5-[[[[4-[2-[(4-methyl-1-oxopentyl)amino]ethyl]phenyl]sulfonyl]amino]carbonyl]-2-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—CH_2-CO_2H

RN 152457-90-4 CAPLUS
CN 2,5-Pyridinedicarboxamide, N2-(2-hydroxyethyl)-N5-[[4-[(1-oxo-4-phenylbutyl)amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 35 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1994:100174 CAPLUS
DOCUMENT NUMBER: 120:100174
TITLE: Novel inhibitors of prolyl 4-hydroxylase. 5. The intriguing structure-activity relationships seen with 2,2'-bipyridine and its 5,5'-dicarboxylic acid derivatives
AUTHOR(S): Hales, Neil J.; Beattie, John F.
CORPORATE SOURCE: Infect. Res. Dep., Zeneca Pharm., Macclesfield/Cheshire, SK10 4TG, UK
SOURCE: Journal of Medicinal Chemistry (1993), 36(24), 3853-8
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB Members of a series of 2,2'-bipyridines have been synthesized and tested as inhibitors of prolyl hydroxylase (EC 1.14.11.2). The structure-activity relationships seen with [2,2'-bipyridine]-5-carboxylic acid (I) closely resemble those of pyridine-2-carboxylic acid (II). Accordingly, [2,2'-bipyridine]-5,5'-dicarboxylic acid (III, IC50 = 0.19 μM) is the most potent inhibitor of its type yet reported. However, 2,2'-bipyridines lacking a 5-carboxylate are poor inhibitors. These contrasting structure-activity relationships are discussed in terms of net anionic charge, iron chelation, and the availability of alternative putative binding modes at a single binding site in each catalytic subunit. This series of inhibitors may provide insight for the design of drugs effective in the inhibition of excess collagen deposition.
IT **152365-37-2P 152365-39-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of and prolyl hydroxylase inhibition by, structure in relation to)
RN 152365-37-2 CAPLUS
CN [2,2'-Bipyridine]-5-carboxamide, N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 152365-39-4 CAPLUS
CN [2,2'-Bipyridine]-5,5'-dicarboxamide, N,N'-bis(phenylsulfonyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 35 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 36 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1993:671084 CAPLUS
DOCUMENT NUMBER: 119:271084
TITLE: 2-(Alkylamino)nicotinic acid and analogs. Potent angiotensin II antagonists
AUTHOR(S): Winn, Martin; De, Biswanath; Zydowsky, Thomas M.; Altenbach, Robert J.; Basha, Fatima Z.; Boyd, Steven A.; Brune, Michael E.; Buckner, Steven A.; Crowell, DeAnne; et al.
CORPORATE SOURCE: Cardiovas. Res. Div., Abbott Lab., Abbott Park, IL, 60064, USA
SOURCE: Journal of Medicinal Chemistry (1993), 36(18), 2676-88
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB A series of pyridines and other six-membered ring heterocycles connected to a biphenyl-tetrazole with a -CH2-NR1-link were discovered to be potent angiotensin II antagonists. In the pyrimidine carboxylic acid series I (W = CR, X = N, Y = CH, Z = COOH), compds. with an alkyl group (R1) on the exocyclic nitrogen were much more potent than compds. with an alkyl group (R) on the heterocyclic ring. The corresponding pyridine, pyridazine, pyrazine, and 1,2,4-triazine carboxylic acids also showed potent in vitro angiotensin II antagonism. The pyridine I (W, X, Y = CH, Z = COOH, R1 = n-C3H7) demonstrated potent in vitro activity (pA2 = 10.10, rabbit aorta, and Ki = 0.61 nM, receptor binding in rat liver) as well as exceptional oral antihypertensive activity and bioavailability. Any nonacidic replacement for the carboxylic acid was detrimental for activity.

IT **151323-15-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and angiotensin II antagonist activity of)

RN 151323-15-8 CAPLUS
CN 3-Pyridinecarboxamide, N-(phenylsulfonyl)-2-[propyl[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amino]- (9CI) (CA INDEX NAME)

L4 ANSWER 36 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





IT **151323-51-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 151323-51-2 CAPLUS
CN 3-Pyridinecarboxamide, N-(phenylsulfonyl)-2-[propyl[[2'-[2-(triphenylmethyl)-2H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]amino]- (9CI) (CA INDEX NAME)



L4 ANSWER 37 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1993:254964 CAPLUS
DOCUMENT NUMBER: 118:254964
TITLE: Preparation of (pyridylthio- or pyridyloxy)pyrimidine or -triazine derivatives as herbicides
INVENTOR(S): Miyazaki, Masahiro; Matsuzawa, Masafumi; Toriyabe, Keiji; Hirata, Michiya
PATENT ASSIGNEE(S): Kumiai Chemical Industry Co., Ltd., Japan; Ihara Chemical Industry Co., Ltd.
SOURCE: PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9217468	A1	19921015	WO 1992-JP362	19920326
W: AU, BR, CA, HU, PL, RO, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
JP 05331163	A2	19931214	JP 1991-84556	19910326
CA 2078336	AA	19920927	CA 1992-2078336	19920326
AU 9214517	A1	19921102	AU 1992-14517	19920326
AU 645193	B2	19940106		
EP 532761	A1	19930324	EP 1992-907592	19920326
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
HU 62761	A2	19930628	HU 1992-3716	19920326
HU 212644	B	19960930		
BR 9204796	A	19930831	BR 1992-4796	19920326
RU 2066321	C1	19960910	RU 1992-16418	19920326
PL 171471	B1	19970530	PL 1992-296936	19920326
RO 112112	B1	19970530	RO 1992-1473	19920326
IN 174958	A	19950408	IN 1992-CA402	19920604
IN 175877	A	19951014	IN 1992-CA401	19920604
CN 1080637	A	19940112	CN 1992-105035	19920622
CN 1080638	A	19940112	CN 1992-105045	19920622
CN 1040280	B	19981021		
US 5385880	A	19950131	US 1992-927281	19920917
IN 178208	A	19970315	IN 1994-CA798	19940930
IN 178419	A	19970419	IN 1994-CA799	19940930
PRIORITY APPLN. INFO.:			JP 1991-84556 A	19910326
			WO 1992-JP362 A	19920326
			IN 1992-CA401 A1	19920604
			IN 1992-CA402 A1	19920604

OTHER SOURCE(S): MARPAT 118:254964
GI



AB The title compds. [I; R = H, HO, alkoxy, alkoxyalkoxy, acyloxyalkoxy, (un)substituted PhCH2O, Me3SiCH2CH2O, etc.; R1, R2 = H, alkoxy, halo,

L4 ANSWER 37 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(di)alkylamino, haloalkoxy, alkyl; W = O, S, NH, N(CHO), alkoxycarbonylimino; Z = CH, N; X = halo, (halo)alkyl, acylamino, (halo)cycloalkyl, alkenyloxy, alkynyloxy, (un)substituted Ph or PhCH2, etc.] are prepd. Thus, sulfonylation of Me 2-hydroxy-4-phenylnicotinate with (CF3SO2)2O in CH2Cl2 at -20° to -10° followed by condensation with 4,6-dimethoxy-2-hydroxypyrimidine in the presence of K2CO3 in DMSO at 80° gave a pyrimidine deriv. (II; R = OMe) which was hydrolyzed to II (R = OH). This at 100 g/10 are in paddy field soil controlled ≥90% Echinochloa crus-galli, Monochoria vaginalis, and Scirpus juncoides. A total of 173 I were prepd.

IT 147078-07-7P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as herbicide)

RN 147078-07-7 CAPLUS

CN 3-Pyridinecarboxamide, 4-(3-chlorophenyl)-2-[(4,6-dimethoxy-2-pyrimidinyl)thio]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)





L4 ANSWER 38 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1992:128593 CAPLUS
DOCUMENT NUMBER: 116:128593
TITLE: Novel inhibitors of prolyl 4-hydroxylase
AUTHOR(S): Dowell, Robert I.; Hadley, Elizabeth M.
CORPORATE SOURCE: Chem. 1 Dep., ICI Pharm., Mereside/Alderley Park/Macclesfield/Cheshire, SK10 4TG, UK
SOURCE: Journal of Medicinal Chemistry (1992), 35(5), 800-4
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Pyridinecarbonylsulfonamides I (R = Me, CHMe2, Ph, CH2Ph, 1-naphthyl, 8-quinolyl, etc.) were prepared by reacting Me 5-carboxylpyridine-2-carboxylate with RSO2NH2 in the presence of DCC. They were examined for their inhibitory activity against prolyl 4-hydroxylase. Structure-activity relationships were also examined

IT 138834-63-6P 138834-64-7P 138834-65-8P
138834-66-9P 138834-67-0P 138834-68-1P
138834-69-2P 138834-70-5P 138834-71-6P
138834-72-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)

RN 138834-63-6 CAPLUS

CN 2-Pyridinecarboxylic acid, 5-[[(methylsulfonyl)amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 138834-64-7 CAPLUS

CN 2-Pyridinecarboxylic acid, 5-[[[(1-methylethyl)sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 38 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 138834-65-8 CAPLUS

CN 2-Pyridinecarboxylic acid, 5-[[(phenylsulfonyl)amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 138834-66-9 CAPLUS

CN 2-Pyridinecarboxylic acid, 5-[[[(phenylmethyl)sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 138834-67-0 CAPLUS

CN 2-Pyridinecarboxylic acid, 5-[[(1-naphthalenylsulfonyl)amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 38 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 138834-68-1 CAPLUS

CN 2-Pyridinecarboxylic acid, 5-[[(8-quinolinylsulfonyl)amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 138834-69-2 CAPLUS

CN 2-Pyridinecarboxylic acid, 5-[[[(5-chloro-2-thienyl)sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 38 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 138834-70-5 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[(4,5-dibromo-2-thienyl)sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 138834-71-6 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[(4-methoxyphenyl)sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 138834-72-7 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-(4,7-dichloro-2-quinolinyl)phenyl]sulfonyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



IT 138834-73-8P 138834-74-9P 138834-75-0P
138834-76-1P 138834-77-2P 138834-78-3P
138834-79-4P 138834-80-7P 138834-81-8P
138834-82-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and inhibitory activity of, against prolyl hydroxylase)

RN 138834-73-8 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[(methylsulfonyl)amino]carbonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 38 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 138834-78-3 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[(8-quinolinylsulfonyl)amino]carbonyl]-, disodium salt (9CI) (CA INDEX NAME)



●2 Na

RN 138834-79-4 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[(5-chloro-2-thienyl)sulfonyl]amino]carbonyl]-, disodium salt (9CI) (CA INDEX NAME)

L4 ANSWER 38 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 138834-74-9 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[(1-methylethyl)sulfonyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 138834-75-0 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[(phenylsulfonyl)amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 138834-76-1 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[(phenylmethyl)sulfonyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 138834-77-2 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[(1-naphthalenylsulfonyl)amino]carbonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 38 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



●2 Na

RN 138834-80-7 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[(4,5-dibromo-2-thienyl)sulfonyl]amino]carbonyl]-, disodium salt (9CI) (CA INDEX NAME)



●2 Na

RN 138834-81-8 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[(4-methoxyphenyl)sulfonyl]amino]carbonyl]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 138834-82-9 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[[[[4-(4,7-dichloro-2-quinolinyl)phenyl]sulfonyl]amino]carbonyl]-, disodium salt (9CI) (CA INDEX NAME)

L4 ANSWER 38 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



●2 Na

L4 ANSWER 39 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)





L4 ANSWER 39 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1990:178928 CAPLUS
DOCUMENT NUMBER: 112:178928
TITLE: Synthesis of some pyrido[2,3-c][1,2,6]triazonine derivatives
AUTHOR(S): Soloducho, Jadwiga
CORPORATE SOURCE: Inst. Org. Phys. Chem., Tech. Univ. Wroclaw, Wroclaw, PL-50-370, Pol.
SOURCE: Journal fuer Praktische Chemie (Leipzig) (1989), 331(3), 503-6
CODEN: JPCEAO; ISSN: 0021-8383
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 112:178928
GI



AB Treating nicotinic acid derivative I (R = tosyl) with K, followed by treatment of the product with Br(CH2)3Br gave 81% pyridotriazonine II (R1= R3 = tosyl, R2 = H) (III). Hydrolysis of III with 48% H2SO4 gave II (R1-R3 = H) (IV). Mannich reaction of IV with formaldehyde and morpholine or piperidine gave II (R1 = R2 = H, R3 = CH2R4; R4 = morpholino, piperidino). Alkylation of IV with ClCH2CH2NEt2 gave II (R1 = R3 = H, R2 = CH2CH2NEt2).

IT 109274-64-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(sequential metalation and cyclocondensation reaction with dibromopropane, pyridotriazonine derivative from)

RN 109274-64-8 CAPLUS
CN Benzenesulfonic acid, 4-methyl-, 2-[3-[[[(4-methylphenyl)sulfonyl]amino]carbonyl]-2-pyridinyl]hydrazide (9CI) (CA INDEX NAME)

L4 ANSWER 40 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1988:131590 CAPLUS
DOCUMENT NUMBER: 108:131590
TITLE: Preparation of (phenylsulfonyl)nicotinamide derivatives as agricultural fungicides
INVENTOR(S): Yoshida, Hiroshi; Koike, Kengo; Konishi, Kenji; Shimano, Shizuo; Nakagawa, Taizo
PATENT ASSIGNEE(S): Nippon Kayaku Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62181261	A2	19870808	JP 1986-22999	19860206
PRIORITY APPLN. INFO.:			JP 1986-22999	19860206

GI



AB The title compds. (I: X = H, halo, MeS; Y = H, halo, Me, MeO, CF3, MeS; n = 1-3), useful as agricultural fungicides, were prepared A mixture of 4-MeC6H4SO2NH2 and 2-chloronicotinoyl chloride in pyridine was stirred for 2 h at room temperature to give 48.4% I (X = 2-Cl, Yn = 4-Me). At 200 ppm, I (X = H, Yn = 4-Me) provided 72% protection to rice plants against Pyricularia oryzae. A formulation containing 2 parts I (X = H, Yn = 2-Me) and 98 parts clay was prepared

IT 113513-61-4P 113513-62-5P 113513-63-6P
113513-64-7P 113513-65-8P 113513-66-9P
113513-67-0P 113513-68-1P 113513-69-2P
113513-70-5P 113513-71-6P 113513-72-7P
113513-73-8P 113513-75-0P 113513-76-1P
113513-78-3P 113513-79-4P 113513-80-7P
113513-81-8P 113513-82-9P 113513-83-0P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as agricultural fungicide)

RN 113513-61-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 40 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 113513-62-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[(2-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 113513-63-6 CAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 113513-64-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-N-[(2-chlorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 113513-65-8 CAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-N-[(2-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 113513-66-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-N-[(2-fluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 40 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 113513-71-6 CAPLUS
CN 3-Pyridinecarboxamide, 4-chloro-N-[(4-fluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 113513-72-7 CAPLUS
CN 3-Pyridinecarboxamide, N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 113513-73-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[(4-methylphenyl)sulfonyl]-2-(methylthio)- (9CI) (CA INDEX NAME)



RN 113513-75-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[(4-chloro-2-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 40 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 113513-67-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 113513-68-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-chloro-N-[(4-fluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 113513-69-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-chloro-N-[(2,4,5-trichlorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 113513-70-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-chloro-N-[(4-methoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 40 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RN 113513-76-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[(4-chlorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 113513-78-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-chloro-2-(trifluoromethyl)phenyl]sulfonyl]-2-(methylthio)- (9CI) (CA INDEX NAME)



RN 113513-79-4 CAPLUS
CN 3-Pyridinecarboxamide, 2-(methylthio)-N-[[4-(methylthio)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 113513-80-7 CAPLUS
CN 3-Pyridinecarboxamide, 2-(methylthio)-N-[[3-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 113513-81-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-(methylthio)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 40 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 113513-82-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-chloro-2-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 113513-83-0 CAPLUS
CN 3-Pyridinecarboxamide, 6-chloro-N-[(4-fluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 41 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(Reactant or reagent)
(prepn. and reaction of, with dibromoethane)
RN 109274-70-6 CAPLUS
CN Benzenesulfonic acid, 4-methyl-, 2-[3-[[[(4-methylphenyl)sulfonyl]amino]carbonyl]-2-pyridinyl]hydrazide, monopotassium salt (9CI) (CA INDEX NAME)





● K

L4 ANSWER 41 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1987:459010 CAPLUS
DOCUMENT NUMBER: 107:59010
TITLE: Synthesis of some pyrido[3,2-g][1,2,5]triazocine derivatives
AUTHOR(S): Soloducho, Jadwiga
CORPORATE SOURCE: Dep. Technol. Drugs, Sch. Med., Wroclaw, 50140, Pol.
SOURCE: Polish Journal of Chemistry (1986), 59(10-12), 1115-20
CODEN: PJCHDQ; ISSN: 0137-5083
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 107:59010
GI



I

AB The title compds. I (R = H, morpholinomethyl, piperidinomethyl; R1 = H, Et2NCH2CH2, 2-hydroxy-3-morpholinopropyl) were prepared starting from 2-chloronicotinamide.
IT 109274-64-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclocondensation of, with dibromomethane)
RN 109274-64-8 CAPLUS
CN Benzenesulfonic acid, 4-methyl-, 2-[3-[[[(4-methylphenyl)sulfonyl]amino]carbonyl]-2-pyridinyl]hydrazide (9CI) (CA INDEX NAME)





IT 109274-70-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

L4 ANSWER 42 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1985:24500 CAPLUS
DOCUMENT NUMBER: 102:24500
TITLE: Sulfoximines
INVENTOR(S): Mueller, Erich
PATENT ASSIGNEE(S): Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.
SOURCE: Ger. Offen., 20 pp. Addn to Ger. Offen. 3,129,444.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3246980	A1	19840620	DE 1982-3246980	19821218
DE 3129444	A1	19830210	DE 1981-3129444	19810725
DK 8305705	A	19840619	DK 1983-5705	19831212
FI 8304578	A	19840619	FI 1983-4578	19831214
DD 216925	A5	19850102	DD 1983-258010	19831215
AT 8304371	A	19861215	AT 1983-4371	19831215
AT 383593	B	19870727		
NO 8304648	A	19840619	NO 1983-4648	19831216
HU 32561	O	19840828	HU 1983-4308	19831216
HU 190515	B	19860929		
ES 528093	A1	19850101	ES 1983-528093	19831216
CA 1201123	A1	19860225	CA 1983-443542	19831216
PRIORITY APPLN. INFO.:			DE 1981-3129444	19810725
			DE 1981-3142904	19811029
			DE 1982-3246980 A	19821218

OTHER SOURCE(S): CASREACT 102:24500
GI



I, R=H
II, R=acyl



III, R=Ac
IV, R=H

AB Sulfoximines I [R1 = Ph (un)substituted C1-3 alkyl, (un)substituted Ph, C4-7 alkyl, C3-7 cycloalkyl, naphthyl (un)substituted with C1-3 alkoxy, pyridyl; X = CH2, CH:CH2CH2 (un)substituted with 1 or 2 C1-3 alkyl; Z = C2-6 alkylene], useful as antithrombotics, tumor metastasis inhibitors, and aggregation-inhibiting prostaglandin I2 synthesis promoters (no data), were prepared by hydrolysis of II. 3,4-Cl2C6H3S(O)(CH2)4Br reacted with 2,4,6-Me3C6H2SO2NH2 to give 3,4-Cl2C6H3S(O)(:NH)(CH2)4Br which was N-acetylated with Ac2O to give 98% 3,4-Cl2C6H3S(O)(:NAc)(CH2)4Br. This

L4 ANSWER 42 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
was etherified with 6-hydroxycarbostyril in Me2SO contg. K2CO3 in 17 h to give 62.5% carbostyril ether III, hydrolysis of which with KOH in MeOH gave 89% IV.

IT **85740-70-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrolysis of)

RN 85740-70-1 CAPLUS

CN 2H-Indol-2-one, 5-[4-[S-(3,4-dimethoxyphenyl)-N-(3-pyridinylcarbonyl)sulfonimidoyl]butoxy]-1,3-dihydro-3,3-dimethyl- (9CI) (CA INDEX NAME)



IT **85740-45-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 85740-45-0 CAPLUS

CN 2(1H)-Quinolinone, 6-[4-[S-(3,4-dichlorophenyl)-N-(3-pyridinylcarbonyl)sulfonimidoyl]butoxy]-3,4-dihydro- (9CI) (CA INDEX NAME)



L4 ANSWER 43 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 85740-45-0 CAPLUS

CN 2(1H)-Quinolinone, 6-[4-[S-(3,4-dichlorophenyl)-N-(3-pyridinylcarbonyl)sulfonimidoyl]butoxy]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 85740-62-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[4-[S-(3,4-dimethoxyphenyl)-N-(3-pyridinylcarbonyl)sulfonimidoyl]butoxy]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 85740-70-1 CAPLUS

CN 2H-Indol-2-one, 5-[4-[S-(3,4-dimethoxyphenyl)-N-(3-pyridinylcarbonyl)sulfonimidoyl]butoxy]-1,3-dihydro-3,3-dimethyl- (9CI) (CA INDEX NAME)



L4 ANSWER 43 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1983:405522 CAPLUS

DOCUMENT NUMBER: 99:5522

TITLE: Sulfimines, their salts and pharmaceutical compositions containing them

INVENTOR(S): Mueller, Erich; Nickl, Josef; Narr, Berthold; Roch, Josef; Haarmann, Walter; Weisenberger, Johannes M.

PATENT ASSIGNEE(S): Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.

SOURCE: Eur. Pat. Appl., 101 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 71150	A1	19830209	EP 1982-106501	19820719
EP 71150	B1	19850703		
R: AT, BE, CH, DE, FR, IT, LI, LU, NL, SE				
DE 3129444	A1	19830210	DE 1981-3129444	19810725
DE 3142904	A1	19830511	DE 1981-3142904	19811029
AT 14120	E	19850715	AT 1982-106501	19820719

PRIORITY APPLN. INFO.: DE 1981-3129444 A 19810725
DE 1981-3142904 A 19811029
EP 1982-106501 A 19820719

OTHER SOURCE(S): CASREACT 99:5522

GI



I



II

AB Sulfimines I [R = H, acyl; R1 = (un)substituted alkyl, cycloalkyl, Ph, pyridyl, naphthyl; X = (un)substituted CH2, CH2CH2, CH:CH; Z = alkylene; n = 0, 1] were prepared Thus, 6-[4-[(4-bromo-3-methylphenyl)sulfinyl]butoxy]carbostyril was dissolved in polyphosphoric acid and treated with NaN3 to give 54% II. II, at 0.039 μmol/L, gave 50% inhibition of cyclic AMP phosphodiesterase activity, and 2.5 mg II/kg orally increased bleeding time in mice > 275%.

IT **85740-45-0P 85740-62-1P 85740-70-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

L4 ANSWER 44 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1983:215493 CAPLUS

DOCUMENT NUMBER: 98:215493

TITLE: Sulfoximines and their pharmaceutical use

INVENTOR(S): Mueller, Erich; Nickl, Josef; Narr, Berthold; Roch, Josef; Haarmann, Walter; Weisenberger, Johannes Maximili

PATENT ASSIGNEE(S): Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.

SOURCE: Ger. Offen., 56 pp. Addn. to Ger. Offen. 3,142,904.
CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3129444	A1	19830210	DE 1981-3129444	19810725
DE 3142904	A1	19830511	DE 1981-3142904	19811029
NO 8202255	A	19830126	NO 1982-2255	19820630
US 4442111	A	19840410	US 1982-395631	19820706
SU 1158041	A3	19850523	SU 1982-3463928	19820716
EP 71150	A1	19830209	EP 1982-106501	19820719
EP 71150	B1	19850703		
R: AT, BE, CH, DE, FR, IT, LI, LU, NL, SE				
AT 14120	E	19850715	AT 1982-106501	19820719
FI 8202550	A	19830126	FI 1982-2550	19820720
DD 202871	A5	19831005	DD 1982-241832	19820721
PL 137725	B1	19860731	PL 1982-237600	19820721
DK 8203295	A	19830126	DK 1982-3295	19820722
HU 27628	O	19831028	HU 1982-2373	19820722
HU 188188	B	19860328		
CS 236488	B2	19850515	CS 1982-5591	19820722
JP 58024559	A2	19830214	JP 1982-128814	19820723
GB 2104515	A	19830309	GB 1982-21294	19820723
GB 2104515	B2	19850605		
ES 514275	A1	19830401	ES 1982-514275	19820723
AU 8286378	A1	19830414	AU 1982-86378	19820723
AU 556082	B2	19861023		
ZA 8205273	A	19840328	ZA 1982-5273	19820723
CA 1175430	A1	19841002	CA 1982-407915	19820723
IL 66384	A1	19860131	IL 1982-66384	19820723
DE 3246980	A1	19840620	DE 1982-3246980	19821218
ES 518826	A1	19831016	ES 1983-518826	19830107
ES 518827	A1	19831016	ES 1983-518827	19830107
ES 518828	A1	19831016	ES 1983-518828	19830107
US 4551464	A	19851105	US 1984-573964	19840126

PRIORITY APPLN. INFO.: DE 1981-3142904 19811029
DE 1981-3129444 A 19810725
US 1982-395631 A1 19820706
EP 1982-106501 A 19820719

GI

L4 ANSWER 44 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



AB Sulfoximes I [A = (un)substituted methylene, vinylene, or ethylene; Q = C2-6 alkylene; R = (un)substituted C7-9 aralkyl, etc.; R1 = acyl, alkylsulfonyl, arylsulfonyl, etc.] were prepared (78 in all) by reaction of the sulfoxides with NH3 or 2,4,6-Me3C6H2SO3NH2 or acylation of sulfoximines and shown to be antithrombotics. Among 78 compds. prepared were II-IV. IV increased the bleeding time in mice 275% 1 h after administration at 2.5 mg./kg. orally.

IT **85740-45-0P 85740-62-1P 85740-70-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as antithrombotic)

RN 85740-45-0 CAPLUS

CN 2(1H)-Quinolinone, 6-[4-[S-(3,4-dichlorophenyl)-N-(3-pyridinylcarbonyl)sulfonimidoyl]butoxy]-3,4-dihydro- (9CI) (CA INDEX NAME)

L4 ANSWER 44 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 85740-62-1 CAPLUS

CN 2(1H)-Quinolinone, 6-[4-[S-(3,4-dimethoxyphenyl)-N-(3-pyridinylcarbonyl)sulfonimidoyl]butoxy]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 85740-70-1 CAPLUS

CN 2H-Indol-2-one, 5-[4-[S-(3,4-dimethoxyphenyl)-N-(3-pyridinylcarbonyl)sulfonimidoyl]butoxy]-1,3-dihydro-3,3-dimethyl- (9CI) (CA INDEX NAME)



L4 ANSWER 45 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1975:458608 CAPLUS
DOCUMENT NUMBER: 83:58608
TITLE: Synthesis and pharmacological properties of some N-acylsulfonamides
AUTHOR(S): Delarge, J.; Lapiere, C. L.
CORPORATE SOURCE: Inst. Pharm., Univ. Liege, Liege, Belg.
SOURCE: Annales Pharmaceutiques Francaises (1974), 32(12), 657-67
CODEN: APFRAD; ISSN: 0003-4509
DOCUMENT TYPE: Journal
LANGUAGE: French
OTHER SOURCE(S): CASREACT 83:58608

GI For diagram(s), see printed CA Issue.

AB Pyridinesulfonamides I (R = 3-CF3C6H4, 2-CF3C6H4, 3-ClC6H4, 4-ClC6H4, 2,3-Me(Cl)C4H3, 3-O2NC6H4, 4-O2NC6H4, 2,3-Cl2C6H3, 2,4-Cl2C6H3, 2,5-Cl2C6H3, 2,6-Cl2C6H3, 3,4-Cl2C6H3, 3,5-Cl2C6H3; R1 = H, CHO, Ac, COEt, COPr, Bz, nicotinoyl, 2-thenoyl) (39 compds.) were prepared by aminating chloropyridinesulfonamides or anilinopyridinesulfonic acids, or acylating anilinopyridinesulfonamides. II (R2 = H, Me, Et, Ph) (10 compds.) were obtained as by products. Some I and II showed diuretic activity comparable that of furosemide and antiinflammatory activity comparable to that of common antiinflammatory agents.

IT **56175-89-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and antiinflammatory and diuretic activity of)

RN 56175-89-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[[4-[[3-(trifluoromethyl)phenyl]amino]-3-pyridinyl]sulfonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 46 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1974:3511 CAPLUS
DOCUMENT NUMBER: 80:3511
TITLE: Derivatives of penam-3-carboxylic acids and cephem-4-carboxylic acids
INVENTOR(S): Fechtig, Bruno; Kocsis, Karoly; Bickel, Hans
PATENT ASSIGNEE(S): Ciba-Geigy A.-G.
SOURCE: Ger. Offen., 78 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2312330	A1	19731004	DE 1973-2312330	19730313
CH 560705	A	19750415	CH 1972-4251	19720322
ZA 7301905	A	19731219	ZA 1973-1905	19730319
DD 105617	C	19740512	DD 1973-169591	19730320
AU 7353499	A1	19740926	AU 1973-53499	19730320
ES 412838	A1	19760516	ES 1973-412838	19730320
CA 1049501	A1	19790227	CA 1973-166491	19730320
BE 797084	A1	19730921	BE 1973-129044	19730321
FR 2181839	A1	19731207	FR 1973-10084	19730321
AT 7302519	A	19750115	AT 1973-2519	19730321
AT 325765	B	19751110		
AT 7408632	A	19750315	AT 1974-8632	19730321
HU 169031	P	19760928	HU 1973-CI1355	19730321
US 3996208	A	19761207	US 1973-344020	19730321
NL 7304036	A	19730925	NL 1973-4036	19730322
JP 49005988	A2	19740119	JP 1973-34000	19730322
GB 1423386	A	19760204	GB 1973-13848	19730322
SE 7602730	A	19760227	SE 1976-2730	19760227
PRIORITY APPLN. INFO.:			CH 1972-4251 A	19720322
			CH 1972-12919 A	19720901
			CH 1972-18530 A	19721220

GI For diagram(s), see printed CA Issue.

AB The N-sulfamylampicillins I (R = alkyl, aryl, substituted amino, N-heterocyclic) (48 compds.) were prepared by treating a trimethylsilylated ampicillin with RCONHSO2Cl. The RCONHSO2Cl were obtained by treating RCO2H with ClSO2NCO. Some related cephalosporins (3 compds.) were similarly prepared Thus, nicotinoylsulfamyl chloride, prepared by treating nicotinic acid with ClSO2NCO, was treated with trimethylsilyl N-trimethylsilyl-6-D-α-phenylglycylaminopenicillanate to give I (R = 3-pyridyl).

IT **50881-20-4P 50881-21-5P 50881-59-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with ampicillin derivative)

RN 50881-20-4 CAPLUS

CN 2-Pyridinecarboxylic acid, 3-[[(chlorosulfonyl)amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 46 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 50881-21-5 CAPLUS
CN Sulfamoyl chloride, [(1,6-dihydro-6-oxo-3-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 50881-59-9 CAPLUS
CN Sulfamoyl chloride, [(2-chloro-3-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)



IT **50881-61-3P 50881-62-4P 50882-05-8P 51032-26-9P 51032-28-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 50881-61-3 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[[[[2-(methoxycarbonyl)-3-pyridinyl]carbonyl]amino]sulfonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 46 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 50881-62-4 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[[[[(1,6-dihydro-6-oxo-3-pyridinyl)carbonyl]amino]sulfonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 50882-05-8 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[[[[[(2-chloro-3-pyridinyl)carbonyl]amino]sulfonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 51032-26-9 CAPLUS
CN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[[phenyl[[[(3-pyridinylcarbonyl)amino]sulfonyl]amino]acetyl]amino]-, [2S-[2α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 46 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 51032-28-1 CAPLUS
CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[(acetyloxy)methyl]-8-oxo-7-[[phenyl[[[(3-pyridinylcarbonyl)amino]sulfonyl]amino]acetyl]amino]-, [6R-[6α,7β(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 47 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1973:58095 CAPLUS
DOCUMENT NUMBER: 78:58095
TITLE: N-Aroylsulfonamides
INVENTOR(S): Moore, George G. I.; Conway, Alvin C.
PATENT ASSIGNEE(S): Minnesota Mining and Manufacturing Co.
SOURCE: U.S., 4 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3705185	A	19721205	US 1969-816038	19690414
PRIORITY APPLN. INFO.:			US 1969-816038 A	19690414

GI For diagram(s), see printed CA Issue.
AB Twenty-three trifluoromethanesulfonamides most of them of structure I (R = F, Cl, H; R1 = NO2, CF3, halo, H; R2 = NO2, Cl, F, CN, H) or their salts, useful anticonvulsants, were prepared by treating F3CSO2NH2 and Na2CO3 (or Et3N) in Me2CO with the appropriate aroyl halide.
IT **39063-09-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 39063-09-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[(trifluoromethyl)sulfonyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

L4 ANSWER 48 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1971:405734 CAPLUS
DOCUMENT NUMBER: 75:5734
TITLE: Quaternary 3-pyridinium-2-quinolones
INVENTOR(S): Bell, Stanley C.
PATENT ASSIGNEE(S): American Home Products Corp.
SOURCE: U.S., 4 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3574216	A	19710406	US 1968-721095	19680412
PRIORITY APPLN. INFO.:			US 1968-721095 A	19680412

GI For diagram(s), see printed CA Issue.
AB Title compds., with depressant activity, were prepared Thus, 4'-chloro-2'-(2-chloro-5-sulfamoylbenzoyl)-2-iodoacetanilide, N-(p-tolylsulfonyl)nicotinamide and Me2CO is refluxed for 24 hr and cooled to give I.
IT **32532-10-8P 32532-12-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 32532-10-8 CAPLUS
CN Pyridinium, 1-[[[4-chloro-2-(2-chloro-5-sulfamoylbenzoyl)phenyl]carbamoyl]methyl]-3-[1-hydroxy-N-(p-tolylsulfonyl)formimidoyl]-, hydroxide, inner salt (8CI) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 48 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A



RN 32532-12-0 CAPLUS
CN Pyridinium, 1-[6-chloro-4-(2-chloro-5-sulfamoylphenyl)-1,2-dihydro-2-oxo-3-quinolyl]-3-[1-hydroxy-N-(p-tolylsulfonyl)formimidoyl]-, hydroxide, inner salt (8CI) (CA INDEX NAME)



L4 ANSWER 49 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1971:3525 CAPLUS
DOCUMENT NUMBER: 74:3525
TITLE: Central nervous system depressant, 1-substituted-3-[1-hydroxy-N-(arylsulfonyl)formimidoyl]pyridines and derivatives
INVENTOR(S): Bell, Stanley Charles
PATENT ASSIGNEE(S): AM HOME
SOURCE: U.S., 3 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3534049	A	19701013	US 1968-721067	19680412
PRIORITY APPLN. INFO.:			US 1968-721067 A	19680412

GI For diagram(s), see printed CA Issue.
AB The title compds. (I, R = m-AcOC6H4COCH2) (II) and (I, R = lower alkyl) (III) and the 1,2,5,6-tetrahydropyridinium (IV) and piperidinium (V) analogs of III, together with the inner salts and anion salts of I are prepared from N-(p-tolylsulfonyl)nicotinamide (VI). Thus, VI, and MeI was refluxed 18 hr in Me2CO and cooled to give III (R = Me, X = I), which was suspended in H2O and neutralized with Na2CO3 to give the inner salt of III (R = Me) (VII). VII was stirred 1 hr with aqueous NaBH4, and the mixture adjusted to pH 6 to give IV (R = Me), which was hydrogenated in H2O over 10% Pd/C to yield V (R = Me). VI and m-(BrCH2CO)C6H4OAc refluxed 2 hr in Me2CO gave II (X = Br). The compds. together with the inner salts and anion salts have central nervous system depressant and bronchodilator activities.
IT **29956-19-2P 29956-20-5P 29956-23-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 29956-19-2 CAPLUS
CN Pyridinium, 3-[1-hydroxy-N-(p-tolylsulfonyl)formimidoyl]-1-methyl-, hydroxide, inner salt (8CI) (CA INDEX NAME)



RN 29956-20-5 CAPLUS
CN Pyridinium, 1-methyl-3-[(p-tolylsulfonyl)carbamoyl]-, iodide (8CI) (CA INDEX NAME)

L4 ANSWER 49 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● I⁻

RN 29956-23-8 CAPLUS
CN Pyridinium, 1-(m-hydroxyphenacyl)-3-[1-hydroxy-N-(p-tolylsulfonyl)formimidoyl]-, bromide, 1-acetate (ester) (8CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

● Br⁻

L4 ANSWER 49 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L4 ANSWER 50 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1963:485182 CAPLUS
DOCUMENT NUMBER: 59:85182
ORIGINAL REFERENCE NO.: 59:15829d-e
TITLE: Metabolic modifications induced by diuretic treatment and urinary elimination of some vitamins of the B complex
AUTHOR(S): Angarano, D.; Marano, R.; Salvia, F. De
CORPORATE SOURCE: Univ. Bari, Italy
SOURCE: Acta Vitaminologica (1963), 17(2), 49-53
CODEN: ACVIA9; ISSN: 0001-7248
DOCUMENT TYPE: Journal
LANGUAGE: Italian
AB Not only the desired effect of diuresis was obtained in 20 patients when using thiazide compds., but also elimination of vitamins B1 and B2 and nicotinic acid in the urine of these subjects. Urine values were determined photometrically and ranged from 400 to 900 γ vitamin B1 eliminated in 24 hrs., 400 to 1120 γ vitamin B2 in 24 hrs., and 6.0 to 10 mg. of nicotinic acid in 24 hrs.
IT **856302-24-4**, 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-, 1,1-dioxide, nicotinic acid
(riboflavine and thiamine in urine after administration of)
RN 856302-24-4 CAPLUS
CN 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-, 1,1-dioxide, nicotinic acid (7CI) (CA INDEX NAME)



L4 ANSWER 51 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1953:62026 CAPLUS
DOCUMENT NUMBER: 47:62026
ORIGINAL REFERENCE NO.: 47:10549e-f
TITLE: Acylated sulfonamides
PATENT ASSIGNEE(S): Badische Anilin- & Soda-Fabrik (I. G. Farbenindustrie Akt.-Ges. "In Auflosung")
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 692651		19530610	GB	

AB See Ger. 830,507 (C.A. 47, 6982g).
IT **113513-61-4**, Nicotinamide, N-p-tolylsulfonyl-
(preparation of)
RN 113513-61-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 52 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1953:62025 CAPLUS
DOCUMENT NUMBER: 47:62025
ORIGINAL REFERENCE NO.: 47:10549e
TITLE: Removal of impurities from 1,4-dicyano-2-butene
PATENT ASSIGNEE(S): E. I. Du Pont de Nemours & Co.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 692827		19530617	GB	

AB See U.S. 2,557,258 (C.A. 46, 1582i).
IT **113513-61-4**, Nicotinamide, N-p-tolylsulfonyl-
(preparation of)
RN 113513-61-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 53 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1953:62024 CAPLUS
DOCUMENT NUMBER: 47:62024
ORIGINAL REFERENCE NO.: 47:10549d-e
TITLE: β,γ-Olefinic ethers of halohydrins
INVENTOR(S): Morris, Rupert C.; Van Winkle, John L.
PATENT ASSIGNEE(S): Shell Development Co.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2608587		19520826	US	

AB Equimolar proportions of CH2:-CHCH2Cl and epichlorohydrin at 130-250° in the presence of a cuprous catalyst give high yields of CH2ClCH(OCH2CH:CH2)CH2Cl. It is essential that the reaction be conducted in a vessel, the inner surface of which is devoid of ferromagnetic ferrous alloys having a microstructure other than austenitic. Cf. preceding abstract
IT 113513-61-4, Nicotinamide, N-p-tolylsulfonyl-
(preparation of)
RN 113513-61-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 54 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1953:41393 CAPLUS
DOCUMENT NUMBER: 47:41393
ORIGINAL REFERENCE NO.: 47:6982f-i,6983a
TITLE: Acylated sulfonamides
INVENTOR(S): Krzikalla, Hans; Plankenhorn, Erwin
PATENT ASSIGNEE(S): Badische Anilin- & Soda-Fabrik (I. G. Farbenindustrie Akt.-Ges. "In Auflosung")
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 830507		19520204	DE	

AB Treating carboxylic acids with sulfonyl isocyanates at elevated temps. (100-200°) and possibly in the presence of a higher-boiling inert diluent gives, corresponding to RCO2H + OCNSO2R' → RCONH-SO2R' + CO2, N-Acylsulfonamides useful as textile auxiliary agents or intermediates in the manufacture of dyes and pharmaceuticals. Heating glacial AcOH 6 and p-MeC6H4SO2NCO (I) 20 at 130° until the gas evolution has ceased gives N-acetyl-p-toluenesulfonamide 15 parts by weight, m. 138° (from EtOH), acid number 260. Replacing I by an alkylsulfonyl isocyanate (prepared from an alkanesulfonylchloride from the sulfochlorination of a liquid paraffin hydrocarbon mixture with Cl and SO2) gives an oily N-acetylalkanesulfonamide. Similarly are prepared: N-benzoyl-p-toluenesulfonamide, m. 146° (from EtOH), acid number 197 (calculated 203), from I and BzOH; N-benzoylbenzenesulfonamide, m. 146°; N-phenylacetyl-p-toluenesulfonamide, m. 148-9°, acid number 191 (calculated 193), from I and PhCH2CO2H; N-stearoyl-p-toluenesulfonamide, m. 78° (from EtOH), acid number 132 (calculated 128), from I and stearic acid; N-oleoyl-p-toluenesulfonamide, m. 59° (from glacial AcOH), acid number 131 (calculated 129), from I and oleic acid; N,N'-bis(p-toluenesulfonyl)adipamide, m. 229° (from BuOH), acid number 243 (calculated 248), from I and adipic acid; N-(p-toluenesulfonyl)nicotinamide, m. 222° (from MeOH), acid number 209 (calculated 203) from I and nicotinic acid; N-(p-toluenesulfonyl)abietinamide, acid number 123, from I and abietic acid.
IT 113513-61-4, Nicotinamide, N-p-tolylsulfonyl-
(preparation of)
RN 113513-61-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 54 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L4 ANSWER 55 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1949:13134 CAPLUS
DOCUMENT NUMBER: 43:13134
ORIGINAL REFERENCE NO.: 43:2597d-i
TITLE: Sulfanilamides. XIII. Reaction with dicarboxylic acids -N1- and N4-acyl and heterocyclic derivatives
AUTHOR(S): Jain, B. C.; Iyer, B. H.; Guha, P. C.
SOURCE: J. Indian Chem. Soc. (1947), 24, 173-6
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
GI For diagram(s), see printed CA Issue.
AB cf. C.A. 42, 6766h. AcNHC6H4SO2NHK with the appropriate acid chloride gave the following compds. (m.ps. given) where R = 4-AcNHC6H4SO2 and R' = 4-NH2C6H4SO2: EtO2CCH2CONHR 159°; CO.CH2.CH2.CO.NR (I) 259°; HO2C(CH2)2CONHR (II) 195°; HO2C(CH2)3CONHR 255° (decomposition); HO2C(CH2)3CONHR' 187°; HO2C(CH2)4CONHR 260° (decomposition); HO2C(CH2)4CONHR' 170°; HO2C(CH2)7CONHR 245°; HO2C(CH2)8CONHR 250° (decomposition); C6H4(CO)2NR (IV) 295°; 2-HO2CC6H4CONHR (V) 304°; 2-HO2CC6H4CONHR' 335°; HO2CCCH.CHC.CCONHR 230° (decomposition); RNHCOC:CH.CH:CH.N:CCONHR 308°. I and IV were converted into II and V with cold dilute alkaline ClCO(CH2)nCOCl (where n = 7 or 8) and 4-NH2C6H4SO2NH2 (VI) giving N4,N4'-heptamethylenedisulfanilamide, m. 251° (decomposition), and N4, N4'-octamethylenedisulfanilamide, m. 238° (decomposition). VI (5.1 g.), 2 g. chelidonic acid, and 25 mL. H2O refluxed 2 h., concentrated to 0.5 volume, filtered to remove unchanged VI, concentrated to a sirup, and treated with alc. gave 3.1 g. of 1-(4-sulfamylphenyl)-4-(4-aminophenylsulfonimido)chelidamic acid (VII), m. 165°, as the sesquihydrate. VII (1 g.) decarboxylated by heating 10 min. at 100° and 45 min. at 160° gave 0.6 g. 1-(4-sulfamylphenyl)-4-(4-aminophenylsulfonimido)-1,4-dihydropyridine, m. 210°. Di-Et 1,4-dihydrocollidine-3,5-dicarboxylate (4.2 g.) heated 1 h. at 135° with 4-AcNHC6H4SO2Cl (VIII) gave 6.4 g. 1-sulfanilyl-1,4-dihydrocollidine-3,5-dicarboxylic acid, m. 300° (decomposition). VIII (2.5 g.), 2 g. chelidamic acid, and 15 mL. C5H5N, refluxed 2 h. gave 3.2 g. 1-(N-acetylsulfanilyl)chelidamic acid, m. 227°, which on hydrolysis gave 1-sulfanilylchelidamic acid, m. 255° (decomposition).
IT 857759-72-9, Quinolinamide, N,N'-bis(N-acetylsulfanilyl)-
(preparation of)
RN 857759-72-9 CAPLUS
CN Quinolinamide, N,N'-bis(N-acetylsulfanilyl)- (5CI) (CA INDEX NAME)

L4 ANSWER 55 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 56 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1948:32159 CAPLUS
DOCUMENT NUMBER: 42:32159
ORIGINAL REFERENCE NO.: 42:6851h-i,6852a-c
TITLE: N-Acyl-p-aminobenzenesulfonamides
PATENT ASSIGNEE(S): J. R. Geigy, A.-G.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 598472		19480219	GB	

AB Products having greater effectiveness against infective agents and low toxicity are prepared by causing a p-aminobenzenesulfonamide to react with a carbonyl halide containing a heterocyclic residue or by condensing a heterocyclic acid amide with p-O2NC6H4SO2Cl, followed by reduction of the nitro group. Thus, O2NC6H4SO2NHNa (I) 44.8 suspended in PhNO2 150 is gradually mixed with 3,5-dimethyl-4-isoxazolecarbonyl chloride 31.9 parts, the mixture heated at 50-60° 4 h., and the product (II) dissolved in 2 N Na2CO3 solution, filtered from unchanged I, precipitated with 2 N HCl, and recrystd. from EtOH. In an Fe reducing kier, Fe chips 68, saturated NaCl solution 400, H2O 400, and 30% HCl 72 parts are thoroughly stirred together for 15 min. at 98°. While maintaining this temperature, N-(p-nitrophenylsulfonyl)-3,5-dimethyl-4-isoxazolecarboxamide (II) 65 parts is introduced in small portions and the reaction is complete in 1 h. The solution is made alkaline with 2 N NaOH, filtered from the sludge, the filtrate is acidified with 30% HCl, and the precipitated N-(p-aminophenylsulfonyl) acid (III) filtered with suction and purified by dissolving in 2 N Na2CO3 solution, precipitating with 2 N HCl, and crystallizing from EtOH.
By using appropriate acids, the following compds. are prepared: N-(4-aminophenylsulfonyl)-2,6-dimethyl-4-chloro-3-pyridinecarboxamide; N-(4-semicarbazidophenylsulfonyl)-2,6-dimethyl-4-chloro-3-pyridinecarboxamide; the Na salt of N-[p-(sulfomethylamino)phenylsulfonyl]-4-chloro-2,6-dimethyl-3-pyridinecarboxamide; N-(4-aminophenylsulfonyl)-1-ethyl-2(1H)-pyridone-6-carboxamide; N-(4-aminophenylsulfonyl)-2,4-dimethylcoumalamide; N-(4-nitrophenylsulfonyl)-5-methyl-4-pyrimidinecarboxamide; N-(4-aminophenylsulfonyl)-2,6-dimethyl-4-ethoxy-3-pyridinecarboxamide; N-(4-aminophenylsulfonyl)-2,6-dimethyl-4-(methylmercapto)-3-pyridinecarboxamide; N-(4-nitrophenylsulfonyl)-5-tert-butylfuramide, m. 212° and its 4-amino analog, m. 239°, obtained by Fe + HCl reduction Cf. C.A. 41, 2440a; 42, 219b.

IT **845718-25-4**, Nicotinamide, 4-chloro-2,6-dimethyl-N-sulfanilyl- **845745-75-7**, Nicotinamide, 2,6-dimethyl-4-(methylthio)-N-sulfanilyl- **845752-18-3**, Nicotinamide, 4-ethoxy-2,6-dimethyl-N-sulfanilyl- **845752-30-9**, Nicotinamide, 1-ethyl-1,6-dihydro-6-oxo-N-sulfanilyl- **845960-89-6**, Nicotinamide, 4-chloro-2,6-dimethyl-N-(N-sulfomethylsulfanilyl)-, sodium salt **845960-92-1**, Nicotinamide, 4-chloro-2,6-dimethyl-N-(N-ureidosulfanilyl)- **858480-20-3**, Semicarbazide, 1-[p-[(4-chloro-2,6-dimethylnicotinoyl)sulfamoyl]phenyl]-
(preparation of)

RN 845718-25-4 CAPLUS

L4 ANSWER 56 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN Nicotinamide, 4-chloro-2,6-dimethyl-N-sulfanilyl- (5CI) (CA INDEX NAME)



RN 845745-75-7 CAPLUS
CN Nicotinamide, 2,6-dimethyl-4-(methylthio)-N-sulfanilyl- (5CI) (CA INDEX NAME)



RN 845752-18-3 CAPLUS
CN Nicotinamide, 4-ethoxy-2,6-dimethyl-N-sulfanilyl- (5CI) (CA INDEX NAME)



RN 845752-30-9 CAPLUS
CN Nicotinamide, 1-ethyl-1,6-dihydro-6-oxo-N-sulfanilyl- (5CI) (CA INDEX NAME)



RN 845960-89-6 CAPLUS
CN Nicotinamide, 4-chloro-2,6-dimethyl-N-(N-sulfomethylsulfanilyl)-, sodium salt (5CI) (CA INDEX NAME)

L4 ANSWER 56 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● Na

RN 845960-92-1 CAPLUS
CN Nicotinamide, 4-chloro-2,6-dimethyl-N-(N-ureidosulfanilyl)- (5CI) (CA INDEX NAME)



RN 858480-20-3 CAPLUS
CN Semicarbazide, 1-[p-[(4-chloro-2,6-dimethylnicotinoyl)sulfamoyl]phenyl]- (5CI) (CA INDEX NAME)



L4 ANSWER 57 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1948:29905 CAPLUS
DOCUMENT NUMBER: 42:29905
ORIGINAL REFERENCE NO.: 42:6379d-h
TITLE: Acylsulfonamides
PATENT ASSIGNEE(S): J. R. Geigy A.-G.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 598536		19480220	GB	

AB Compds. of the general formula R2R1CNSO2R, where R1 is aliphatic, aromatic, aralkyl, cycloalkyl, or heterocyclic, R is a substituted or unsubstituted residue, and R2 is a substituted or unsubstituted amino or imido ester group, can be easily hydrolyzed to the corresponding acylsulfonamide of formula R1CONHSO2R. Thus, p-MeC(NH2):NSO2C6H4NO2 (I) 10 and 3.5% HCl 100 parts are stirred at 90-100° 4 h. After cooling, the mass is made alkaline with NaOH, filtered, and acidulated, giving N-acetyl-4-nitrobenzenesulfonamide, m. 194°. From the corresponding amidines, the following compds. were obtained by similar procedure: N1-Acyl-p-nitrobenzenesulfonamides: isovaleryl, m. 144-5°; (β,β-dimethylacrylyl), m. 155°; (3,4-dimethylbenzoyl), m. 192°; (3,4-dimethylhydrocinnamoyl), m. 85-6°; 1-naphthoyl, m. 198-200°; 2-furoyl, m. 208-10°. N1-Acylsulfanilamides: isovaleryl, m. 130°; butyryl, m. 126°; isobutyryl, m. 199°; (β, β-dimethylacrylyl), m. 184-5°; (α,β,β-trimethylacrylyl), m. 181-2°; (α-propoxypropionyl), m. 140°; (α-propoxyisobutyryl), m. 135-6°; (β,β-dimethylacrylyl), m. 155°; (4-methylbenzoyl), m. 178-9°; (4-ethylbenzoyl), m. 162-3°; (4-propylbenzoyl), m. 162°, [4-(ethylmercapto)benzoyl], m. 185°; (3,4-dimethylbenzoyl), m. 222°; (3-propyl-4-methoxybenzoyl), m. 213°; (3-allyl-4-methoxybenzoyl), m. 202-3°; 1-cyclopentenoyl, m. 202°; (1-cyclohexenylacetyl), m. 176-7°; (3,4-dimethylhydrocinnamoyl), m. 75-8°; (4-methylcinnamoyl), m. 209-10°; (4-methoxy-β-methylcinnamoyl), m. 182-4°; hydrocinnamoyl, m. 160-1°; 1-naphthoyl, m. 206-7°; (4-methyl-1-naphthoyl), m. 222°; 2-naphthoyl, m. 205°; (1-methoxy-2-naphthoyl), m. 230°; (1-methyl-2-indenylcarbonyl), m. 233° (decomposition); 2-furoyl, m. 188-9°; nicotinyl, m. 256-7°. Benzenesulfonamides: N-(4-chlorobenzoyl)-4-Me, m. 195°; N-(3,4-dimethylbenzoyl), m. 140°; N-1-naphthoyl-2,3,5,6-tetramethyl, m. 220°; N-proprionyl-3,4-dichloro, m. 126°; N-stearoyl-3,4-dichloro. Other compds. formed are: N-1-naphthoyl-2-naphthalenesulfonamide, C10H7CONHSO2C10H7; N-(4-methylbenzoyl)-1-naphthalenesulfonamide, MeC6H4CONHSO2C10H7, m. 196°; and N-(3,4-dimethylbenzoyl)-2-naphthalenesu fonamide, 3,4-Me2C6H3CONHSO2C10H7 m. 210°. Cf. C.A. 41, 2440g.

IT 6005-34-1, Nicotinamide, N-sulfanilyl-
(preparation of)

RN 6005-34-1 CAPLUS

CN Nicotinamide, N-sulfanilyl- (8CI) (CA INDEX NAME)

L4 ANSWER 57 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 58 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1947:29342 CAPLUS
DOCUMENT NUMBER: 41:29342
ORIGINAL REFERENCE NO.: 41:5898f-i,5899a
TITLE: N-Sulfanilyl carboxamides
INVENTOR(S): Martin, Henry; Hafliger, Franz; Neracher, Otto
PATENT ASSIGNEE(S): J. R. Geigy A.-G.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2417006		19470304	US	

AB Hydrolysis of N'-sulfanilylamidines is a practical method of preparing acyl sulfanilamides. N-Sulfanilylisovaleramide, m. 130° (from dilute MeOH), is obtained by hydrolysis of 10 parts N'-sulfanilylisovaleramidine, m. 118-20°, with 10 parts of 3.5% HCl at 90-100° 2 hrs., followed by neutralization with Na2CO3 and acidification with AcOH. Similarly N-sulfanilyl derivs. of the following amides were prepared: butyramide, m. 126° (amidine, m. 70-2°); isobutyramide, m. 199°; β,β-dimethylacrylamide, m. 184-5° (amidine m. 128-9°); 4-methylbenzamide (I), m. 178-9° (cf. preceding abstract, m. 144°) (amidine, m. 236°); 4-ethylbenzamide (II), m. 162-3°; 4-propylbenzamide, m. 162°; 4-(ethylmercapto)benzamide (III), m. 185°; 3,4-dimethylbenzamide (IV), m. 222° (amidine, m. 218-20°); 3-propyl-4-methoxybenzamide, m. 213°; 3-allyl-4-methoxybenzamide, m. 202-3°; 1-cyclopentene-1-carboxamide, m. 202°; 1-cyclohexene-1-acetamide, m. 176-7°. IV is also obtained by a 24-hr. hydrolysis of the following derivs. of N'-sulfanilyl-3,4-dimethylbenzamidine: N,N-diethyl-, m. 148-50°; N-phenyl-, m. 198-200°; N,N-dimethyl-; N-tolyl-; and by a 12-hr. hydrolysis of Et N-sulfanilyl-3,4-dimethylbenzimidate, m. 328-9° (decomposition). I and II are also obtained from the corresponding benzimidic acid esters. A 4-hr. hydrolysis of the proper amidines yields N-sulfanilyl derivs. of the following amides: 3,4-dimethylhydrocinnamamide, m. 76-8°; p-methylcinnamamide, m. 209-10°; p-methoxy-α-methylcinnamamide, m. 182-4°; hydrocinnamamide, m. 160-1°; 1-naphthamide; 4-methyl-1-naphthamide, m. 222°; 2-naphthamide; 1-methoxy-2-naphthamide, m. 230°; 1-methyl-2-indenecarboxamide, m. 233°. A 3-hr. hydrolysis of the proper amidines yields N-sulfanilyl derivs. of 2-furamide, m. 188-9° (cf. preceding abstract, m. 191-2°) (amidine, m. 165-6°), and nicotinamide, m. 256-7°.

IT 6005-34-1, Nicotinamide, N-sulfanilyl-
(preparation of)

RN 6005-34-1 CAPLUS

CN Nicotinamide, N-sulfanilyl- (8CI) (CA INDEX NAME)

L4 ANSWER 58 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 59 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1947:29228 CAPLUS
DOCUMENT NUMBER: 41:29228
ORIGINAL REFERENCE NO.: 41:5864e-i,5865a-c
TITLE: Certain sulfanilamide derivatives of nicotinic acid
AUTHOR(S): Sadykov, A. S.; Maksimov, V. I.
CORPORATE SOURCE: Middle-Asiatic State Univ.
SOURCE: Zhurnal Obshchei Khimii (1946), 16, 1719-28
CODEN: ZOKHA4; ISSN: 0044-460X
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB In view of the partial control of the toxic effects of sulfa drugs by administration of nicotinic acid, several derivs. of sulfa drugs containing a nicotinic acid residue were prepared Sulfanilamide (7.2 g.) in 30 cc. pyridine bases (crude) was treated with 7 g. nicotinyl chloride (I) and the mixture was heated on a steam bath 2 h.; after removal of the solvent in vacuo and dilution with H2O, the crude product was purified by crystallization from 50% EtOH, then from EtOH, to yield. N1-nicotinylsulfanilamide, m. 256-7° (84.6%), identical with the Crossley, et al., product (C.A. 34, 392.8). I (28.8 g.) in 100 cc. pyridine bases was treated with 42 g. p-AcNHC6H4SO2NH2 and heated on a steam bath for 3 h.; after dilution with water, 45 g. N1-nicotinyl-N4-acetylsulfanilamide, m. 213-15° (from 50% EtOH) (methiodide, m. 196-7° (from EtOH)) was obtained; the Ac group is readily removed by hydrolysis with 15% HCl at 50-60° 3 h. I (14.1 g.) in 30 cc. pyridine bases was treated with 9.4 g. 2-aminopyridine and the mixture was heated on a steam bath for 3 h.; after removal of the solvent in vacuo 20 g. 2-nicotinylaminopyridine, m. 230° (from EtOH) (picrate, m. 220-1° (from EtOH); methiodide, m. 192-3° (from EtOH)) was obtained. I (7.2 g.) in 25 cc. pyridine bases and 12 g. sulfapyridine heated on a steam bath 3 h. yielded after dilution with water 12 g. N4-nicotinyl-N1-(2-aminopyridyl)sulfanilamide (nicotinylsulfapyridine), m. 185-6° (from EtOH); picrate m. 149-50° (from EtOH); methiodide m. 228-9° (from EtOH). I (14.2 g.) in 50 cc. pyridine bases and 10.8 g. sulfaguanidine heated on a steam bath 2 h. yielded dinicotinylsulfaguanidine, m. 219-20° (from 50% EtOH), in 12-g. yield; picrate m. 191-2° (from EtOH); similar reaction, using N4-acetylsulfaguanidine, gave 12 g. nicotinyl derivative (from 7.2 g. I), m. 258-9° (from 50% EtOH); picrate m. 200-2° (from EtOH). Similar reaction of sulfa-4-methylthiazole gave the N4-nicotinyl derivative (15 g. from 7.2 g. I), m. 230-2°. Nicotinic acid (12.3 g.), 12.1 g. PhNEtH, and 10 g. PCl5 were heated to 200-10° 4 h.; on cooling, diluting with 200 cc. H2O, and making alkaline with 50% NaOH there was obtained N-phenyl-N-ethylnicotinamide, b3 186-90°, m. 63° (from Me2CO); picrate m. 154-5° (from EtOH); methiodide m. 137-7.5° (from EtOH). PhNHEt (121 g.) treated, with cooling, with 78.5 g. AcCl gave 150 g. N-Ac derivative, m. 53°, which was treated at 20-5° with 350 cc. ClSO3H; the mixture was heated to 60-70° 3 h., poured on ice, and filtered to yield 200 g. p-(N-ethylacetamido)benzenesulfonyl chloride, m. 139-40° (from (CH2Cl)2); this was added slowly to 380 g. concentrated NH4OH to yield 150 g. p-(N-ethylacetamido)benzenesulfonamide, m. 123-4° (from water).

L4 ANSWER 59 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
The latter (50 g.) in 150 cc. 20% HCl was heated to 65-70° for 3 h., to yield on cooling and neutralization with Na2CO3, N4-ethylsulfanilamide, m. 110-1°. When this (5 g.) and 3.6 g. I were heated on a steam bath 4 h. in 20 cc. pyridine bases there was obtained, after the removal of the solvent in vacuo, 5.6 g. N1-nicotinyl-N4-ethylsulfanilamide, m. 229-30° (from 70% EtOH); picrate m. 218° (from EtOH); methiodide m. 214-15° (decompn.; from EtOH); the prepn. was confirmed by a similar condensation of I with the N4-acetyl-N4-Et deriv. to yield N1-nicotinyl-N4-ethyl-N4-acetylsulfanilamide, m. 242-3° (from EtOH), which on hydrolysis with 20% HCl for 5 h. at 65-70° gave a product identical with that of direct condensation.

IT **6005-34-1**, Nicotinamide, N-sulfanilyl- **845754-75-8**, Nicotinamide, N-(N-ethylsulfanilyl)- **845754-82-7**, Nicotinamide, N-(N-ethylsulfanilyl)-, methiodide **845754-83-8**, Nicotinamide, N-(N-ethylsulfanilyl)-, picrate **845960-04-5**, Nicotinamide, N-(N-acetyl-N-ethylsulfanilyl)- **845960-39-6**, Nicotinamide, N-(N-acetylsulfanilyl)- **845960-40-9**, Nicotinamide, N-(N-acetylsulfanilyl)-, methiodide **860430-81-5**, Sulfanilamide, N4-ethyl-N1-nicotinoyl-, picrate **860430-83-7**, Sulfanilamide, N4-ethyl-N1-nicotinoyl-, methiodide
(preparation of)

RN 6005-34-1 CAPLUS
CN Nicotinamide, N-sulfanilyl- (8CI) (CA INDEX NAME)



RN 845754-75-8 CAPLUS
CN Nicotinamide, N-(N-ethylsulfanilyl)- (5CI) (CA INDEX NAME)



RN 845754-82-7 CAPLUS
CN Nicotinamide, N-(N-ethylsulfanilyl)-, methiodide (5CI) (CA INDEX NAME)

CM 1

CRN 845754-75-8
CMF C14 H15 N3 O3 S



CM 2

CRN 74-88-4
CMF C H3 I



RN 845754-83-8 CAPLUS
CN Nicotinamide, N-(N-ethylsulfanilyl)-, picrate (5CI) (CA INDEX NAME)

CM 1

CRN 845754-75-8
CMF C14 H15 N3 O3 S



CM 2

CRN 88-89-1
CMF C6 H3 N3 O7



RN 845960-04-5 CAPLUS
CN Nicotinamide, N-(N-acetyl-N-ethylsulfanilyl)- (5CI) (CA INDEX NAME)

L4 ANSWER 59 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 845960-39-6 CAPLUS
CN Nicotinamide, N-(N-acetylsulfanilyl)- (5CI) (CA INDEX NAME)



RN 845960-40-9 CAPLUS
CN Nicotinamide, N-(N-acetylsulfanilyl)-, methiodide (5CI) (CA INDEX NAME)

CM 1

CRN 845960-39-6
CMF C14 H13 N3 O4 S



CM 2

CRN 74-88-4
CMF C H3 I



RN 860430-81-5 CAPLUS
CN Sulfanilamide, N4-ethyl-N1-nicotinoyl-, picrate (5CI) (CA INDEX NAME)

CM 1

CRN 845754-75-8
CMF C14 H15 N3 O3 S

L4 ANSWER 59 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 88-89-1
CMF C6 H3 N3 O7



RN 860430-83-7 CAPLUS
CN Sulfanilamide, N4-ethyl-N1-nicotinoyl-, methiodide (5CI) (CA INDEX NAME)



● I⁻

L4 ANSWER 60 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1947:24017 CAPLUS
DOCUMENT NUMBER: 41:24017
ORIGINAL REFERENCE NO.: 41:4809a-i,4810a-i,4811a
TITLE: Valuable derivatives of sulfonamides
INVENTOR(S): Dohrn, Max; Diedrich, Paul
PATENT ASSIGNEE(S): Schering Corp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2411495		19461119	US	

GI For diagram(s), see printed CA Issue.
AB Sulfonamide derivs. acylated at the sulfonamide N, of the general formula RSO2NHX, in which R stands for an aromatic, heterocyclic, or mixed residue and X for an acyl radical, are described. In these compds. the H atom can be replaced by metals, the resulting salts being easily soluble in water with neutral reaction. The new compds. are made either by direct acylation of the sulfa drugs and partial saponification of the diacyl derivs. or by reacting sulfonyl chlorides or anhydrides with acyl amides. Another method consists in acylating nitro- or halo-substituted sulfonamides and then substituting the nitro or halogen groups by the NH2 group. The alkali or alkaline earth salts of the new compds. are prepared by simply adding the calculated amount of hydroxide in aqueous solution and precipitating with alc. Heavy-metal salts are made from their sulfates and the Ba salt of the new compds. Organic bases can also be used for salt formation. The products have the same therapeutic use as the parent sulfa compds. p-RNHC6H4SO2NHX; Number, R, X, M.p.; I, Ac, Ac, 253° (d.); II, H, Ac, 181°; III, EtCO, COEt, 232°; IV, H, COEt, 130-1°; V, Ac, Bz, 245-6° (d.); VI, H, Bz, 179-86°; VII, PhCH2, Ac, 143-4°; VIII, p-AcNHC6H4SO2, Ac, 178°; IX, p-H2NC6H4SO2, Ac, 187°; X, H, C6H4SO2NH2(m), 156°; XI, Ac, C6H4SO2NHAc(m), 145-6°; XII, PhCH2OCO, H, 192-2.5°; XIII, PhCH2OCO, Ac, 167-8°; XIV, EtOCO, H, 238°; XV, EtOCO, Ac, 244°; XVI, MeOCO, H, 226-7°; XVII, glucoside, Ac, 191°; XVIII, H, nicotinoyl, 246°; XIX, EtOCO, nicotinoyl, 241°; XX, EtOCO, COPr, 217-18°; XXI, H, COPr, 125°; XXII, EtOCO, COCH:CHMe, 224°; XXIII, H, COCH:CHMe, 175°; XXIV, Ac, COC6H4NO2(p), 256°; XXV, EtOCO, COEt, 208°; XXVI, EtOCO, COCH2Ph, 209°; XXVII, H, COCH2Ph, 182°; XXVIII, EtOCO, COCH2Cl, 229°; XXIX, EtOCO, COCH2NH2, 223°; XXX, EtOCO, COC6H4OH(o), 242°; XXXI, H, COC6H4OH(o), 200-1°; XXXII, EtOCO, COC.O.CH, 259° (d.); XXXIII, H, COC.O.CH, 188-9°; XXXIV, H, CH-CH hydnochauloyl (chaulmoogroyl), 131°; XXXV, EtOCO, CO2Et, 162°; XXXVI, H, CO2Et, 133°; XXXVII, AcNH, Ac, 278-9°; XXXVIII, H2N, Ac; XXXIX, PhNH, H, 178°; I, prepared from sulfanilamide and Ac2O, prisms from alc., insol. in water, soluble in alkalies, forms neutral salts. When it is refluxed in a quantity of 2 N NaOH insufficient for complete saponification, then acidified, and the precipitate is

L4 ANSWER 60 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
treated with dil. Na2CO3 soln., II dissolves and the p-AcNHC6H4SO2NH2 formed simultaneously remains undissolved; II, colorless crystals, is easily sol. in alc. and acetone, difficultly in water, insol. in benzene and CHCl3. V is prepd. from p-AcNHC6H4SO2NH2 and BzCl in NaOH. X, from p-AcNHC6H4SO2Cl and m-H2NC6H4, followed by sapon., gives XI with Ac2O. XII is obtained in 250-g. yield by adding 340 g. ClCO2CH2Ph to 172 g. sulfanilamide at 0° with stirring, sepg. the XII after several hrs., washing it with dil. HCl, and crystg. it from MeOH; boiled with 5 times its wt. of Ac2O it gives XIII, 200 g. of which, shaken in 3 l. alc. with 5 g. Pd black and H, yields 106 g. II. XIV, from NH3 and an ether soln. of N-carbethoxysulfanilyl chloride (m. 104-5°, prepd. from PhNHCO2Et and ClSO3H at 0° and then at 55-60°, pptd. in ice water, and purified from MeOH and water). XV, from XIV and Ac2O, gives II when heated 10 min. at 80° with 7 times its wt. of 2 N NaOH. N-Carbomethoxysulfanilyl chloride, from p-MeO2CNHC6H4SO3Na and PCl5, m. 117-18°. XVII, from II and glucose refluxed in EtOH, needles from abs. EtOH, easily sol. in water; its alkali salts dissolve easily in water with neutral reaction. XIX, from XIV and nicotinoyl chloride in pyridine, sapond. by 2 N NaOH 24 h. at room temp. to XVIII. XX, from XIV and PrCOCl, sapond. to XXI by 2 N NaOH at room temp. XXII is prepd. by heating 24.5 g. XIV, 125 g. MeCH:CHCO2H, and 11 g. MeCH:CHCOCl 2 h. to 145°, decompg. with ice water, dissolving the ppt. in Na2CO3, and pptg. with AcOH. XXVI, from XIV heated several hrs. at 160-70° with PhCH2COCl. XXVIII, from XIV and (ClCH2CO)2O heated 1 h. at 120-5°, gives XXIX with concd. NH3 soln. at room temp. XXX, from XIV and o-HOC6H4COCl heated several hrs. at 170-80°, sapond. to XXXI by 2 N NaOH. XXXII, from XIV and pyromucyl chloride in C5H5N with cooling, sapond. to XXIII by 2 N NaOH. XXXIV, prepd. by heating XIV with hydnochauloyl chloride at 140°, pptg. in water, and repptg. from Na2CO3 soln. XXXV, from XIV and ClCO2Et in C5H5N, from sulfanilamide and 2 mols. ClCO2Et, or from p-EtO2CNHC6H4SO2Cl heated with urethane at 140-50° until a sample is readily sol. in dil. Na2CO3 soln. 2-Acetamido-5-(acetylsulfamyl)pyridine (XXXVII), from 2-chloro-5-pyridinesulfonamide reacted with concd. NH4OH in a closed container at 150° and the product boiled with Ac2O and recrystd. from water. Other compds. mentioned are: 4-(Acetylsulfamyl)-2',4'-diaminoazobenzene (XL), prepd. from diazotized II and m-C6H4(NH2)2, is pptd. by AcOH from hot Na2CO3 soln. in blue-red lustrous leaflets, decompg. 180°. 1,3-Bis[4-(acetylsulfamyl)phenyl]urea, prepd. from II in NaOH at 50° with phosgene and purified by pptg. with AcOH from hot Na2CO3 soln., needles, decomp. 255°, very difficultly sol. in water. 1-[4-(Acetylsulfamyl)phenylazo]-2-naphthol-6,8-disulfonic acid, from diazotized II and 2,6,8-C10H5(OH)(SO3Na)2 in Na2CO3 soln.; after acidifying slightly the Na salt is pptd. by satg. with NaCl and recrystd. from dil. alc. in vermilion reddish prismatic needles, decomp. 333°. N,N'-Bis(N-carbethoxysulfanilyl)adipamide, from XIV and adipyl chloride at 150°, crystals from dil. alc., m. 220° (decompn.), sapond. to the 4,4'-diamino compd., m. 212° (from dil. alc.). N,N'-Bis(N-carbethoxysulfanilyl)mucic acid amide, from XIV and mucic acid chloride at 190°, m. 201°, sapond. by 2 N NaOH to the 4,4'-diamino compd., m. 233°. 1-[4-(Acetylsulfamyl)phenylazo]-2,6-diaminopyridine, from diazotized II and 2,6-diaminopyridine in acid soln. after addn. of NaOAc, orange reddish needles from alc., m. 191-2°, sol. in Na2CO3 soln. Salts of II: Na, from 21.4 g. II dissolved in 100 mL. N NaOH, concd., pptd. with EtOH, and recrystd. from dil. alc., m. 257°; Ba, m. 185° (decompn.), from dil. alc.; Cu, from the Ba salt with CuSO4, greenish powder; NH4, m. 156° (decompn.); pyridine, from II dissolved in hot C5H5N, cooled, and the ppt. recrystd. from alc., m. 120°; diethanolamine, m. (about)

L4 ANSWER 60 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
155°; Ca, from II and CaCO3; Ag, pptd. from II in water with AgNO3, washed with water, alc., and ether, and dried, m. 216°; Hg, from II in water with Hg(OAc)2, m. 251° (decompn.); quinine, from 31.4 g. II and 32.4 g. quinine in alc. and evapn. of the latter, sol. in water, m. 73°; morphine, from the components in alc., with heating, pptd. by addn. of ether, m. about 160°. Ca salt of IV, from IV and CaCO3 in water, crystals from dil. alc., decomp. 283°. Mg salt of XXXIII, from XXXIII and MgCO3 in boiling water, crystals from dil. alc. Na salt of XVIII, from dil. alc., decomp. above 270°. Mg salt of XVII, from XVII and MgCO3 in boiling water, m. 165-7°. Na salt of IX, from IX with dil. NaOH and pptn. with alc. Ca salt of VII, from VII and CaCO3 by boiling several hrs. in water and pptg. from the concd. soln. with alc., m. 268° (decompn.). Na salt of XL, orange-brown needles from water with alc. and ether, decomp. 207°.

IT 6005-34-1, Nicotinamide, N-sulfanilyl- 845674-82-0, Carbanilic acid, p-(nicotinoylsulfamoyl)-, ethyl ester (preparation of)

RN 6005-34-1 CAPLUS
CN Nicotinamide, N-sulfanilyl- (8CI) (CA INDEX NAME)



RN 845674-82-0 CAPLUS
CN Nicotinamide, N-(N-carboxysulfanilyl)-, ethyl ester (5CI) (CA INDEX NAME)

L4 ANSWER 61 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1947:2208 CAPLUS
DOCUMENT NUMBER: 41:2208
ORIGINAL REFERENCE NO.: 41:409h-i,410a-i,411a-b
TITLE: Amidines. II. Preparation of cyanides, amides, and amidines from carboxylic acids
AUTHOR(S): Oxley, P.; Partridge, M. W.; Robson, T. D.; Short, W. F.
CORPORATE SOURCE: Boots Pure Drug Co. Ltd., Nottingham, UK
SOURCE: Journal of the Chemical Society, Abstracts (1946) 763-71
CODEN: JCSAAZ; ISSN: 0590-9791
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
OTHER SOURCE(S): CASREACT 41:2208

AB cf. C.A. 40, 4367.1. It is suggested that the reaction between RCO2H and R'SO2NH2 can be represented as occurring in 5 stages: (A) RCO2H + R'SO2NH2 RCONH2 + R'SO3H; (B) RCONH2 + R'SO2NH2 + R'SO3H → RCONHSO2R' + R'SO3NH4; (C) RCONHSO2R' RC(:NH)OSO2R'; (D) RC(:NH)OSO2R' → RCN + R'SO3H; (E) RCN + R'SO3NH4 → RC(:NH)NH2.R'SO3H. BzOH and PhSO2NMe2, heated at 235-40°, react exothermically to yield 83% BzNMe2 and PhSO3H. The constituents in hot Me2CO yield nicotinic acid benzenesulfonate (I), m. 160°. I and PhSO2NEt2 at 220° for 1 h. give 81% nicotinodiethylamide (II). More direct evidence for the functional exchange is provided by the fact that the reaction between RCO2H and RSO2NH2 can be arrested at this stage. Nicotinic acid (12.3 g.) and 31.4 g. PhSO2NH2, kept at 225° for 4.5 h., give 9 g. PhSO2NH2 and 17.5 g. nicotinamide benzenesulfonate, m. 157°; this results also from the components in Me2CO. On the other hand, I and PhSO2NH2, heated at 230° for 40 min., yield 75% 3-cyanopyridine benzenesulfonate, m. 132°. When the RCO2H contains no basic group, the reaction can be arrested at stage A by the addition of a base. Thus, 1 mol each of p-HO2CC6H4SO2Me, PhSO2NH2, and C5H5N give 33.4% (95% on acid consumed) p-carbamylphenyl Me sulfone (III), H2NCOC6H4SO2Me, m. 226-6.5°, when refluxed 3.25 h. C5H5N or quinoline almost completely inhibits the reaction between BzOH and PhSO2NH2 at 230-50°. The RCO2H-R'SO2NH2 exchange appears to be catalyzed by acids; thus, a small quantity of a sulfonic acid eliminates the period of induction sometimes observed in this reaction and shortens the duration of the first weakly exothermic phase in the reaction of PhSO2NH2 and p-O2NC6H4COCl; when heated at 145-50° for 5 h., these compds. give 60% N-p-nitrobenzoylbenzenesulfonamide (IV), m. 216-17°; IV results also from PhSO2NH2 and p-O2NC6H4CO2H on heating at 220°, the reaction being accelerated by the addition of a small quantity of PhSO3H.H2O; the temperature changes which occur during the reaction are shown in curves; the temperature rise is much greater with the catalyst. IV, heated at 220° 40 min., gives 81% p-O2NC6H4CN (66% after heating 18 min.). The o-NO2 isomer of IV, m. 171° (46% on basis of acid or 64% on basis of amide); heated at 225° for 8 min., it yields 42% o-O2NC6H4CN. p-HO2CC6H4SO2Me and PhSONH2, heated at 225° 70 min., give 62% p-NCC6H4SO2Me (V) and 20.5% N-(p-methylsulfonylbenzoyl)benzenesulfonamide (VI), m. 214.6-15°. If a small quantity of anhydrous PhSO3H is added, the yields are 80.3 and 1.2%, resp. p-ClOCC6H4SO2Me and PhSO2NH2, heated at 145° for 3.5 h., give 50.8% VI. An equimol. mixture of III, PhSO2NH2, and PhSO3H, heated at 198° 0.5 h., gives 81% V and 8% VI. When heated at 230° 1 h., VI gives 95% V. p-HO2CC6H4SO2Et and PhSO2NH2, heated at 225° 30 min., give 79% PhSO3NH4, 59% p-NCC6H4SO2Et, and 12.7% of the Et homolog of VI, m. 189°. Thus, it seems clear that "mixed imides" of the type of IV and VI are the precursors of the cyanides produced from RCO2H and R'SO2NH2. The 2 exothermic phases involved in the prepn. of p-O2NC6H4CN represent the acid-amide exchange (phase A) and the decompn. of the mixed amide (phases C and D). BzNHO2Ph results in 3% yield on heating BzNH2, PhSO2NH2, and PhSO3H at 155° for 3 h. PhSO2NHBz, heated at 200°, gives 89% PhCN and 82% PhSO3H. This establishes reaction D and the isomerization postulated in C is analogous to that which occurs in the Beckmann transformation of oximes. Stage E has been discussed in Part I. Details are given of the prepn. of o- and p-HO2CC6H4SO2Me, p-O2NC6H4SO2Me, p-H2NC6H4SO2Me, p-NCC6H4SO2Me, and p-HO2CC6H4SO2Et. p-MeC6H4SO2Pr (116 g.) in 600 cc. H2O at 90°, treated 12 h. with 185 g. KMnO4, give 47% p-carboxyphenyl Pr sulfone, m. 191-3°. p-MeC6H4SO2Na and p-O2NC6H4COCl in EtOH, boiled 1 h., give 56.5% p-tolyl p-nitrobenzyl sulfone, m. 185-9°; oxidn. with Na2Cr2O7 in boiling AcOH gives 68% of p-carboxyphenyl p-nitrobenzyl sulfone, m. 295-300°. Examples are given of the prepn. of 19 cyanides from an acid and a PhSO2NH2; 2-cyanophenyl Me sulfone, 83.5%, m. 103-4°; 4-cyanodiphenyl sulfone, 74%, m. 118°; 4-cyanophenyl 4-nitrobenzyl sulfone, 38%, m. 168-9°. The method fails with acids which are readily decarboxylated (e.g., p-HOC6H4CO2H) and much decarboxylation occurs with p-MeOC6H4CO2H, the yield of p-MeOC6H4CN being only 10%. It is convenient to employ PhSO2NH2 and p-MeOC6H4SO2NH2 because of their accessibility, although a somewhat lower yield (5%) of cyanide is usually obtained with the latter. There is usually no difficulty in regulating the exptl. conditions so that very little amidine is formed when a cyanide is the desired product of the reaction. Several examples are given in which an increased yield of amidine salt is obtained if the sulfonic acid is neutralized with dry NH3 before raising the temp. to accelerate the reaction of phase E. p-NCC6H4SO2Et (23 g.) and 25 g. PhSO3NH4, stirred at 245° for 4 h., give 52.5% p-amidinophenyl Et sulfone benzenesulfonate, m. 240°. p-Nitrobenzamidine picrate m. 240°. 3,4-Dichlorobenzamidine m. 94-5°; HCl salt m. 239.5°; benzenesulfonate m. 240-1°. Benzamide benzenesulfonate m. 121.5-2°.

IT 113513-72-7, Nicotinamide, benzenesulfonate (preparation of)
RN 113513-72-7 CAPLUS
CN 3-Pyridinecarboxamide, N-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 62 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1946:24053 CAPLUS
DOCUMENT NUMBER: 40:24053
ORIGINAL REFERENCE NO.: 40:4747b-g
TITLE: Sulfonic acid amides of organic sulfonic acids and primary or secondary amines or amides
PATENT ASSIGNEE(S): Aktieselskabet Grindstedvaerket
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DK 63458		19450507	DK	

GI For diagram(s), see printed CA Issue.

AB A primary or secondary amine or amide is condensed with an aldehyde, and the product treated with the halide or anhydride of the desired sulfonic acid. Water is then added and, if necessary, a substance capable of splitting off H halide. The reaction proceeds as follows - R1NH2 →R2CHO R1N:CHR2 →R3SO2X R3SO2R1N-CHXR2 →H2O R1NH.SO2R3 The aldehyde is regenerated in the last step of the process. Examples are given of the first intermediate compound by interaction of (1) BzH and AcNH2, (2) 2-hydroxynaphthaldehyde and 4-nitroaniline, (3) BzH and 5-amino-2-cyanothiazole and 5-amino-2-thiazolethiocarboxamide, (4) BzH and 5-amino-6-quinolinecarboxylic acid, (5) BzH and 4-aminomorpholine, (6) AcH and anthranilic acid, (7) PhCH:CHCHO and anthranilic acid, and (8) BzH and 4-amino-1,2,4-triazole. Specific examples are given of the preparation of (1) p-tolylsulfonamidobenzene from PhCH:NPh and p-MeC6H4SO2Cl, (2) p-acetamidophenylsulfonamidobenzene from PhCH:NPh and p-AcNHC6H4SO2Cl (I), (3) p-acetamidophenylsulfonamidothiazole from 2-salicylideneaminothiazole and I, (4) p-acetamidophenylsulfonamidopyridine from 2-salicylideneaminopyridine and p-H2NC6H4SO2Cl, (5) N-methylbenzenesulfonamide from PhCH:NMe and PhSO2Cl, (6) N-(p-acetamidophenylsulfonyl)anthranilic acid from N-ethylideneanthranilic acid and I, (7) phenylsulfonamidothiazole from N,N'-benzylidenebis(2-aminothiazole) (II) and benzenesulfonic anhydride, (8) N-methyl-2-naphthalenesulfonamide from PhCH:NMe and 2-C10H7SO2Cl, (9) 2-(2-naphthylsulfonamido)thiazole from II and 2-naphthalenesulfonic anhydride, and (10) a sulfonamide from 4-benzylideneamino-1,2,4-triazole and p-MeC6H4SO2Cl. The preparation of N1,N4-diacetylsulfanilamide and, N4-acetyl-N1-nicotinylsulfanilamide (III) by similar methods is also described. N1-Nicotinylsulfanilamide may be obtained by the saponification of III.

IT 6005-34-1, Nicotinamide, N-sulfanilyl- (preparation of)
RN 6005-34-1 CAPLUS
CN Nicotinamide, N-sulfanilyl- (8CI) (CA INDEX NAME)



L4 ANSWER 63 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1946:11379 CAPLUS
DOCUMENT NUMBER: 40:11379
ORIGINAL REFERENCE NO.: 40:2125e-i,2126a
TITLE: Some N4- and N1-heterocyclic-acyl-sulfanilamides
AUTHOR(S): Jain, B. C.; Iyer, B. H.; Guha, P. C.
CORPORATE SOURCE: Indian Inst. Sci., Bangalore
SOURCE: Science and Culture (1945), 11, 270-1
CODEN: SCINAL; ISSN: 0036-8156
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB Sulfanilamide (I) was reacted with quinolinyl anhydride to give pyridine-2-carboxy-3-carbonyl-N4-sulfanilamide, which m. 210°, solidified and remelted at 260°, and reacted with thionyl chloride to yield pyridine-2,3-dicarbonyl-N4-monosulfanilamide, m. 310-11° (decomposition). I was reacted with quinolinyl chloride to give pyridine-2,3-dicarbonyl-N4-disulfanilamide, m. 293° (decomposition); with chelidonic acid to give N-p-sulfonamidophenyl-4-(p-aminophenylsulfonimino)chelidamic acid, m. 163°, which could be decarboxylated to N-p-sulfonamidophenyl-4-(p-aminophenylsulfonimino)-1,4-dihydropyridine, m. 210° (decomposition). Di-Et dihydro-s-collidine-3,5-dicarboxylate condensed with I upon heating under vacuum, giving dihydrocollidine-3,5-dicarbonyl-N4-disulfanilamide, m. 285° (decomposition). Fusion of I with s-collidine-3,5-dicarboxylic acid gave s-collidine-3,5-dicarbonyl-N4-disulfanilamide, m. 260° (decomposition); with chelidamic acid, 4-pyridone-2,6-dicarbonyl-N4-disulfanilamide, m. 322° (decomposition); with 2,5-furandicarboxylic acid, furan-2,5-dicarbonyl-N4-disulfanilamide, m. 255° (decomposition); with cantharidin, 1,4-endoxycyclohexane-2,3-dimethyl-2,3-dicarbonyl-N4-sulfanilamide, m. 234°. Fusion of I under vacuum with oxalodiglycolic ester gave 3,4-dihydroxyfuran-2,5-dicarbonyl-N4-disulfanilamide, which shrunk at 250° and decomposed; with di-Et furo-3,4-p-dioxane-2,5-dicarboxylate, 3,4-ethylenedioxyfuran-2,5-dicarbonyl-N4-disulfanilamide, decompose above 275°; with thiodiglycolic ester, 3,4-dihydroxythieno-2,5-dicarbonyl-N4-disulfanilamide (decomposition); with di-Et thieno-3,4-p-dioxane-2,5-dicarboxylate, 3,4-ethylenedioxythieno-2,5-dicarbonyl-N4-disulfanilamide. p-AcNHC6H4SO2Cl (II) condensed with di-Et dihydrocollidinedicarboxylate to give N-(N-acetylsulfanilyl)dihydrocollidinedicarboxylic acid, m. above 300° (decomposition). II reacted with chelidamic acid in pyridine to give N-(N-acetylsulfanilyl)-chelidamic acid, m. 227° (decomposition), and could be hydrolyzed to N-(N'-sulfanilyl)chelidamic acid. The K salt of p-AcNHC6H4SO2NH2 condensed with 2,5-furandicarbony chloride to give 2-carboxyfuran-5-carbonyl-N'-acetylsulfanilamide, m. 230°, and with quinolinyl chloride to give pyridine-2,3-dicarbonyl-N'-diacetylsulfanilamide, m. 308° (decomposition).
IT 857759-72-9, Quinolinamide, N,N'-bis(N-acetylsulfanilyl)-
(preparation of)
RN 857759-72-9 CAPLUS
CN Quinolinamide, N,N'-bis(N-acetylsulfanilyl)- (5CI) (CA INDEX NAME)

L4 ANSWER 63 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L4 ANSWER 64 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1945:27380 CAPLUS
DOCUMENT NUMBER: 39:27380
ORIGINAL REFERENCE NO.: 39:4398b-d
TITLE: Effects of sulfonamides on chick-brain tissue cultivated in vitro
AUTHOR(S): deC. Saunders, John B.; Haymaker, Webb
SOURCE: Proceedings of the Society for Experimental Biology and Medicine (1945), 59, 306-9
CODEN: PSEBAA; ISSN: 0037-9727
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB Brain of 8-day-old chick embryos was cultivated in vitro in plasma to which sulfonamides were added in various concns. Cultures containing sulfadiazine and succinylsulfathiazole grew better than the controls at all concns. tested, even up to 5 times the saturation concentration
Sulfapyrazine, sulfapyridine, and sulfaguanidine in concns. up to saturation had no significant influence on growth. Sulfathiazole, sulfanilamide, succinylsulfanilamide, and nicotinylsulfanilamide were more or less toxic. The solubilities of the different sulfonamides in plasma, their effect on the pH of the plasma, and the influence of pH on brain-tissue growth were determined
IT 6005-34-1, Nicotinamide, N-sulfanilyl-
(effect on brain)
RN 6005-34-1 CAPLUS
CN Nicotinamide, N-sulfanilyl- (8CI) (CA INDEX NAME)



L4 ANSWER 65 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1945:16764 CAPLUS
DOCUMENT NUMBER: 39:16764
ORIGINAL REFERENCE NO.: 39:2624e-f
TITLE: N-Sulfanilylnicotinamide
INVENTOR(S): Rosicky, Johann
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 741685		19430930	DE	

AB This compound is prepared from sulfanilamide or benzenesulfonamide substituted in the p-position by a group that can be transformed into a free amino group. The starting compound is made to react with quinolinic acid anhydride. The condensation is carried out either by fusing the two or by heating them in a solvent capable of withstanding a high temperature Either simultaneously with the condensation reaction or by subsequent treatment the product is decarboxylated.
IT 6005-34-1, Nicotinamide, N-sulfanilyl-
(preparation of)
RN 6005-34-1 CAPLUS
CN Nicotinamide, N-sulfanilyl- (8CI) (CA INDEX NAME)



L4 ANSWER 66 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1945:11165 CAPLUS
DOCUMENT NUMBER: 39:11165
ORIGINAL REFERENCE NO.: 39:1737d-g,1738a-b
TITLE: Sulfonamide derivatives of diaminodiphenyl sulfones
INVENTOR(S): Tullar, Benjamin F.
PATENT ASSIGNEE(S): Parke, Davis & Co.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2358365		19440919	US	

AB The new compds. valuable as therapeutics, e.g., internal antiseptics, and intermediates for therapeutics have the general formula 5-R3HN-2(p-R2HNC6H4SO2)C6H3SO2NR1R, where R2 and R3 represent members of the group consisting of H and organic carboxylic acid radicals, R1 is a member of the class consisting of H and organic carboxylic acid radicals and R is a member of the class H and an alkali metal. The compds. of the invention may be obtained by more than one method. For example, the corresponding sulfonamide substituted diphenyl sulfone having a nitro group substituted in one of the phenyl nuclei can first be prepared and the nitro group reduced to an amino group. Alternatively, the corresponding dinitrodiphenyl sulfide having a sulfonic acid group attached to the 2-position of one of the phenyl nuclei can be reduced to the diamino sulfide and the sulfide oxidized to sulfone with or without protection of the amino groups by organic carboxylic acid. The resulting 2-sulfonic acid sulfone derivative can then be converted to the corresponding 2-sulfonamide compound The preparation of 4,4'-diaminodiphenyl-sulfone-2-sulfonamide, m. 236°; 4,4'-diacetamido-diphenyl-sulfone-2-sulfonamide, m. 275°; 4,4'-diacetamidodiphenyl-sulfone-2-N-acetylsulfonamide, m. approx. 295°; 4,4'-diaminodiphenyl-sulfone-2-N-acetylsulfonamide, m. approx. 285°; 4,4'-diacetamidodiphenyl-sulfone-2-N-nicotinyl-sulfonamide and the corresponding 4,4'-diamino compound, m. 245-50° is described. U.S. 2,358,366. 2-(4,4'-Diaminodiphenylsulfone-2-sulfonamido)pyridine, m. 215° is prepared by oxidizing 4,4'-dinitrodiphenyl-sulfide-2-sulfonic acid Na salt to the Na salt of 4,4'-dinitrodiphenyl-sulfone-2-sulfonic acid, converting the latter by means of PCl5 into 4,4'-dinitrodiphenyl-sulfone-2-sulfonyl chloride, treating the sulfonyl chloride with 2-aminopyridine to obtain 2-(4,4'-dinitrodiphenyl-sulfone-2-sulfonamido)pyridine and reducing the nitro groups of the latter with production of α-(4,4'-diaminodiphenyl-sulfone-2-sulfonamido)pyridine (2-(5-amino-2-sulfanilylphenylsulfonamido)pyridine).
IT **861045-37-6**, Nicotinamide, N-[5-acetamido-2-(N-acetylsulfanilyl)phenylsulfonyl]- **861045-77-4**, Nicotinamide, N-(5-amino-2-sulfanilylphenylsulfonyl)-
(preparation of)
RN 861045-37-6 CAPLUS
CN Nicotinamide, N-[5-acetamido-2-(N-acetylsulfanilyl)phenylsulfonyl]- (4CI) (CA INDEX NAME)

L4 ANSWER 66 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 861045-77-4 CAPLUS
CN Nicotinamide, N-(5-amino-2-sulfanilylphenylsulfonyl)- (4CI) (CA INDEX NAME)



L4 ANSWER 67 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1942:21515 CAPLUS
DOCUMENT NUMBER: 36:21515
ORIGINAL REFERENCE NO.: 36:3323i,3324a
TITLE: N-p-Toluenesulfonylpyridinecarboxamide
INVENTOR(S): Frohring, William O.; Szabo, Lester J.; Landy, Maurice
PATENT ASSIGNEE(S): S. M. A. Corp.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2270201		19420113	US	

AB This compound (suitable for use as a therapeutic agent in the treatment of infections of the coccus type) and the corresponding picolinoyl and isonicotinoyl amides are produced by a process which involves treating the acid amide with an aqueous solution of Na2CO3, adding p-toluenesulfonyl chloride
thereto and treating with acetone to precipitate the amide.
IT **113513-61-4**, p-Toluenesulfonamide, N-[3-pyridylcarbonyl]-
(preparation of)
RN 113513-61-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 68 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1942:21088 CAPLUS
DOCUMENT NUMBER: 36:21088
ORIGINAL REFERENCE NO.: 36:3262a-b
TITLE: Ocular absorption of sulfonamide derivatives after local application
AUTHOR(S): P'an, Shih-Yi
SOURCE: Proceedings of the Society for Experimental Biology and Medicine (1942), 49, 384-6
CODEN: PSEBAA; ISSN: 0037-9727
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB cf. C. A. 35, 2215.8. The powdered compds. were placed in the eyes of rabbits. Sulfanilamide and N1-nicotinylsulfanilamide were absorbed in effective amts. by all tissues and fluids except the vitreous humor. Sulfapyridine and N1,N4-dinicotinylsulfanilamide were found in therapeutic concns. in the conjunctiva, cornea, sclera and aqueous humor. Sulfathiazole,
sulfaguanidine and sulfadiazine were absorbed in effective concns. only by the conjunctiva and cornea.
IT **6005-34-1**, Nicotinamide, N-sulfanilyl- **782502-22-1**, Sulfanilamide, N1,N4-bis(3-pyridylcarbonyl)-
(preparation of)
RN 6005-34-1 CAPLUS
CN Nicotinamide, N-sulfanilyl- (8CI) (CA INDEX NAME)



RN 782502-22-1 CAPLUS
CN Sulfanilamide, N1,N4-bis(3-pyridylcarbonyl)- (4CI) (CA INDEX NAME)



L4 ANSWER 69 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1942:21087 CAPLUS
DOCUMENT NUMBER: 36:21087
ORIGINAL REFERENCE NO.: 36:3261i,3262a
TITLE: Drug prophylaxis against lethal effects of severe anoxia. II. Alcohol, amytal and pentobarbital
AUTHOR(S): Emerson, George A.; Van Liere, E. J.; Morrison, James L.
SOURCE: Proceedings of the Society for Experimental Biology and Medicine (1942), 49, 376-9
CODEN: PSEBAA; ISSN: 0037-9727
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB cf. C. A. 34, 5938.1. Narcotic doses of EtOH reduced the lethal effects of acute anoxic anoxia in mice if administered 1 hr. previously. Amytal and pentobarbital did not produce comparable effects.
IT 6005-34-1, Nicotinamide, N-sulfanilyl- 782502-22-1, Nicotinanilide, 4'-(3-pyridylcarbonylsulfamyl)-
(preparation of)
RN 6005-34-1 CAPLUS
CN Nicotinamide, N-sulfanilyl- (8CI) (CA INDEX NAME)



RN 782502-22-1 CAPLUS
CN Sulfanilamide, N1,N4-bis(3-pyridylcarbonyl)- (4CI) (CA INDEX NAME)



L4 ANSWER 70 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1940:24248 CAPLUS
DOCUMENT NUMBER: 34:24248
ORIGINAL REFERENCE NO.: 34:3741i,3742a-c
TITLE: N1,N4-Nicotinyl derivatives of sulfanilamide
AUTHOR(S): Daniels, T. C.; Iwamoto, Harry
SOURCE: Journal of the American Chemical Society (1940), 62, 741-2
CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB Nicotinyl chloride and sulfanilamide in anhydrous C5H5N, refluxed 1 h., give 50-75% of N4-nicotinylsulfanilamide (I), m. 257-8°. Nicotinanilide (0.05 mol.), added to 0.5 mol. ClSO3H below 15°, the temperature gradually increased to 60°, maintained at this temperature for 2 h., the mixture cooled and treated with an excess of cold 28% NH4OH, gives 40-50% of I. I does not titrate to a phenolphthalein (II) end point. The N1-isomer (III) of I, prepared according to Crossley, Northey and Hultquist (C. A. 34, 392.8) also m. 257-8° but because of its greater acidity titrates quant. to a II end point. A 50% mixture of I and III m. 233-5°; titration shows that III does not rearrange during the melting. I and Ac2O give 50% of the N1-Ac derivative, m. 255-6°. I and nicotinyl chloride in C5H5N, refluxed 1 h., give 40% of N1,N4-dinicotinylsulfanilamide, m. 222°, resolidifies and then m. 248°; titration with NaOH of the higher-melting form gives the same equivalent weight as before melting. The preliminary pharmacol. investigation indicates that I is effective in the treatment of exptl. hemolytic streptococcus infections and also certain types of pneumococcus infections. The toxicity of I is lower than that of either sulfanilamide or sulfapyridine.
IT 6005-34-1, Nicotinamide, N-sulfanilyl- 782502-22-1, Nicotinanilide, 4'-(3-pyridylcarbonylsulfamyl)-
(preparation of)
RN 6005-34-1 CAPLUS
CN Nicotinamide, N-sulfanilyl- (8CI) (CA INDEX NAME)



RN 782502-22-1 CAPLUS
CN Sulfanilamide, N1,N4-bis(3-pyridylcarbonyl)- (4CI) (CA INDEX NAME)



L4 ANSWER 70 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L4 ANSWER 71 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1940:2663 CAPLUS
DOCUMENT NUMBER: 34:2663
ORIGINAL REFERENCE NO.: 34:392h-i,393a-i
TITLE: Sulfanilamide derivatives. IV. N1,N4-Diacylsulfanilamides and N1-acylsulfanilamides
AUTHOR(S): Crossley, M. L.; Northey, E. H.; Hultquist, Martin E.
SOURCE: Journal of the American Chemical Society (1939), 61, 2950-5
CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
AB cf. C. A. 32, 8382.6. The most generally applicable method for the synthesis of N1-acylsulfanilamides and that giving the best yield consists in the use of acyl halides and N4-acetylsulfanilamide (I) in C5H5N, followed by alkaline hydrolysis, the yield based on the halide averaging 60%.
Acid anhydrides may also be used, Ac2O giving 60% of the di-Ac derivative, hydrolysis of which gives 32% of the N1-Ac derivative (solubility in H2O at room temperature, 0.9%). The N1-Na, derivative of I, prepared from I and NaOH with recrystn. from H2O and dehydration in vacuo at 60-70°, was used in earlier work but was discarded in favor of the C5H5N method. Dry fusion of I and acyl halides led in general to decomposition products together with the desired N1-acyl derivs. I and BzCl in PhMe, refluxed 20 h., give 40% of the N1-Bz derivative Attempts to prepare N1-alkyl-N1-acylsulfanilamides by hydrolysis of the corresponding N4-Ac derivs. resulted in complete hydrolysis of the N1-Ac derivative Such derivs. were prepared by acylating N-alkylnitrobenzenesulfonamides and reducing with Fe and AcOH in PhMe. In the series of derivs. of fatty acids, the lower members were moderately H2O-soluble; on ascending the series, the H2O solubility decreased and the solubility in fat solvents increased; H2O solubility of derivs. having chains of 12 C or more was less than 0.001 g./100 cc. All of the derivs. in which a H remained on the amide N formed very soluble Na salts, which were neutral for the lower members of the series but became increasingly alkaline for the higher members. All of these compds. could be titrated quant. to a phenolphthalein end-point, however, while sulfanilamide itself cannot be so titrated, since its Na salt is highly hydrolyzed at this pH. In general, the derivs. could be hydrolyzed quant. to the organic acid and the amide (or sulfanilic acid) by boiling with alc. HCl or more rapidly by heating to 180-200° with 65% H2SO4. The lower members of the series could be titrated quant. by diazotization of the N4-NH2 group. Alkylation of the N1-N gave derivs. which no longer formed salts with cations; these had increased solubility in organic solvents. These derivs. were sensitive to hydrolytic agents and in this resembled the N1-alkyldisulfanilamides (C. A. 32, 8382.3). In the tables of data qual. data are given for the solubility and the crystalline form.
N1-Acylsulfanilamides:
Ac (II) m. 182-4°, propionyl m. 134-5°, butyryl m. 125.4-6.6°, isobutyryl m. 198.5-200°, 2-ethylbutyryl m. 189-93.5°, hexanoyl m. 129.2-9.9°, heptanoyl m. 121.8-3.6°, 2-ethylhexanoyl m. 165.5-8°, octanoyl m. 101-3°, decanoyl m. 119-21°, hexdecanoyl m. 112.5-14.5°, dodecanoyl (III) m. 127-8.5°, tetradecanoyl m. 113.5-17.7°, octadecanoyl m. 98-102°, 9-octadecenoyl,

L4 ANSWER 71 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

amorphous, hexahydrobenzoyl m. 198.5-200°, chaulmoogryl m. 97.9-9°, Bz m. 181.2-2.3°, p-nitrobenzoyl m. 235-40°, p-aminobenzoyl m. 197.8-9°, hydrocinnamoyl m. 160.3-1.5°, cinnamoyl m. 130-3° and then 174-5°, 4'-carboxybenzoyl m. above 225° (decompn.), mandelyl m. 192.5-4.5° (decompn.), diphenylacetyl m. 210.5-12°, furoyl m. 191.5-2°, 2-phenylcinchoninyl m. 305-10°, nicotinyl m. 256-7.5°, 3-hydroxy-2-naphthoyl m. 245-50°. N1-Acetylmetanilamide, m. 153.5-5.5°; tetradecanoyl analog, m. 113.5-14.2°. N1-Methyl-N1-dodecanoylsulfanilamide, m. 59.3-60.5°. N1-Acyl derivs. of N4-acetylsulfanilamides: Ac m. 253.5-5°, propionyl m. 242.5-4.3°, isobutyryl m. 247-8°, butyryl 238.2-40°, isovaleryl m. 215-17.5°, 2-ethylbutyryl m. 270-2°, hexanoyl m. 191-3°, heptanoyl m. 205-7.5°, 2-ethylhexanoyl (IV), m. 214-15.6°, octanoyl m. 195-7.6°, decanoyl m. 143.2-4.8°, hendecanoyl m. 153.2-5°, dodecanoyl m. 130-6° tetradecanoyl m. 144.2-5°, 9-octadecanoyl m. 131-5°, chaulmoogryl, Bz m. 280-5°, hexahydrobenzoyl m. 210-22°, p-nitrobenzoyl m. 270-2°, p-aminobenzoyl m. 260-3°, hydrocinnamoyl m. 160° and then 202.8 -5.4°, cinnamoyl m. 228-9.5°, diphenylacetyl m. 248.5-51°, furoyl m. 240.5-41.5°, 2-phenylcinchoninyl m. 166-70°, nicotinyl m. 295-300°. N1,N4-Didodecanoylsulfanilamide, m. 144-5°, N1-dodecanoyl-N4-(N-acetylsulfanilyl)sulfanilamide, m. 120° and then 150-2°; N1-dodecanoyl-N2-sulfanilylsulfanilamide, m. 102-4°. The Na salt (with 1 mol H2O), NH4 and Et2NH2 salts of II and the Ag, Hg++ and Ca salts of III and the Na and Mg salts of IV were prepd. and analyzed. Preliminary pharmacol. results indicate that III is effective in mice against infections by β-hemolytic streptococci and arrests the spread of tuberculous infections in cavies.

IT 6005-34-1, Nicotinamide, N-sulfanilyl- 845960-39-6, Sulfanilamide, N4-acetyl-N1-3-pyridylcarbonyl-
(preparation of)

RN 6005-34-1 CAPLUS

CN Nicotinamide, N-sulfanilyl- (8CI) (CA INDEX NAME)



RN 845960-39-6 CAPLUS

CN Nicotinamide, N-(N-acetylsulfanilyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 71 OF 71 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)